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ABSTRACT 
 Aptamers are short single-stranded nucleic acids that can bind to their targets with high 
specificity and high affinity.  To study aptamer function and dynamics, the malachite green aptamer 
was chosen as a model.  Malachite green (MG) bleaching, in which an OH- attacks the central carbon 
(C1) of MG, was inhibited in the presence of the malachite green aptamer (MGA).  The inhibition of 
MG bleaching by MGA could be reversed by an antisense oligonucleotide (AS) complementary to the 
MGA binding pocket.  Computational cavity analysis of the NMR structure of the MGA-MG 
complex predicted that the OH- is sterically excluded from the C1 of MG.  The prediction was 
confirmed experimentally using variants of the MGA with changes in the MG binding pocket.  This 
work shows that molecular reactivity can be reversibly regulated by an aptamer-AS pair based on 
steric hindrance.  In addition to demonstrate that aptamers could control molecular reactivity, aptamer 
dynamics was studied with a strategy combining molecular dynamics (MD) simulation and 
experimental verification.  MD simulation predicted that the MG binding pocket of the MGA is 
largely pre-organized and that binding of MG involves reorganization of the pocket and a 
simultaneous twisting of the MGA terminal stems around the pocket.  MD simulation also provided a 
3D-structure model of unoccupied MGA that has not yet been obtained by biophysical measurements.  
These predictions were consistent with biochemical and biophysical measurements of the MGA-MG 
interaction including RNase I footprinting, melting curves, thermodynamic and kinetic constants 
measurement.  This work shows that MD simulation can be used to extend our understanding of the 
dynamics of aptamer-target interaction which is not evident from static 3D-structures.  To conclude, I 
have developed a novel concept to control molecular reactivity by an aptamer based on steric 
protection and a strategy to study the dynamics of aptamer-target interaction by combining MD 
simulation and experimental verification. The former has potential application in controlling 
metabolic reactions and protein modifications by small reactants and the latter may serve as a general 
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approach to study the dynamics of aptamer-target interaction for new insights into mechanisms of 
aptamer-target recognition. 
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CHAPTER 1. GENERAL INTRODUCTION 
DISSERTATION ORGANIZATION 
This dissertation contains five chapters and an appendix.   
Chapter 1 is a general introduction to the dissertation organization and the research aims and 
significance of the studies.  The two research aims stated in chapter 1 are specifically addressed 
in chapters 3 and 4.   
Chapter 2 is a literature review of aptamer and the SELEX (Sequential Evolution of Ligands 
by Exponential Enrichment) procedure in general.  Aptamers are first briefly introduced in 
comparison to chemicals and antibodies (Table1).  Aptamer modifications (Fig. 1) are then 
described that are made to improve their pharmacokinetics and functionality.  Multivalent 
aptamers are also discussed that have been made to 1) increase potency, 2) carry multiple 
functions and 3) have allosteric regulation (Table 3).  SELEX, an in vitro technique to select 
aptamers, is then described in regard to its principle (Fig. 2) and technical details.  A summary of 
312 aptamer selection experiments is also presented (Table 2, Fig. 3). 
Chapter 3 addresses the first research aim.  In the first research aim, a novel concept is 
developed to control molecular reactivity by an aptamer based on steric hindrance.  The concept 
is supported by a model in which the malachite green aptamer (MGA) is shown to control 
malachite green (MG) bleaching.  MG bleaching is a pH dependent chemical reaction in which an 
OH- attacks the central carbon (C1) of MG (Fig. 1, 2).  MG bleaching can be inhibited by the 
MGA, which can be reversed by an antisense oligonucleotide that targets the MGA binding 
pocket (Fig. 3).  The mechanism by which MGA inhibits MG bleaching was predicted by a 
computational cavity analysis to be steric hindrance (Fig. 4).  The computational prediction was 
confirmed by experimental analysis of MGA mutants with altered binding pockets (Fig 5, 6, 7).  
 The research described in chapter 3 is in a manuscript in preparation for submission to the 
Journal of Biological Chemistry.  The contributions of the authors are described as follows. 
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Tianjiao Wang designed experiments, collected and analyzed data (Figs. 1, 2, 3, 5, 6 and 7) and 
wrote the manuscript.  Julie Hoy designed an experiment, collected and analyzed data for the 
experiment (Fig. 4) and edited the manuscript.  Monica Lamm designed an experiment, collected 
and analyzed data for the experiment (MD simulation of MGA variants for cavity assay, in 
progress) and edited the manuscript.  Marit Nilsen-Hamilton worked with Tianjiao Wang to 
design experiments, analyze the data and write the manuscript. 
Chapter 4 addresses the second research aim .  In the second research aim, molecular 
dynamics (MD) simulation with experimental validation was used to study the dynamics of 
aptamer-target interaction with the MGA-MG interaction as a model.  MD simulation showed a 
combined preorgnization and induced-fit mechanism in the MGA-MG interaction and a twisting 
of the MGA upon MG binding (Fig 1.)  There are structural discrepancies between simulated and 
experimental (NMR and crystal) structures (Table 1).  The simulated structures of the MGA alone 
and the MGA-MG complex are more in line with the structures present under the buffer 
conditions used for binding studies as shown in RNase I footprinting (Fig. 2).  The discrepancy 
between the simulated structure and the 3D-structure determined by NMR spectrometry and 
crystallography could be due to the different buffer conditions used for measurement.  This is 
consistent with the differences in NMR spectra (Fig. 3) and the melting profiles (Fig. 4, Table 2) 
of the MGA and the MGA-MG complex in buffers that differed in pH and salt components and 
their concentrations.  The prediction of a twisting of MGA upon MG binding was also confirmed 
with RNase I footprinting data of four MGA units linked tandemly with linkers (Fig. 5).  The 
kinetic and thermodynamic constants were then measured to support a structural rearrangement 
during the MGA-MG interaction (Fig. 6, 7).  Finally, a two-step mechanism of the MGA-MG 
interaction is proposed (Fig. 8).  
The research work presented in chapter 4 is in preparation for submission to Journal of 
Molecular Biology.  The contributions of the authors are described as follows. Tianjiao Wang 
designed experiments, collected and analyzed data (Fig. 1-8, Table 1-3) and wrote the manuscript. 
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Monica Lamm designed an experiment, analyzed the data for the experiment (Fig.1) and edited 
the manuscript.  Julie Hoy analyzed the data (Fig. 8) and edited the manuscript.  Marit Nilsen-
Hamilton worked with Tianjiao Wang to design experiments, analyze the data and write the 
manuscript. 
Chapter 5 is the general conclusion of the studies addressed in chapters 3 and 4.  This 
chapter summarizes 1) the results from studies of the effect of the MGA on MG hydroxylation 
that resulted in developing a new concept for controlling molecular reactivity by an aptamer 
(chapter 3) and 2) the results of studies to develop the application of MD simulation with 
experimental validation for studying the mechanism of an aptamer-target interaction (chapter 4).  
Other topics of discussion in chapter 5 are 1) future directions and potential applications of the 
insights achieved in chapter 3 and chapter 4.  Finally, a perspective of aptamer research in general 
is discussed. 
Appendix describes Tianjiao Wang’s preliminary results from a SELEX procedure to select 
aptamers against the Lcn2 protein.  The preliminary data is presented and future work is 
discussed. 
RESEARCH AIMS AND SIGNIFICANCE 
Aptamers are short nucleic acids that behave like antibodies but that have more dynamic 
structures.  The dynamics in their structure allows the regulation of aptamer structure and 
function.  Aptamers function mainly as binding partners and occasionally as catalysts.  
Understanding the molecular bases of aptamer functions and their dynamics is fundamental for 
effectively developing aptamer applications.  Two specific aims have been pursued in this 
research work. 
Aim 1: Controlling chemical reactivity by an aptamer.  Chemical reactions in vivo are 
controlled by regulatory small molecules and proteins and by compartmentalization of the 
relevant enzyme(s).  Various techniques have been developed to control chemical reactions in 
vivo by interfering with genes that encode enzymes or by interfering with an enzyme’s function.  
 4 
These techniques include gene knockout, RNA interference, antisense oligonucleotides and 
chemical inhibitors [1, 2].  By contrast, very few tools are available to control a chemical reaction 
in vivo by directly targeting the chemical reactants.  Mutant enzymes that retain their ability to 
bind substrates but lose their ability for catalysis may be generated to compete with wild type 
enzymes for substrates but it is often difficult to generate such enzyme mutants [1].  Aptamers 
can encapsulate chemicals inside their binding pockets with high affinity and high specificity [3].  
This leads to the hypothesis that an aptamer against a chemical reactant could sequester the 
reactant from other reactants in a chemical reaction, thus preventing the reaction from occurrence.  
This hypothesis is supported by the observation in chapter 3 that the MGA inhibits MG bleaching 
in vitro.  This proof of the concept that chemical reactivity can be controlled by an aptamer in 
vitro provides a first step toward controlling chemical reactions in vivo by aptamers.   
In vivo there are also spontaneous chemical reactions that don’t involve any enzymes and 
reactions catalyzed by enzymes for which there is gene redundancy and that require knock-down 
of multiple genes to change the phenotype.  In these situations aptamers could serve as unique 
tools to control chemical reactions at the reactant level.  The concept of controlling chemical 
reactivity with aptamers has potential applications in vivo in controlling metabolism, protein 
modifications and the reactivity of endogenous toxic chemicals.  
Aim 2: Developing MD simulation as a tool to study aptamer-target interactions with 
experimental validation.  Knowing the dynamics of aptamer-target interactions is fundamental 
to understanding many aptamer functions.  Various experimental techniques have been developed 
to study aptamer structure and dynamics including single molecule measurement, NMR and 
structure probing (see references in chapter 4).  Molecular dynamics (MD) simulation, on the 
other hand, can lead to hypotheses for experimental validation or extend the structure and 
dynamics information beyond the limitations of current experimental techniques.  Although some 
MD simulations of aptamer-target interaction have been tried, they have not been tested 
rigorously against experimental data (see reference in chapter 4).  The MGA-MG interaction was 
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studied using MD simulation with experimental validation.  The results showed that MD 
simulation could, with reasonable accuracy, extend structure and dynamics information beyond 
the 3D-structures of the MGA-MG determined by NMR spectrometry and the MGA-TMR 
determined by crystallography.  These studies showed that the MD simulation could provide an 
experimentally verifiable model for the 3D-structure of an unoccupied MGA whose experimental 
3D-structure has not been reported yet.  There are more than 40 experimentally determined 3D-
structures of aptamer-target complexes and a few experimentally determined 3D-structures of 
unoccupied aptamers in the pdb database (http://www.pdb.org).  This may be due to the dynamic 
nature of short nucleic acids that makes it difficult to collect high resolution data for 3D-structure 
determination of unoccupied aptamers by NMR spectrometry and crystallography.  Thus MD 
simulation provides a tool to model the 3D-structure of an unoccupied aptamer for further 
experimental validation when the biophysically-determined structure for an aptamer is 
unavailable. 
 
REFERENCES 
1. Lindsay, M. A., Target discovery. Nat Rev Drug Discov, 2003. 2(10): p. 831-8. 
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and validation. Curr Opin Chem Biol, 2004. 8(4): p. 371-7. 
3. Hermann, T. and D. J. Patel, Adaptive recognition by nucleic acid aptamers. 
Science, 2000. 287(5454): p. 820-5. 
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CHAPTER 2.  LITERATURE REVIEW 
 
APTAMER 
A nucleic acid aptamer is a single stranded DNA or RNA molecule that can bind to its target 
with high affinity and high specificity.  Peptide aptamers also exist with similar properties.  However, 
the term “aptamer” was coined to describe nucleic acid aptamers and peptide will not be discussed 
here.  Hereafter, the term “aptamer” refers exclusively to nucleic acid aptamers.   
Aptamers were first selected in vitro and later found to exist in nature.  There is 18 years of 
history of aptamer science so far.  An aptamer handbook has been published to describe various 
aspects of aptamer research, development and application [1].  An aptamer database has also been 
created to collect aptamers selected in vitro (http://aptamer.icmb.utexas.edu/) [2].  Natural aptamers 
such as riboswitches can also be searched in RegRNA, a regulatory RNA motifs and elements 
database (http://bidlab.life.nctu.edu.tw/RegRNA2/website/) [3].  
In many ways, aptamers can be considered as nucleic acid-type antibodies with properties 
comparable with or even superior to conventional protein-type antibodies (Table 1).  An aptamer 
binds its target with the affinity in the µM to pM range.  The binding of an aptmer to its target is very 
specific.  An aptamer can discriminate a single chemical group difference between two molecules or 
even the same molecules with different conformations [4-6].  The affinity and specificity of aptamers 
and antibodies are comparable.  Aptamers have been selected in vitro for various targets (Table 2).  
These targets range from small molecules to macromolecules and even to cells.  Because aptamers are 
selected in vitro, they are amenable to various chemical modifications, various selection conditions 
and scale-up synthesis up to the kilogram level.  In contrast to in vitro chemical synthesis and 
selection for aptamers, antibodies are developed and produced by in vivo biological systems and 
antigens for antibodies are usually limited to nontoxic macromolecules.  So aptamers are superior to 
antibodies in target ranges, in flexibility of selection and post-modifications and in cost.  In addition, 
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aptamers can function both inside and outside cells [7-11] whereas antibodies usually only work 
outside cells to target secretory proteins or cell surface receptors.  For therapy, aptamers have shown 
no intrinsic toxicity and immunogenicity [12-15] but antibodies, even humanized, could induce 
immunogenicity [16].  In sum, aptamers are competitive with or even superior to antibodies in many 
respects.  
APTAMER MODIFICATIONS 
Aptamers were originally selected from single stranded DNA or RNA molecules made of 
natural nucleotides.  To increase functionality, affinity and nuclease resistance and to improve 
pharmacokinetics of aptamers, modifications have been introduced to different parts of aptamers 
including the nucleosides, the phosphodiester backbone and the 5’ and 3’-termini (Figure 1).  The 
modifications can be introduced either during SELEX or after SELEX or both.  The modifications 
introduced during SELEX require compatible enzymology (T7 RNA polymerase, reverse 
transcriptase and DNA polymerase) and modifications introduced post-SELEX should be screened to 
avoid compromising aptamer function.  Consistent efforts have been made to engineer enzymes to 
incorporate modified nucleotides efficiently [17,18].  These efforts will facilitate successful 
modifications during SELEX.  So far,  ~100 different modifications can be readily introduced into 
aptamers at the 2’-position of ribose, the 5-position of pyrimines, the 8-position of purines, the 7-
position of 2’-deoxypurines, the oxygen of phosphodiester bond and others [19-22]. 
• To improve pharmacokinetics: 
            The pharmacokinetics of aptamers is determined by various properties of aptamers including 
their nuclease-resistance, their uptake and distribution in tissues and their circulation half-life in the 
blood of organisms.  Modifications of aptamers can help to improve their pharmacokinetics for 
therapy and in vivo diagnosis.  
Single or combinatorial modifications of aptamers with 2’-primary amines (2’-NH2), 2’-
fluorides (2’-F) and 2’-O-methyl groups (2’–OME) have been done extensively as shown in Table 1.  
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These modifications can be introduced with modified nucleotides either during SELEX or post-
SELEX.  The 2’-F modified nucleotides, 2’F-dATP, 2’F-dCTP and 2’F-dGTP have been used in 
combination as substrates for thermostable DNA polymerases including Pfu (exo-), Vent(exo-), Deep 
Vent (exo-) and UITma [23].  Engineered T7 RNA polymerases have also been used to increase the 
efficiency of introducing modified nucleotides during SELEX.  The Sousa group generated Y639F 
and Y639F/H784A T7 RNA polymerase mutants by rational design.  The Y639 F variant can use 2’-
deoxy, 2’-NH2 and 2’-F NTPs as substrates while the Y639F/H784A double mutant can further use 
NTPs with bulky 2’-substitutions (2’-OME, 2’-N3) [24,25].  With optimized conditions, the 
Y639F/H784A/(K378R) T7 RNA polymerase can incorporate all four 2’-OME-NTPs [26].  In 
addition, the Ellington group selected a Y639V/H784G/E593G/V685A T7 RNA polymerse (RGVG-
8.1 variant) by in vitro evolution. The variant can incorporate 2’-OME U, 2’-OME C and 2’-OME A 
but not 2’-OME G [27].   
2’-NH2, 2’-F and 2’-OME were introduced to increase the nuclease resistance of aptamers.   
The half lives of natural RNAs in human serum are from seconds to hours but those of modified 
aptamers are days (e.g. >> 96 hr for the 2’-OME-VEGF aptamer).  In addition to nuclease resistance, 
these modifications also increase the affinities of aptamers by increasing their thermostability and 
chemical diversity.  Pagratis, et al, introduced 2’-NH2 and 2’-F deoxypyrimidines into KGF aptamers 
during SELEX.  They demonstrated that the 2’-F modification is superior to the 2’-NH2 modification 
in providing the aptamer with better thermostability, affinity and bioactivity [28].   In another study, 
Kubik, et al, introduced 2’-F, 2’-NH2 and 2’F/NH2 deoxypyrimdines in parallel into IFN-γ aptamers 
during SELEX, and showed that the 2’-NH2 modified aptamer had 3-4 times better affinity than the 
2’-F modified aptamer.  They suggested that these modifications contributed to high affinity aptamers 
by providing chemical and structural diversity [29].  The 2’-NH2-Py-2’-OME-Pu-modified VEGF 
aptamer is a good example of combining modifications during and post-SELEX.  A 2’-NH2-Py 
modified VEGF aptamer was first selected by SELEX.  Then 10 out of 14 deoxyribopurines of the 
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selected aptamer (24 nt) were replaced with 2’-OME deoxyribopurines.  This 2’-OME modification 
increased the VEGF aptamer affinity by 17 fold due to its decrease in koff [30].  Fully 2’-OME and 2’-
deoxy-Pu-2’-OME-Py modified aptamers have also been generated [26,31]. They have superior 
stability in plasma and after being autoclaved at 125 oC.  The 2’-OME modifications occur naturally 
and are not substrates of human DNA polymerase.  So 2’-OME modifications are less likely to cause 
toxicity compared to the 2’-F and 2’-NH2 modifications.  Besides, 2’-OME modifications are less 
expensive compared with 2’-F and 2’-NH2 modifications. 
Another form of 2’-modification introduced post-SELEX is the locked nucleic acid (LNA) in 
which the 2’-O and 4’-C are linked by a methylene group.  LNA has been introduced to the stem I of 
a tenascin binding aptamer, TTA1 that was also 2’-F-Py and 2’-OME modified.  The LNA 
modification further increased the thermostability and plasma stability of TTA1.  In addition, the 
LNA-modified TTA1 showed higher tumor uptake and blood retention [32].  In an LNA and DNA 
chimeric aptamer against an HIV-1 TAR RNA element, the half life of the modified aptamer was 
increased  from << 1 h to >> 20 h in 10% calf serum [33].  Combinatory screening of LNA and 2’-
OME modifications in the loop region of an aptamer against the HIV-1 TAR RNA element also 
identified three derivatives that showed about 10 times higher affinity than the parental aptamer.  One 
of them could inhibit TAR dependent transcription [34].  
The 4’-thio modification is another way to provide nuclease resistance for aptamers.  Post-
SELEX modification of an NF-κB aptamer in stem I and in loop region increased the aptamer’s 
thermostability (Tm from 34.8 oC to 45.7 oC).  At the same time, the nuclease resistance of the 
aptamer was increased by three-fold [35].  After 4’-thioCTP and 4’-thioUTP were introduced into a 
human α-thrombin aptamer during SELEX, the half life of the thioaptamer in the presence of 50 pg/µl 
RNase A was 19.5 h while that of the natural aptamer was 22 min [36].  
Phosphodiester backbone modifications can also provide nuclease resistance for aptamers.  
One or two of the nonbridging oxygens on the phosphodiester backbone can be replaced by thiol 
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groups.  Phosphorothioate nucleotides can be incorporated into nucleic acids during SELEX with 
lower efficiency by T7 RNA polymerase, DNA polymerase and reverse transcriptase [37] but 
phosphorodithioate nucleotides can only be introduced through post-SELEX modification.  The 
modified aptamer is called a thioaptamer and is nuclease-resistant.  Ds-DNA thioaptamers made from 
dATPαS, dTTP, dCTP and dGTP have been selected for NF-IL6 [38], NFκB(p50, p60, RelA) [39,40] 
and RNase H domain of HIV RT [41] with Kds in the low nM range.  The half life of the thioaptamer 
against NF-IL6 was increased from about 5 min to about 20 min at the treatment of 0.12 pg/ml DNase 
I [38].  A RNA aptamer made from ATPαS, UTP, CTP and GTP has also been selected for 
Venezuelan equine encephalitis virus capsid protein with the Kd of 7 nM [42].  In addition, a fully 
phosphorothiolated RNA aptamer against bFGF was generated with the Kd of 1.8 nM [43].  
Althought thioaptamers are nuclease-resistant, they tend to be more sticky and may bind 
nonspecifically to other proteins.  This needs to be fine-tuned for thioaptamers. 
In addition to modifications at the nucleoside and the phosphodiester backbone, capping at 
the 5’ and 3’-termini can also increase resistance of aptamers to exonucleases. The degradation of 
aptamers in human blood is largely due to 3’→5’ exonucleases.  A commonly used 3’-capping of 
aptamers is an inverted thymidine (3’-idT), which creates an additional 5’-end without a 3’-end.  The 
3’-capping with 3’-idT can greatly increase aptamer stability in an organism’s blood.  The half-life of 
a PDGF DNA aptamer modified with 2’-F, 2’-OME  and 3’-capping by 3’-idT was increased from 
0.6 h to 8 h in 85% rat serum [44]. 3’-idT capping was also used to further protect a 2’-F modified 
Factor IXa RNA aptamer. The modified aptamer could inhibit Factor IXa function and prolong the 
clotting time of human plasma in a dose-dependent manner [45].  3’-biotin capping of a thrombin 
aptamer has also been reported.  The half-life of the nonmodified thrombin-DNA aptamer was 5-10 
min in fresh noncirculating mouse and rabbit blood and those of 3’-biotin and 3’-biotin-streptavidin 
capped thrombin aptamers were 40-160 min and >160 min respectively [46].  Because 
phosphorothioate DNA or RNA is nuclease-resistant, short phosphorothioate caps at the 5’ and 3’ 
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ends can also improve aptamer stability [30].  A special way to cap the 5’ and 3’ ends is 
circularization. Multivalent circular DNA aptamers have been generated through building blocks 
using both thrombin and L-selectin aptamers as examples.  The circular DNA aptamers have been 
shown to be nuclease resistant.  The half life of a circular divalent thrombin DNA aptamer was 
increased from 15 min to 6.8 - 13.6 h in pooled human serum and from 36 min to 15.4 - 32.1 h in 
human plasma.  The half life of a circular heterovalent thrombin-selectin DNA aptamer was increased 
from 4.8 h to 9.5 h in pooled human serum and from 16 h to 50 h in human plasma [47,48].  A 
circular RNA aptamer for streptavidin generated through self-ligating permutated intron-exon 
sequence has already been reported.  The circular RNA aptamer can be produced in vitro as well as in 
vivo [49,50].  
A different concept of providing nuclease-resistance, called spiegelmers, is based on chirality 
[51].  D-aptamers are first selected against molecules which are chiral to the desired targets.  
According to the chiral principle, the chiral aptamer (L-apatmers) will recognize the desired targets.  
Because nucleases can only use natural D-DNA/RNA as substrates, the L-aptamers (spiegelmers) are 
nuclease-resistant.  A limitation of this approach is the synthesis of chiral targets.  For example, 
instead of an integral protein, only a small domain of a protein can be chemically synthesized as the 
D-form.  Spiegelmers are stable in serum.  For example, no obvious degradation was observed in 
human serum even after 60 h for a spiegelmer (L-RNA) that binds D-adenosine.  On the contrary, the 
D-RNA was completely degraded in 24 s.  Examples of spiegelmers can be found in Table 2.  
Nuclease-resistance is only one part of the story of aptamer pharmacokinetics.  Uptake and 
distribution in tissues and circulation half-lives of aptamers are other important aspects of aptamer 
pharmacokinetics.  Aptamers are relatively small (10-15 kDa, 30-45 nt) and can be easily cleared 
from human blood through the kidney and liver.  To increase the circulation half lives of aptamers, 
tagging aptamers at the termini is often used.  The most commonly used tag is polyethylene glycol 
(PEG).  Pegylation usually has little effect on the affinities of aptamers but it can dramatically 
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increase the circulation half life of aptamers, thus enhancing in vivo aptamer activity.  In addition, 
pegylation can affect the tissue distribution of aptamers.  The effect of pegylation has been studied on 
both the 2’-F modified RNA and ss-DNA L-selectin aptamers.  The results showed that affinities of 
pegylated L-selectin aptamers decreased from little up to 30 times with the increase of the PEG 
molecule weight.  Although the Kds of pegylated selectin aptamers were compromised, the plasma 
clearance rate of the pegylated selectin aptamers administered by tail vein injection in Sprague-
Dawlet rat was dramatically decreased.  For the 2’-F modified RNA selectin aptamer, the half life 
(t1/2 ) was10 min for the nonpegylated aptamer, 60 min for the 20 KDa PEG conjugate and 228 min 
for the 40 KDa PEG conjugate.  Correspondingly, the in vivo ability of the pegylated L-selectin 
aptamer to inhibit lymphocyte trafficking in SCID mice was increased by ~3 times for the 20 KDa 
PEG conjugate and by ~27 times for the 40 KDa conjugate compared with the L-selectin aptamer 
without pegylation [52].  Pegylation of a TGFβ2 aptamer has also been reported.  The pegylation 
didn’t affect the KDa but changed the pharmacokinetics of the TGFβ2 aptamer.  Subconjuctivally 
injected into Dutch-belted rabbits, the TGFβ2 aptamer without PEG entered into rabbits’ plasma 
rapidly and reached the maximal drug concentration (Cmax) in 1 h with an elimination half life (t1/2) 
of 2.4 h.  The TGFβ2 aptamer conjugated with 20 KDa and 40 KDa PEG entered the rabbits’ plasma 
more slowly and reached the Cmax in 6 and 12 h respectively with t1/2s of 7.4 h and 6.8 h respectively.  
PEG conjugation also increased the Cmax of the TGFβ2 aptamer by 20-100 times in plasma and 5-6 
times in aqueous humor.  In aqueous humor, the 40 KDa PEGylated TGFβ2 apatmer had a t1/2 of 25.8 
h [53].  PEGylation of a PDGF aptamer has also been attempted.  A 40 KDa PEGylation didn’t affect 
the Kd of the PDGF aptamer and the PEGylated aptamer showed a biphasic clearance pattern in rat 
plasma with t1/2s of 32 min and 134 min after i.v. injection [44].  The pharmacokinetics of Macugen, a 
40 KDa PEGylated VEGF aptamer, has also been studied thoroughly in Rhesus monkeys.  Macugen 
showed t1/2s of 9.3 h in plasma after intravenous injection, 12 h in plasma after subcutaneous injection 
[54] and 94 h in vitreous humor [12].  
 13 
In addition to pegylation, tagging with lipids may also increase the circulation half lives of 
aptamers and tagging with cell-penetrating peptides may help tissue uptake of aptamers.  A VEGF 
aptamer has been tagged with dialkylglycerol (DAG), which can anchor the aptamer on liposomes.  
The tagging with DAG decreased the aptamer’s affinity by 1.6 times. The anchoring of DAG-tagged 
aptamer to liposomes through DAG further decreased the apatmer’s affinity by about 5 times.  The t1/2 
in plasma in Sprague-Dawley rats after intravenous bolus administration was 49 min for the VEGF 
aptamer, 67 min for the DAG-VEGF aptamer and 113 min for the liposome-DAG-VEGF aptamer.  
The increase of circulation half life in vivo is correlated to the dramatically increased ability of the 
tagged VEGF aptamers to inhibit vascular permeability and angiogenesis in vivo [55].  Cholesterol is 
another choice of lipid tag.  Tagging with cholesterol prolonged the circulation half life of antisense 
oligonucleotides but had the opposite effect in an aptamer study [56].  To study the effect of various 
factors on aptamer pharmacokinetics, an inactivated TGFβ2 aptamer was used.  The study showed 
that the aptamers had circulation half lives of 0.6-16 h.  PEGylation and aptamer sugar modifications 
played more important roles in aptamer pharmacokinetics and tissue distribution than the low 
molecular weight tags (cholesterol and cell-penetrating peptides).  The aptamer abundance in plasma 
followed the trend of 20 KDa PEG > 2’F, 2’OME mix > Arg7 > fully 2’OME.  The 20 KDa PEG 
could prevent renal clearance as well as the 40 KDa  PEG.  The major uptake and distribution tissues 
for aptamers are the highly perfused organs (kidney and liver) and the mediastinal lymph nodes [56]. 
• To improve functionality 
To improve pharmacokinetics is only one reason for aptamer modifications.  Another reason 
for aptamer modification is to introduce new functionality.  Unlike proteins composed of 20 different 
amino acids, nucleic acids are made from only four different nucleotides (A, G, C, T/U).  To increase 
the numbers of functional groups and the complexity of nucleic acids, aminoacyl, hydrophobic, 
hydrophilic, charged and fluorescent modifications have been introduced into the 5-position of 
pyridine, the 8-position of purines and the 7-position of deoxyuridines during and post SELEX. 
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For modifications during SELEX, the compatibility of the unnatural nucleotides with 
enzymes needs to be determined first.  Compatibility depends on the types of modification, the 
polymerase and the nucleic acid sequence to be amplified or transcribed.  UTP derivatives with 
hydrophobic and charged groups at the 5 position including phenyl, 4-pyridyl, 2-pyridyl, indolyl, 
isobutyl, imidazole and amino groups are as good substrates as natural nucleotides for T7 RNA 
polymerase [57].  For deoxynucleotide derivatives as substrates, in general the family B DNA 
polymerases (Vent, KOD Dash, Pwo) more efficiently  use the modified substrates than the family A 
DNA polymerases (Taq, klenow, Tth).  The Famulok group synthesized a series of C5, C7, C8 
modified dATPs, dUTP, dCTPs and dGTPs with carboxyl, amino, amide and guanidinium groups.  
They tried to synthesize functionalized DNA enzymatically using multiple modified 
deoxynucleotides simultaneously as substrates.  They found that the amount of the full length DNA 
synthesized by Pwo and Vent(exo-) DNA polymerases with multiple modified deoxynucleotides as 
substartes  was > 70% of that with natural nucleotides as substrates [58].  The Kuwahara group 
synthesized 26 different dCTP and dUTP analogs that were modified at the C5 position by amino, 
hydroxyl, amide and guanidinium groups with different lengths of aliphatic linkers.  They screened 
260 different combinations of modified dCTP and dUTP, DNA polymerases and DNA templates to 
find the optimal compatibility of modified dCTP and dUTP with DNA polymerases and found that 
the substrate spectra followed the trend of Vent(exo-) > KOD Dash/(exo-) > Tth, Taq and the fidelity 
of incorporation followed the pattern of KOD Dash/(exo-) > Vent (exo-).  They also showed that the 
efficiency of DNA enzymes to use modified dCTP and dUTP as substrates was affected by the 
modification chemistry, the linker length and the compositions of modified dCTP and dUTP [59].   
The same group demonstrated that the KOD Dash DNA polymerase could efficiently use C5-
modified dUTP with amino acyl groups (arginyl, histdidyl, lysyl, phenylalanyl, tryptophanyl, lecucyl, 
prolyl, glutaminyl, seryl, O-benzyl seryl, threonyl, aspartyl and glutamyl cysteinyl) as substrates [60].  
In addition to the C5,C7 and C8 modifications, N7- cyanoborane- dGTP was shown to be a good 
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substrate  for Taq and  klenow (exo-) DNA polymerases [61].  Some DNA polymerases have also 
been engineered to extend their substrate spectra.  For example, the Holliger group selected a Taq 
(M1) (G84A/D144G/K314R/E520G/F598L/A608V/E742G) by direct evolution with a 
compartmentalized self-replication method.  The Taq (M1) can incorporate 7-deazaGTP, 
thiotriphospates and dNTPs labeled with rhodamine, fluorescein and biotin [62].  
Because various modified nucleotides can be used as substrates for the synthesis of nucleic 
acids, modified nucleotides have been used in SELEX to increase the functionalities of aptamers.  A 
5-(1-pentynyl)-dUTP instead of TTP has been used to select thrombin DNA aptamers.  The resulting 
aptamers showed a dramatic sequence difference from the aptamers selected with natural nucleotides.  
The 5-(1-pentynyl)-dU was also required for aptamer function [63].  Unlike 5-(1-pentynyl)-dUTP 
carrying a hydrophobic group, 5-(3”-aminopropynyl)-dUTP has a cationic functional group.  An ATP 
aptamer has been selected with 5-(3”-aminopropynyl)-dU as one of its nucleosides.  The selected 
aptamer also showed sequence differences from that selected using natural nucleotide triphosphate 
substrates [64].  A thymidine derivative (pppTHM) bearing an amino group with a positive charge has 
also been used in selecting a sialyllactose DNA aptamer.  THM was present at the three-way junction 
structures of the aptamer, which could be the binding pocket for sialyllactose and THM might interact 
with the negatively charged sialyllactose [65]. 
Boron neutron capture therapy has been investigated for cancer therapy.  Boron (10B) can 
capture neutrons to form 11B.  11B can then divide into 4He and 7Li and kills cells within a distance of 
5-9 µm.   So, aptamers consisting of boronated nucleotides will gain new functionalities for cancer 
therapy if the aptamers are targeted to cancer markers.  Aptamers against ATP have been selected 
using either 5’-(α-P-borano)-UTP (bUTP) or 5’-(α-P-borano)-GTP (bGTP) during SELEX 
experiments.  The selected aptamers showed novel aptamer folding and the bU and bG were essential 
for aptamer function [66].  This provides an example of developing boronated aptamers. 
 16 
Fluorescence modifications have also been introduced to aptamers during and after SELEX to 
produce signaling aptamers.  Several types of signaling aptamers have been reviewed [67].  One type 
of signaling aptamers has only a single fluorophore attached.  The attached fluorophore changed its 
fluorescence intensity due to the structural reorganization of an aptamer upon ligand binding.  
Another type is called an aptamer beacon.  In an aptamer beacon, ligand binding to its aptamer breaks 
the fluorphore and quencher pair at the 5’ and 3’ ends, thus resulting in increased fluorescence.  A 
third type of signaling aptamer is called a structure-switching signaling aptamer.  In this case, an 
aptamer is labeled with a fluorophore at one end and hybridized to an oligonucleotide with a quencher.  
Upon ligand binding, the hybridized oligonucleotide with quencher is then released and the 
fluorophore emission can be detected.  In addition, some signaling aptamers generate signals based on 
fluorescence resonance energy transfer (FRET). 
Another type of modification provides cross-linking ability by introducing 5-Br(d)U or 5-
I(d)U during SELEX.  This type of aptamer is developed by SomaLogic Inc. for protein diagnosis and 
is called an photoaptamer [68,69].  The 5-BrUTP and 5-IUTP are good substrates for T7 RNA 
polymerase and the 5-BrdUTP requires the combination of Taq and Pwo DNA polymerases for 
efficient incorporation.  Cross-linking only happens when an aptamer and a protein can be positioned 
closely enough with the right orientation.  Under irradiation (308nm laser), 5-Br(d)U or 5-I(d)U can 
specifically cross-link with proximal amino acids having aromatic or sulfur groups.  The cross-linked 
aptamer-protein complex can be washed with harsh conditions, thus providing superior specificity 
and signal/noise ratio. 
Aptamers can also be used as delivery vehicles rather than sensors.  Drugs or signaling 
molecules can be directly covalently linked to aptamers or indirectly through a hybridized 
oligonucleotide.  Valine phosphonate (ValP), an irreversible inhibitor of neutrophil elastase, was 
linked to an oligonucleotide hybridized to a random DNA/RNA library.  In vitro selection generated 
an aptamer-ValP complex with increased potency by three to four orders of magnitude and with better 
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specificity compared to ValP alone [70,71].  An Ala-Ala-Pro-Val tetrapeptide, a weak inhibitor of 
human nutrophil elastase (hNE), was directly covalently linked to the 3’-end of a hNE aptamer with 
three 18-carbon linkers through post-SELEX modification.  By this way, the aptamer could deliver 
the tetrapeptide to the active site of hNE and increase the drug potency by 105 times [72].  In addition 
to delivering drugs, aptamers can be coupled to fluorescent molecules for flow cytometry [73] or to 
radioisotopes(18F, 99mTc, 123I) for imaging [74]. 
MULTIVALENT APTAMERS 
 Multivalent aptamers have been generated by rational design as well as by in vitro selection 
to increase potency, to carry multiple functions or for allosteric regulation. 
• To increase potency 
More units of an aptamer in a single molecule can capture more ligands, thus increasing 
aptamer potency.  Expressing tobramycin and kanamycin aptamers inside E. coli could cause drug-
resistance and the resistance increased with the number of aptamer units in the expression vector.  
When inserted into the 5’-UTR, the multivalent tobramycin and kanamycin aptamers could also 
inhibit translation in the presence of tobramycin and kanamycin [10].  Multivalent aptamers have also 
been used to knock down protein function.  A multivalent (12 pentavalent) B52 aptamer was 
expressed in cells and an organism (fly).  The multivalent aptamer showed a 10-fold increase in 
affinity compared with the monovalent aptamer.  Stable expression of the multivalent B52 aptamer 
inhibited B52 functions and reversed the phenotypes caused by overexpression of B52 [11].  
Similarly, a multivalent thrombin aptamer showed stronger anticoagulant activity than a monovalent 
thrombin aptamer [47].  Another example is a tetravalent CTLA-4 aptamer.  The T-cell receptor, 
CTLA-4, is a negative signal for T-cell activation.  It exists as a dimer and is cross-linked by a pair of 
B7-1 proteins, which are its ligands.  To inhibit CTLA-4 function, a CTL-4 aptamer was selected and 
its tetravalent form was tested and shown to be better able to inhibit CTLA-4 function than a 
monovalent form and thus enhance T cell immunity against tumors [75].  
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Divalent aptamers to cell surface receptors can stimulate signal transduction by inducing the 
dimerization normally caused by ligand binding.  For example, a divalent aptamer against 4-1BB, a 
cell surface receptor on CD8+ T cells stimulate CD8+ T-cell activation while the monovalent 4-1BB 
aptamer was unable to do so [76].  
Another purpose of constructing multivalent aptamers is to increase the signal and the 
resolution for imaging or diagnosis.  A divalent human neutrophil elastase aptamer showed ~ 20 fold 
increase in affinity and stronger fluorescence compared with a monovalent form [73].  A molecule 
with multivalent malachite green aptamer was also found to bind more malachite green per molecule 
and emit a stronger fluorescence per molecule than a molecule with monovalent malachite green 
aptamer [77].  Another example is multivalent MS2 coat protein aptamers.  Multivalent MS2 coat 
protein aptamers were inserted into the 3’ end of lacZ mRNA.  The inserted MS2 coat protein 
aptamers could capture coexpressed MS2-GFP fusion proteins to the lacZ mRNA, thus imaging lacZ 
mRNA movement in a cell.  The results showed that individual lacZ mRNA movement inside a cell 
could be observed for lacZ mRNA containing 24 units of MS2 aptamers while only population 
resolution of lacZ mRNA movement inside a cell could be achieved for lacZ mRNA containing 6 and 
12 units of MS2 aptamers [78]. 
• Multifunctional aptamers 
To have different aptamers in a molecule carrying out multiple tasks has potential application 
in catalysis, biosensors and therapy.  Some multifunctional aptamers have been reported.  Burke DH 
[79] reported a general approach to generate bifunctional aptamers through chimeric SELEX.  In the 
chimeric SELEX, a pool of CoA aptamer and a pool of chloramphenicol aptamer at two ends were 
linked through a homologous sequence in the middle.  The linked pool was then reselected for its 
ability to bind to both CoA and chloramphenicol.  The linked pool had a low affinity to both CoA and 
chloramphenicol at round 1 compared with the original CoA aptamer pool and the original 
chloramphenicol aptamer pool respectively.  After five rounds of selection, bifunctional aptamers 
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were generated from the linked pool.  The selected bifunctional apatmers bound to both CoA and 
chloramphenicol with as good affinities as the original CoA and chloramphenicol individual pools.   
Instead of in vitro selection, rational design was also used to generate multifunctional 
aptamers. For example, a thrombin aptamer, an L-selectin aptamer and a DNA element conjugated to 
biotin or fluorescin were linked together through duplex linkers or three way junctions.  The resulting 
multivalent aptamers had multiple functions including anticoagulation activity and application as 
biosensors [47,48].  Another bifunctional aptamer could sense either AMP or cocaine.  The AMP and 
cocaine aptamer was linked into one piece, which was hydridized to another piece of DNA.  Either 
AMP or cocaine could compete with the hybridized sequence and release the hybridized sequence to 
give colorimetric or electric signals for detection [80].  Yet another bivalent aptamer was also 
reported to bind simultaneously to the HIV transactivation responsive element (TAR) and the 
dimerization initiation site (DIS) in the 5’ untranslated region.  The two aptamers were linked through 
a PEG linker. The resulting bifunctional aptamer showed about 10 times higher affinity for HIV RNA 
5’-untranslated region compared with those of individual aptamers.  The enhanced affinity was due to 
slower dissociation rate [81]. 
• Allosteric aptamers 
Analogous to allosteric enzymes, allosteric aptamers refer to nucleic acids that have multiple 
domains for multiple targets.  Binding of a target to its binding domain in an allosteric aptamer affects 
the binding of other targets to their corresponding domains. Various allosteric ribozymes have been 
generated by in vitro selection, rational design or the combination of both [82].  Allosteric aptamers 
can be developed with similar approaches.  Allosteric aptamers also exist in nature.  Some examples 
of allosteric aptamers are listed in Table 3.  An allosteric aptamer can consist of as many as three 
domains: an effector module(s), communication module(s) and allosteric module(s).  Binding of a 
target to an effector module transfers a signal to an allosteric module.  The allostery mechanism can 
be i) An effector binding to the effector module stabilizes the communication module and thus the 
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allosteric module, thus allowing a target to bind to the allosteric module [83-87] or ii) An effector 
binding to the effector module guides the proper folding of allosteric module for targte binding 
[88,89].  Allostery can be achieved through the change of dissociation rate [81]. 
SELEX 
 Systematic Evolution of Ligands by Exponential Enrichment (SELEX) is an in vitro 
technique to select aptamers and ribozymes using random nucleic acids libraries and in vitro selection 
and evolution technologies. The SELEX methodology was first developed in 1990 [90-92].  Since 
then, aptamers have been selected for various targets from small molecules (ions, small organic 
chemicals), macromolecules (proteins, carbohydrates and nucleic acids) to cells and tissues (Table 2).  
The SELEX methodology itself has evolved with time.  Various SELEX formats have been 
developed beyond the conventional SELEX [93].  Some detailed protocols about conventional 
SELEX have been published that should be very helpful for novices for adapting this technology into 
their laboratories [94-99].  Here the focus of discussion is on the principle and technical issues of 
conventional SELEX. 
 The SELEX protocol consists of several steps (Figure 2).  First, a random DNA pool of 1013-
1015 complexity needs to be synthesized.  From the DNA pool, ds-DNAs are produced by either 
Klenow extension or polymerase chain reaction (PCR).  The ds-DNAs then serve as templates to 
generate RNAs by in vitro transcription (for RNA-SELEX) or to generate ss-DNAs by strand 
separation (for DNA-SELEX).  Next, iterative selection-amplificaton is carried out to enrich target 
binders.  The ssDNAs or RNAs are first incubated with a target molecule.  The target binders are then 
collected and the nonbinders are discarded.  The ss-DNA binder or cDNA reversely transcribed from 
RNA binders are then amplified by PCR to generate ds-DNA for next selection-amplificaton cycle.  
The iterative selection-amplification steps will be done until no further enrichment can be achieved.  
This usually takes 2-20 cycles.  Finally, the binders will be cloned and sequenced for further 
characterization. 
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 The principle and technical issues of conventional SELEX are discussed below. 
1) Random pool and primers 
The ss-DNA random pool for SELEX is usually synthesized at a 1 µmol scale.  This yields a 
complexity of ~1015 different amplifiable sequences.  As calculated from SELEX results, the 
probability of there existing an aptamer with high specificity and selectivity for its target ranges from 
10-3 to 10-14 with mean and mode probability of 10-11 [100].  In practice, a complexity of 1013-1015 
different ss-DNA is usually used in the initial pool in which each ss-DNA molecules consists of a 
random region in the middle and two constant regions at both ends for PCR amplification (Figure 2A).  
In DNA pool design, several factors need to be considered: pool length, degree of randomness and 
constant regions.  
There are some debates about what is the optimal pool length for SELEX.  On one hand, 
longer DNAs and RNAs are more likely to form more complex structures while keeping the smaller 
motifs present in shorter DNA and RNAs.  On the other hand, extra sequences outside a motif may 
interfere with the correct folding of the motif.  It has been suggested that longer random sequences 
(70-200 random positions) should be used to select rare activity (e.g. ribozymes) while shorter 
sequences (# 70 random positions) can be used to select simple activity (e.g. aptamers) [101].  It has 
also been suggested that the optimal pool length is equal to 20x and x is the number of stems of an 
aptamer.  This latter suggestion is based on the computational analysis of the secondary structure 
distribution of random pools according to graph theory [102].  In addition to computational analysis, 
an experiment has been designed to select an isoleucine aptamer from pools containing 16, 22, 26 50, 
70 and 90 random residues.  The results showed that the optimal random pool length for selecting an 
isoleucine aptamer is 50-70 nucleotides long [103].  In sum, ss-DNA pools with random positions # 
75 nucleotides are empirically used. 
In addition to length, the degree of randomness is another factor to consider for pool design.  
Although most random pools used to select for novel binding are completely random, there are 
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arguments that biased random pools should be designed.  Computational analysis of the secondary 
structure distribution of completely random pools has shown that the pools tend to have simple motifs 
while more complex motifs are rare [102].  This argues that we may be able to select aptamers for 
better activities if we can design a pool to sample both simple and complex motifs.  To meet this aim, 
a web server called Rag PooLs has been developed (http://rubin2.biomath.nyu.edu) [104,105].  The 
Rag PooLs server consists of two parts, pool designer and pool analyzer.  In pool designer, users need 
to specify three inputs, RNA topology distribution, number of mixing matrices and starting sequences.  
There are 30 starting sequences that represent different topologies, lengths and functions and 34 
mixing matrices that determine the degree of randomness in the database.  Once the inputs are 
specified, the pool designer will calculate the optimal combination of starting sequences and mixing 
matrices as output.  In pool analyzer, users can verify the structure distribution generated from the 
output at pool designer.  Then the output from pool designer can be used to guide users’ pool 
syntheisis.  In sum, completely random pools are used to select most novel aptamers so far.  It will be 
interesting to see the effect of biased random pool on aptamer selection in the future. 
Another feature of pool design is the constant regions and the matching primers.  Although 
constant regions have been shown to affect aptamer binding, the major concern about constant region 
design is the (RT-)PCR efficiency.  The constant regions should not form stable secondary structures 
[103].  The matching primers should not have structural features that can cause PCR artifacts like 
primer dimers.  Two features of the 3’-ends of primers can help to improve amplification efficiency.  
One is to have WSS (W=A, or T, S= C or G) to ensure good extension and the other is to have A/T-
rich regions to avoid mispriming [95].  For RNA-SELEX, a T7 promoter needs to be included in one 
of the primers.  I prefer to have primers that work at relatively high temperatures (65-70 oC) because 
aptamers often have stable secondary structures.  Relatively high temperature (65-70 oC) helps to 
overcome stable secondary structures of aptamers for efficient (RT-)PCR amplification.  Many 
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successful random pools and primer sets have been reported that  can be readily used or serve as 
references for design [95,96]. 
In addition to the design concerns just mentioned, cross contamination of pool and primers 
should be avoided during synthesis or later SELEX experiments. 
2) Targets 
 Aptamers have been selected for various targets.  Theoretically, aptamers can be selected for 
any targets but it is not true in practice.  Some targets may be just better than others in SELEX.  
According to Table 2, the number of aptamers selected for targets follows the trend of proteins > 
small organic molecules >> peptides, nucleic acids > carbohydrates > ions, lipids.  The affinity and 
specificity of a binder is often assumed to correlate to the rigidity of its target.  Although this is not 
always true, the trend observed from Table 2 may reflect that in general the rigidity of a target may 
contribute to successful SELEX.  There are two reports of aptamers binding to divalent ions.  The 
affinity and specificity of these aptamers are not very good.  This is expected because ions have too 
small surfaces to interact extensively with their aptamers.  It has been shown that aptamers can bind 
to the aliphatic side chain of L-valine [CH(CH3)2] with the Kd of 12 mM [106] and to cholic acids 
with Kd of 6.4-67.5 µM [107,108].  It will be interesting to see whether aptamers can be developed 
more broadly to study lipids in the future.  
 Proteins have been the major targets for SELEX.  This is partly due to the importance of 
protein functions and potential diagnostic and therapeutic applications of aptamers against proteins.  
Another reason is that proteins have large surfaces that allow extensive interactions between proteins 
and aptamers.  Empirically, proteins with basic patches are considered to be good targets for SELEX 
[94].  This is exemplified by nucleic acids and nucleotides binding proteins and heparin-binding 
proteins such as thrombin and bFGF.  Hydrophobic proteins on the other hand, are considered as poor 
targets for SELEX because nucleic acids have limited capacity for hydrophobic interactions [100].  
The second largest class of targets is small organic molecules.  Small organic molecules with 
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heterocyclic rings  and planar structures are considered as good targets for SELEX [109].  This is 
exemplified by aptamers for NTPs and their analogs, theophyline, histidine, tryptophan, tyrosine, 
phenylalaninamide, tetracyclines, porphyrin and organic dyes (Table 2).  As mentioned above, small 
hydrophobic molecules are poor targets for SELEX.  
 In sum, although there are some empirical rules to indicate what targets may be good for 
SELEX, trial and error is used by scientist in practice. 
3) Generation of ss-DNA or RNA  
RNA for SELEX can be readily generated by in vitro transcription with T7 RNA polymerase.  
This can be done with commercially available kits (e.g. Ampliscribe T7-Flash from Epicentre) or 
using recombinant T7 RNA polymerase [24,25] prepared in a research lab.  Complete digestion of ds-
DNA templates after in vitro transcription is an important step because residual ds-DNA from this 
step may be introduced to the (RT-) PCR step later.  If this happens, unwanted amplification from the 
undigested ds-DNA will be carried forward and slow down or even fail SELEX.  It is suggested to 
gel-purified RNA from in vitro transcription at every selection cycle.  Usually 1-2 nmol RNA can be 
readily produced from a 20 µl reaction with a 50-100 pmol ds-DNA template. 
Single-stranded DNA templates for SELEX can be readily produced from denatured ds-DNA 
by streptavidin-bead capture or other means.  For the same argument mentioned above, the quality of 
the ss-DNA needs to be checked to avoid ds-DNA being carried forward.  
4) Target-nucleic acids incubations 
 There are several factors to consider for target-nucleic acids incubations.  These include 
binding buffer, incubation time and temperature and selection stringency.  Some mathematical 
models have been constructed to predict optimal conditions for SELEX [110,111].  Empirically, a 
SELEX can be started with low stringency to enrich binders.  Once the enrichment of binders is 
oberserved, more stringent conditions are applied to select high affinity binders [94].  A rule of thumb 
is to choose a target concentration under which 5-10% of ss-DNA or RNA will bind to the target.  In 
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practice, many targets may not have obvious binding to ss-DNA or RNA (<1%) in the first round of 
selection.  In this case, the starting concentration of proteins can be set to 1-10 µM and that of small 
molecules to mM because aptamers against proteins usually have Kds of nM-pM and aptamers 
against small molecules have Kds of µM.  The target/nucleic acids ratio can be set to 0.1-10. 
 Binding buffers:  Usually a binding buffer consists of a buffering agent (Tris, HEPES, 
phosphate, pH 6-8), salts (NaCl or KCl, 50-200 mM) and Mg2+ (1-10 mM).  In practice, buffers are 
user-defined to meet their specific purposes. Aptamers have been selected in various binding 
solutions including organic solvents.  An aptamer for bisphenol A has been selected in 2-50% of 
either one or the mixture of dioxane, dimethyl sulfoxide, N,N-dimethylformamide, tetrahydrofuran, 
ethanol and methanol (USPTO#: 20050282226).  In addition, an FMN aptamer has been shown to 
function properly even in 80% acetonitrile [112]. 
 Incubation time and temperature:  Usually SELEX is carried out at either 25 oC or 37 oC.  The 
incubation time varies according to the nature of targets.  Longer incubation time helps rare high 
affinity binders to have chances to bind. Usually 5-30 min is sufficient for binding. 
 Selection stringency:  Selection stringency is affected by many factors.  These include the 
concentration and ratio of target/nucleic acids, competitors, dilution and washing.  As mentioned 
above, it may be wise to start with low stringency until enrichment is observed.  A binding assay is 
needed to monitor the SELEX in progress.  Usually the binding assay is carried out every three cycles. 
5) Separation 
 There are many ways to separate binders from nonbinders.  These include nitrocellulose 
membrane filtration, affinity chromatography, electromobility shift assay, immunoprecipitation, 
centrifugation, flow cytometry, surface plasmon resonance and capillary electrophoresis (Table 2) 
[113].  For separation, there are two factors to consider; one is resolution and the other is nonspecific 
binding to a matrix.  
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The most commonly used separation methods are nitrocellulose membrane filtration and 
affinity chromatography (Table 2).  Both methods require matrices (membrane vs resin) for 
separation.  Usually nonspecific binding of nucleic acids to matrices is 0.1-1% and the average 
probability of aptamers existing in a pool is 10-11.  This may explain why SELEX needs multiple 
selection cycles to enrich aptamers.  Nitrocellulose membrane filtration and affinity chromatography 
have their own advantages and disadvantages for selection.  The advantage of nitrocellulose 
membrane filtration is that no coupling of proteins to matrices is required, thus fewer proteins are 
needed.  The disadvantage is that it is usually used only for selecting RNA aptamers against proteins.  
Although there are some successful examples of ss-DNA aptamers selected with nitrocellulose 
membrane filtration, nitrocellulose membrane filtration in general is not good for selecting ss-DNA 
aptamers because ss-DNA molecules can be easily enriched as nitrocellulose membrane binders due 
to the hydrophobic property of ss-DNA molecules [99].  On the other hand, affinity chromatography 
can be used for selecting apatmers for broader range of targets than nitrocellulose membrane filtration.  
Compared to nitrocellulose membrane filtration, affinity chromatography usually requires much more 
target due to the need to couple the targets to affinity resins.  Because of the high density of the target 
on the affinity matrix, it is more difficult to select very high affinity aptamers in affinity 
chromatography. 
Capillary electrophoresis is well known for its high resolution in separation. Recently, 
capillary electrophoresis has been applied in SELEX as a means of separation of binders from 
nonbinders [114-121].  Usually it only takes 2-4 cycles to select an aptamer with capillary 
electrophoresis SELEX, compared to about 12 cycles in conventional SELEX.  Capillary 
electrophoresis SELEX holds promise for developing highly efficient SELEX but it may not be 
applicable to situations in which the aptamer-target interaction is sensitive to electric fields.  
6) Reverse transcription-polymerase chain reaction (RT-PCR) 
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 After binders are separated from nonbinders, they need to be amplified for the next selection 
cycle.  This is done by PCR.  RNA binders need to be reversely transcribed by a reverse transcriptase 
first to generate cDNAs for PCR.  Various reverse transcriptases have been used in SELEX to 
generate cDNA from RNA binders but there is no report yet to compare the efficiency of reverse 
transcriptases on cDNA generation from RNA binders.  Because aptamers usually have stable 
structures, I prefer reverse transcriptases that work at high temperature (55-70 oC), such as 
SuperScript, ThermoScript and Thermo-X reverse transcriptase from Invitrogen. 
 Efficient PCR is also very important.  An amplification efficiency of 90-100% (equivalent to 
1.8-2 times amplification per DNA per cycle) is required to avoid biased amplification in PCR.  It has 
been shown that PCR amplication of a random pool is very different from PCR amplification of a 
homogenous DNA.  In PCR amplication of a random pool, the ds-DNA products reach a maximum 
after 15-18 PCR cycles while ss-ds DNA byproducts due to random hybridization of ds-DNA 
products begin to appear at around cycle 15 in the presence of excess amounts of primers.  
Overamplification (>20 cycles) will cause the ds-DNA products to disappear.  It has also been shown 
that increasing the Taq DNA polymerase concentrations in the range of 0.025-0.1 U/ul helps to 
increase the yield of ds-DNA products [122].  In our SELEX conditions, PCR is usually carried out 
for less than 15 PCR cycles and the PCR amplication yield and quality is monitored after 7-10 cycles.  
Although there are some reports that the addition of single-stranded DNA binding protein, DMSO 
and betaine helps to improve PCR quality [123,124].  We have found that the effect of these additions 
is not consistent in our SELEX PCR condition (data not shown), so we do not add them. 
7) Number of iterative selection rounds needed for SELEX 
 The number of iterative rounds for selecting an aptamer depends on the target nature and the 
selection conditions.  It takes 2-26 rounds to enrich an aptamer with mean and modal number of 
rounds of 10 and 12 respectively (Figure 3, summarized from Table 2).  It has also been reported that 
the number of rounds to complete a SELEX experiment ranges from 7 to 22 with a mean of 12 ± 4 
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and a median of 12 in a summary of 26 successful SELEX experiments using proteins as targets [111].  
The difference between these two sets of numbers is a function of two different, but overlapping data 
sets.  In practice, a binding assay is carried out at about every three rounds to determine the SELEX 
progress.  The selections are stopped when no further enrichment is observed.   If various conditions 
have been tried and no obvious enrichment is observed repeatedly after 15 rounds of SELEX, then the 
selected target may not be suitable for SELEX. 
8) Cloning, sequencing and further characterization of aptamers 
 After a SELEX experiment has been completed, the selected binders need to be cloned for 
sequencing and further characterization of aptamers.  There are many ways to clone binders.  I 
recommend TOPO TA cloning (Invitrogen), which is fast and efficient.  High throughput plasmid 
preparation and high throughput sequencing can be done in several days.  The sequencing results can 
be analyzed by alignment tools, e.g. Vector NTI and secondary structure prediction tools, e.g. Sfold.  
Minimization, functional and structural studies can be done by footprinting, NMR, x-ray 
crystallography among other techniques. 
9) Reselection to improve affinity 
 If the affinity of an aptamer after selection is not satisfactory, reselection to improve its 
affinity can be done by doping [125] or nonhomologous random recombination [126].  It has been 
shown that nonhomologous random recombination is even more efficient than doping [126].  Doping 
involves partially randomizing an aptamer composition.  It has been shown computationally that the 
doping percentage has a large effect on the sequence distribution in the pool, thus affecting the 
reselection results.  A web tool for calculating the effect of doping rate is provided at 
http://bayes.colorado.edu/doped pools [125].  If an aptamer sequence is similar to a starting sequence 
in RagPool, RagPool may also be used as a guideline to choose an appropriate doping percentage 
[104,105].   
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In nonhomologous random recombination, ds-DNAs derived from imperfect aptamers are 
digested with DNase I randomly and the digested fragments are extended by T4 DNA polymerase to 
generate blunt-ends.  The fragements with blunt-ends are then ligated with excess of a DNA hairpin 
to produce ligation products that have DNA hairpins at both ends.  The ligation products are then 
treated with a restriction endonuclease to cleave off the loop regions of the hairpins. The resulting ds-
DNAs then serve as templates for the reselection pool [126].  Compared with doping, nonhomologous 
random recombination can provide more diversity of structures.  This may explain why it can 
improve affinity even more than doping. 
 In summary, the principle and technical issues of conventional SELEX have been discussed.  
SELEX technology itself has also been evolving with time.  A future challenge is to develop SELEX 
into an automated, highly efficient and high throughput methodology.  Some efforts have been made 
toward this end.  A SELEX procedure has been integrated into a robotic workstation to carry out 
automatic selection with modified vacuum filtration as a separation method [127].  The system can 
also be coupled to high throughput aptamer characterization including sequencing and affinity 
measurements [128].  To monitor the SELEX progress and to avoid overamplification of target 
binders, a fluorescence reader is also integrated into a robotic system [129].  A method combining in 
vitro transcription, translation and biotinylation has also been developed to generate biotinylated 
proteins for SELEX directly from their gene sequences [130].   It has also been proposed that proteins 
can be immobilized in 96-well plates through hydrophobic interactions, which is compatible with a 
robotic workstation [131].  Theoretically, 96 SELEXes can be finished in just 2 days in a robotic 
workstation integrated with 96-well plates immobilized with targets.  In another automation system, a 
robotics is integrated with an affinity column, a PCR thermal cycler, an HPLC and a sample operation 
system [132].  Instead of using a workstation, another way to implement high throughput SELEX is 
through miniaturization.  An automated microfluidic SELEX prototype has been reported [133].  This 
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represents the first effort toward a microfabricated chip-based SELEX platform.  Although automatic 
SELEX platforms have been attempted, they are not available commercially so far. 
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TABLES AND FIGURES 
 
Table 1. Comparison of chemicals, aptamers and antibodies 
 
 
  chemicals aptamers antibodies 
size <1 kDa 10-15 kDa 150 kDa 
targets proteins everything including 
toxic targets (from ions 
to macromolecules) 
haptens or 
macromolecules 
affinity mM-nM µM-pM nM-pM 
specificity fit to a binding site 
of a molecule 
distinguish even a single 
chemical group 
difference and 
conformation difference 
distinguish even a 
single chemical group 
difference and 
conformation difference 
immunogenicity no no yes 
tissue 
penetration 
enter into tissues and 
cells easily 
moderate ability to enter 
into tissues and cells  
difficult to penetrate 
into tissues and cells 
function inside 
cells 
Yes Yes No 
antidotes sometimes antisense 
oligonucleotides 
no 
breaking the 
interface 
between 
macromolecules  
difficult to break 
extensive interface 
between 
macromolecules 
capable of blocking 
macromolecule 
interactions 
capable of blocking 
macromolecule 
interactions 
screening 
process 
in vitro rational 
design or 
combinatory 
chemistry selection 
in vitro combinatory 
chemistry selection 
in vivo selection in 
biological systems  
selection 
conditions 
various various physiological condition 
chemical 
modifications 
various various limited 
Thermostability stable  stable  temperature sensitive 
shelf life unlimited unlimited ~5 years 
biological half 
life  
minutes to days hours to days hours to days 
cost inexpensive relatively expensive very expensive 
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Table 2.  Aptamer selected in vitro 
target types Separation 
methods (rounds) 
Kds 3D-structures 
(PDB ID) 
Ions 
divalent (Zn2+, 
Ni2+, Co2+, Cd2+ ) 
Cd2+ and Ni2+ 
 
 
Nucleotides and 
cofactors 
adenine or 
adenosine 
portions  
 
 
 
 
 
 
 
 
 
 
 
biotin 
 
FAD and FMN 
 
GTP 
 
m7-GTP, m7-
GDP, m7GpppG 
and m7GpppA 
NMN and NAD 
 
VB12 
 
xanthine and 
guanine 
 
Amino acids 
D-tryptophan 
 
D/L-arginine and 
argininamide  
 
L-arginine 
 
 
RNA 
 
RNA 
 
 
 
 
RNA 
 
 
 
 
 
 
 
 
 
 
boronated-RNA 
DNA 
L-RNA 
RNA 
 
RNA 
 
RNA 
 
RNA 
 
 
RNA 
 
RNA 
 
RNA 
 
 
 
RNA 
 
DNA 
 
 
L-RNA 
 
 
affinity chroma-
tography (7) 
affinity chroma-
tography (8) 
 
 
 
affinity chroma-
tography  
ATP/AMP- (8) 
 
SAM- (7) 
SAH- (14) 
FMN/FAD -(7,5) 
CoA- (8, 13, 7, 
12) 
cAMP-(5) 
adenine- (12) 
ATP/AMP- (8) 
ATP-(8) 
adenosine (5) 
affinity chroma-
tography (7) 
affinity chroma-
tography (8,9) 
affinity chroma-
tography (10) 
affinity chroma-
tography (8) 
 
affinity chroma-
tography (8) 
affinity chroma-
tography (8) 
affinity chroma-
tography (5) 
 
 
affinity chroma-
tography (7) 
affinity chroma-
tography (12) 
 
affinity chroma-
tography  (11) 
 
1.2 mM [134] 
 
0.8-29 µM [135] 
 
 
 
 
 
 
0.7-50  µM [136] 
 
N.D. [137] 
50-100 nM [138] 
0.5-1.4 µM [139] 
0.5-2.4 µM 
[140,141] 
10 µM [142] 
10 µM [143] 
10 µM [66] 
6  µM [144] 
1.8 µM [145] 
5.7 µM [146,147] 
 
0.5-50 µM 
[139,148,149] 
25-500 nM [150] 
 
0.5-2 µM [151] 
 
 
2.5 µM [148]  
 
0.09-8.8 µM 
[152]  
3.3 µM [153] 
 
 
 
18  µM [154] 
 
0.1-2.5 mM [168] 
 
 
129 µM [167] 
 
 
 
 
 
 
 
 
 
 
 
1RAW [158] 
1AMO [159] 
 
 
 
 
 
 
 
 
1AW4 [160] 
 
1F27 [161] * 
 
1FMN [162] 
 
2AU4 [163] 
 
 
 
 
 
 
1DDY [164] * 
1ET4 [165] * 
 
 
 
 
 
 
1OLD [184] 
2ARG[185] 
1DB6 [186] 
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Table 2.  Aptamer selected in vitro (continued) 
targets types Separation 
methods (rounds) 
Kds 3D-structures 
(PDB ID) 
L-arginine 
 
 
 
 
 
L-citrulline 
 
L-histidine 
 
L-isoleculine 
 
L-tyrosine and L-
tryptophan 
L-tyrosinamide 
and L-
phenylalaninamide 
L-valine 
 
 
Antibiotics 
chloramphenicol 
 
kanamycin A/B 
 
 
lividomycin 
 
moenomycin A 
 
neomycin 
 
streptomycin 
 
tetracycline 
 
tobramycin 
 
viomycin 
 
 
Organic or 
fluorescent dyes 
cibacron blue 3GA 
RNA 
 
 
 
 
 
RNA 
 
RNA 
 
RNA 
 
RNA 
 
DNA 
 
 
RNA 
 
 
 
RNA 
 
RNA 
 
 
RNA 
 
2’-NH2-Py-RNA 
 
RNA 
 
RNA 
 
RNA 
 
RNA 
 
RNA 
 
 
 
 
RNA and DNA 
 
affinity chroma-
tography   
(7) 
(11) 
(20) 
(9) 
affinity chroma-
tography (7) 
affinity chroma-
tography (6-7) 
affinity chroma-
tography (15) 
affinity chroma-
tography (13) 
affinity chroma-
tography (15) 
 
affinity chroma-
tography (9) 
 
 
affinity chroma-
tography (12) 
affinity chroma-
tography (4, 14, 
12) 
affinity chroma-
tography (4) 
affinity chroma-
tography (12) 
affinity chroma-
tography (8) 
affinity chroma-
tography (7) 
affinity chroma-
tography (12) 
affinity chroma-
tography (6,13) 
affinity chroma-
tography (7) 
 
 
 
affinity chroma-
tography (6,5) 
 
 
0.2-1 mM [155] 
60 µM [156] 
0.33 µM [6] 
1.4-48 mM [157] 
62-68 µM [156] 
 
8-54 µM [169] 
 
0.2-0.5 µM [170] 
 
35-743 µM [171] 
 
45-80 µM [172] 
 
 
12 mM [106] 
 
 
 
2.1-270 µM [173]  
 
0.18 µM 
[10,174,175]  
 
0.22 µM [175] 
 
0.3-0.4 µM [176] 
 
0.1 µM [177] 
 
1 µM [178] 
 
1 µM-0.77 nM 
[179,180]  
8 µM-2 nM [181] 
 
11-21 µM [182] 
 
 
 
 
< 0.1 mM [92] 
 
 
 
 
1KOC [166] 
 
 
1KOD [166]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1NEM [187] 
 
1NTA and 1NTB 
[188] * 
  
 
1TOB [189] 
2TOB [190] 
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Table 2.  Aptamer selected in vitro (continued) 
targets types Separation methods 
(rounds) 
Kds 3D-structures 
(PDB ID) 
fluorescin 
 
Hoechst dye 33258 
 
Hoechst derivative 7e 
 
malachite green 
 
reactive red 120 
 
reactive yellow 86 
 
reactive browm 10 
 
reactive green 19 
 
reactive blue 4 
 
sulforhodamine B 
 
 
 
 
Other small organics  
CCdApPuro 
 
cocaine 
 
codeine 
 
daunomycin and 
doxorubicin 
dopamine 
 
ethanolamine 
 
hemaptoporphyrin IX 
 
4,4’-
methylenedianiline 
porphyrins 
 
theophylline 
 
thyroxin 
 
RNA 
 
RNA 
 
DNA 
 
RNA 
 
RNA 
 
RNA 
 
RNA 
 
RNA 
DNA 
RNA and DNA 
 
DNA 
 
RNA 
 
 
 
RNA 
 
DNA 
 
RNA 
 
DNA 
 
RNA 
 
DNA 
 
DNA 
 
RNA 
 
DNA 
 
RNA 
 
RNA 
 
affinity chroma-
tography (6,5) 
affinity chroma-
tography (10) 
affinity chroma-
tography (9) 
affinity chroma-
tography (8) 
affinity chroma-
tography (6) 
affinity chroma-
tography (6) 
affinity chroma-
tography (6) 
affinity chroma-
tography (6,6) 
affinity chroma-
tography (6,5) 
affinity chroma-
tography (8) 
affinity chroma-
tography (7) 
 
 
affinity chroma-
tography (10) 
N/A 
 
affinity chroma-
tography (15) 
affinity magnetic 
beads (10) 
affinity magnetic 
beads (9) 
affinity magnetic 
beads (10) 
affinity chroma-
tography (7-10) 
affinity magnetic 
beads (9) 
affinity chroma-
tography (12) 
affinity chroma-
tography (8) 
affinity chroma-
tography (12) 
N.D. [183] 
 
N.D. [10] 
 
0.88 µM [86] 
 
1 µM [191] 
 
N.D. [92] 
 
N.D. [92] 
 
N.D. [92] 
 
0.6 nM [92] 
33 µM [192] 
N.D. [92,192] 
 
 0.66 µM [193] 
 
0.31 µM [183] 
 
 
 
10 nM [194] 
 
0.4-10 µM 
[195,196] 
2.5, 4 µM [197] 
 
20 nM [198] 
 
1.6 µM [199] 
 
6-19 nM [200] 
 
22 mM-1.6 µM 
[201] 
0.45-12 µM [202] 
 
0.5-4.9 µM [203-
205]  
0.1 µM [4] 
 
50 µM [206] 
 
 
 
 
 
 
 
1F1T [207] * 
1Q8N [208] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1EHT [209] 
1O15 [210] 
 
 35 
Table 2.  Aptamer selected in vitro (continued) 
targets types Separation methods 
(rounds) 
Kds 3D-structures 
(PDB ID) 
Carbohydrates 
cellobiose and 
cellulose 
chitin 
 
sLex 
 
sialyllactose 
 
 
 
sephadex G-100 
 
 
Llipids 
cholic acids 
 
 
Peptides 
amyloid peptide βA4 
(1-40)/fibril 
ARM model peptide 
 
α-CGRP 
 
farnesylated Ras 
peptide 
ghrelin 
 
GnRH 
 
 
 
MUC1 (peptides) 
 
N/OFQ 
 
neuropeptide Y 
 
 
 
PrPC-peptide (90-129) 
 
 
DNA 
 
DNA 
 
RNA 
 
THM-DNA 
 
 
 
RNA 
 
 
 
DNA 
 
 
 
RNA 
 
RNA 
 
L-RNA 
 
RNA 
 
L-RNA 
 
L-DNA 
 
L-RNA 
 
DNA 
 
L-RNA 
 
DNA 
 
2’-NH2-Py-
RNA 
2’-NH2-Py-
RNA 
 
affinity chroma-
tography (14) 
affinity chroma-
tography (8) 
affinity chroma-
tography (17) 
Sialyllactose-
biotin-streptavidin 
magnetic beads 
(13) 
affinity chroma-
tography (11) 
 
 
affinity chroma-
tography (13) 
 
 
affinity chroma-
tography (8) 
quartz-crystal 
microbalance (7) 
affinity chroma-
tography (15) 
affinity chroma-
tography (10) 
affinity chroma-
tography (17, 18) 
affinity chroma-
tography (8, 12) 
affinity chroma-
tography (6) 
affinity chroma-
tography (10) 
affinity chroma-
tography (13) 
capillary 
electrophoresis (4) 
affinity chroma-
tography (12) 
affinity chroma-
tography (12) 
 
1-100 µM [211] 
 
N.D. [212] 
 
0.085-10 nM 
[213] 
4.9 µM [65]  
 
 
 
N.D. [214] 
 
 
 
6.4-67.5 µM 
[107,108] 
 
 
29-48 nM [215] 
 
10 nM [216] 
 
2.5 nM [217] 
 
0.14-0.93 µM 
[218] 
45-90 nM [219] 
4.5-20 nM [220] 
20-55 nM 
[15,221] 
92 nM [221] 
 
0.1-34 nM [222] 
 
0.3-3 µM [223] 
 
0.3-1 µM [118] 
 
0.4 µM [224] 
 
0.1-10 µM [225] 
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Table 2.  Aptamer selected in vitro (continued) 
targets types Separation methods 
(rounds) 
Kds 3D-structures 
(PDB ID) 
substance P 
 
vasopressin 
 
microcystin-LR 
 
angiotensin I 
 
 
Proteins 
Antibodies 
anti-g10 antibodies 
 
anti-NES Ab and 
CRM1/exportin 1 
mAb 20 (anti-insulin 
receptor antibody) 
 
 
mAb 198 (anti-
AChR antibody) 
 
 
mAb C595 (anti-
MUC1) 
Ig E 
 
 
 
mAb G6-9 
 
 
Cell surface proteins 
4-1BB (murine) 
cytotoxic T cell 
antigen 4 
sCD4 (rat) 
 
β2 integrin LFA-1 
(αL β2, 
CD11a/CD18) 
DC-SIGN 
RNA  
 
L-DNA 
 
RNA 
 
DNA 
 
 
 
 
RNA 
 
RNA 
 
RNA 
 
2’-NH2-Py-RNA 
 
2’-NH2-Py-RNA 
 
2’-F-Py-RNA 
 
DNA 
 
2’-NH2-Py-RNA 
DNA 
DNA 
 
RNA 
 
 
 
2’-F-Py-RNA 
2’-F-Py-RNA 
 
2’-F-Py-RNA 
 
RNA 
 
 
DNA 
affinity chroma-
tography (24) 
affinity chroma-
tography (13) 
affinity chroma-
tography (13) 
affinity chroma-
tography (9) 
 
 
 
Immuno-
precipitation (3) 
affinity magnetic 
beads (5) 
affinity magnetic 
beads (11) 
magnetic affinity 
column (12) 
Immuno-
precipitation (12) 
Immuno-
precipitation (11) 
immobilization on 
PCR-tube (10) 
filtration (9) 
filtration (15) 
capillary electro-
phoresis (4) 
affinity chroma-
tography (22) 
 
 
filtration (12) 
filtration (9) 
 
affinity chroma-
tography (15) 
affinity chroma-
tography (11) 
 
microtiter plate 
(11) 
0.19-2 µM [226] 
 
1.2 µM [227] 
 
> 1 µM [228] 
 
0.1-0.5 µM [229] 
 
 
 
 
N.D. [230] 
  
0.1 µM [231,232] 
 
2 nM [233] 
 
30 nM [234] 
 
6-60 nM 
[235,236] 
25 nM [237] 
 
0.05-0.67 µM 
[238] 
30 nM [239] 
10 nM [239] 
29 nM [116,117] 
 
2 nM [240] 
 
 
 
40 nM [76] 
10 nM [75] 
 
low nM [241] 
 
0.5-1 µM [9] 
 
 
22-50 nM [242] 
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 Table 2.  Aptamer selected in vitro (continued) 
targets types Separation methods 
(rounds) 
Kds 3D-structures 
(PDB ID) 
Fibronectin (RGD) 
 
 
GABA receptor 
 
HER-3 ECD 
oligomer 
 
αvβ3 integrin 
 
 
KMP-11 
(leishmania) 
 
MUC1-5TR 
 
nAChR 
(T.Californica) 
 
 
neurotensin receptor 
(NST-1, rat) 
PSMA 
 
TNFR (RANK, 
CD30, NGFR, 
TRAIL-R2) 
P-selectin 
 
L-selectin 
 
 
 
tenascin-C 
 
 
 
 
Enzymes 
APC 
Factor VIIa 
DNA 
 
 
2’-F-Py-RNA 
 
RNA 
 
 
2’-F-Py-RNA 
 
 
DNA 
 
 
DNA 
 
RNA 
 
2’-F-Py-RNA 
 
RNA 
 
2’-F-Py-RNA 
 
RNA 
 
2’-F-Py-RNA 
2’-F-Py-RNA 
 
DNA 
 
2’-NH2-Py-RNA 
 
2’-F-Py-2’-
OCH3-Pu-RNA 
DNA 
 
 
 
RNA 
2’-NH2-Py-RNA 
affinity chroma-
tography (5) + 
microtiter plate (5) 
filtration (11) 
 
filtration (8) + 
EMSA (7) 
 
affinity polystyrene 
beads (7,15, 17) 
 
affinity colloidal 
gold and 
centrifugation (10) 
affinity chroma-
tography (10) 
filtration + EMSA 
(9) 
filtration + EMSA 
(9) 
affinity magnetic 
beads (7) 
affinity magnetic 
beads (6) 
affinity chroma-
tography (7) 
 
affinity chroma-
tography (12) 
affinity chroma-
tography (17) 
affinity chroma-
tography (14) 
microtiter plates (8, 
11) 
cell monolayer (21) 
 
 
 
filtration (7) 
filtration (13) 
N.D. [243] 
 
 
10.5, 86 nM 
[244] 
45 nM (-hrg)  
400 nM (+hrg) 
[245] 
2 nM-4 µM 
[246,247] 
 
N.D. [248]  
 
 
47-58 nM [249] 
 
2-12 nM [250] 
 
0.47, 4.1 nM 
[251] 
0.37-19 nM [252] 
 
2-12 nM [253] 
 
0.11-960 nM 
[254] 
0.1 µM [254] 
0.019-0.039 nM 
[255] 
1.8-5.5 nM [256] 
 
3 nM [257] 
 
5 nM [258] 
 
0.1-1 µM [259] 
 
 
 
0.12 µM [260] 
11-336 nM [261] 
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Table 2.  Aptamer selected in vitro (continued) 
targets types Separation 
methods (rounds) 
Kds PDB IDs 
(3D-structures) 
Factor IXa 
hNE 
 
hnps-PLA2 
 
 
HCV NS3 
 
 
 
 
 
lysozyme 
protein kinase C β 
II 
protein kinase C δ 
 
 
pro-urokinase 
 
ppERK2 and 
ERK2 
 
PTPase (Yersinia) 
Raf-1 RBD 
subtilisin 
 
α-thrombin 
(human)  
 
 
 
 
 
 
thrombin (bovine) 
 
Growth factors 
and cytokines 
angiopoietin-2 
bFGF 
 
HGF 
2’-F-Py-RNA 
valP-2’-NH2-Py-
RNA 
2’-NH2-Py-RNA 
 
 
RNA 
 
 
 
 
 
RNA 
RNA 
 
DNA 
 
 
DNA 
 
RNA 
DNA 
 
RNA 
RNA 
RNA 
 
DNA 
 
 
RNA 
4’-thio-RNA 
2’-deoxy-Pu-2’-
OCH3-Py 
 
RNA 
 
 
 
2’-F-Py-RNA 
RNA 
2’-NH2-Py-RNA 
DNA 
 
filtration (8) 
EMSA (10) 
 
affinity 
chromatography + 
filtration (11) 
filtration (6) 
filtration (10) 
filtration (9) 
filtration (8) 
affinity chroma-
tography (21) 
filtration (12)  
filtration + EMSA 
(14) 
capillary 
electrophoresis 
(9) + EMSA (1) 
affinity chroma-
tography (12) 
filtration (15) 
filtration (1) + 
immunoblot (1) 
filtration (8) 
filtration (9) 
affinity chroma-
tography (8) 
affinity chroma-
tography (5) 
filtration (11) 
filtration (12) 
filtration (10) 
microtiter plate 
(6) 
 
microtiter plate 
(7) 
 
 
filtration (11) 
filtration (10, 13) 
filtration (11) 
?? 
 
0.58 nM [45] 
71-170 nM 
[71,262] 
1.7 nM [263] 
 
 
0.2 µM [264] 
0.65 µM [265] 
10 nM [266] 
20 nM [267] 
0.99 nM [268] 
 
31 nM [130] 
7 nM [269] 
 
122 nM [270] 
 
 
N.D. [271]  
 
1-5, 50nM [5]  
63 nM [272] 
 
18, 28 nM [273] 
0.15-0.36 µM [274] 
2.5 µM [275] 
 
25-200 nM [276] 
 
0.5 nM [277] 
9-155 nM [278] 
4.7 nM [36] 
26-200 nM [31] 
 
 
0.16-0.24 µM [279]  
 
 
 
2.2 nM [280] 
0.1-23 nM [281] 
0.35 nM [282] 
19-25 nM [283] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1HUT, 1HAP, 
1HAO [285] * 
148D [286] 
2IDN [287] 
1QDF, 1QDH 
[288]  
1RDE [289] 
 
 
 
 39 
Table 2.  Aptamer selected in vitro (continued) 
targets types Separation 
methods (rounds) 
Kds PDB IDs 
(3D-structures) 
hTSH 
IL-23 
 
interferon-γ 
 
KGF 
 
NGF 
oncostain M 
 
PDGF 
 
 
TNFα 
VEGF 
 
 
 
 
 
 
 
 
Nucleic acids 
binding proteins 
AMV RT 
B52 (drosophila) 
colicin E3 (E. 
coli) 
DNA polymerase 
β/κ (E. coli) 
  
E2F 
 
EF-Tu  
(T. thermophilus) 
eIF4A (mouse) 
 
 
 
eIF4E (mouse) 
 
eIF4G 
 
2’-NH2-Py-RNA 
2’-deoxy-Pu-2’-
OCH3-Py 
2’-NH2 and/or 
2’F-Py-RNA 
2’-NH2-Py-RNA 
2’F-Py-RNA 
RNA 
2’-F-Py-2’-
OCH3-Pu-RNA 
DNA 
DNA (PEG,3’T, 
2’F, 2’-OCH3) 
2’-NH2-Py-RNA 
RNA 
 
2’-NH2-Py-2’-
OCH3-Pu-RNA 
2’-F-Py-2’-
OCH3-Pu-RNA 
fully 2’-OCH3-
RNA 
 
 
 
RNA 
RNA 
RNA 
 
RNA 
 
 
RNA 
 
RNA 
 
RNA 
 
 
 
RNA 
 
RNA 
 
filtration (9) 
microtiter plate 
(8) 
filtration (17) 
 
filtration (8) 
filtration (8) 
filtration (10) 
microtiter plate 
(12) 
EMSA(12) 
 
 
?? 
filtration (13) 
 
filtration (11) 
 
filtration (12) 
 
microtiter plate 
(10) 
 
 
 
filtration (12) 
filtration (9) 
filtration (12) 
 
filtration + 
microtiter plater 
(7) 
affinity chroma-
tography (13) 
filtration (6) 
 
affinity 
precipitation (12, 
12) or filtration 
(15, 12) 
affinity chroma-
tography (14) 
affinity chroma-
tography (12) 
2.5-100 nM [284] 
8.4-30 nM [31] 
 
1.8-760 nM [29] 
 
400 pM [28] 
0.3-3 pM [28] 
0.1-0.7 µM [290] 
7 nM [291] 
 
0.1 nM [292] 
0.1 nM [44] 
 
?? [293]  
0.19-20 nM [294] 
 
0.14-320 nM [30] 
 
0.049-0.13 nM 
[295] 
1-4 nM [26] 
 
 
 
 
0.5-7.3 nM [296] 
20-50 nM [11,297] 
2-14 nM [298] 
 
0.3-0.5 µM [299] 
 
 
4 nM [300] 
 
4.5-20 nM, 7-19 
nM [301] 
27 nM-8 µM [302] 
 
 
 
11.2 nM [303] 
 
0.1-0.3 µM [304] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1XWU, 1XWP 
[310] 
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Table 2.  Aptamer selected in vitro (continued) 
targets types Separation 
methods (rounds) 
Kds PDB IDs 
(3D-structures) 
FIV RT 
 
g5p (Ff phage) 
HCV RdRp (NS5B) 
 
 
 
HDM2 
 
Hel-N1 
 
HIV-1 integrase 
 
HIV-1 Tat protein 
HIV nucleocapsid 
protein  
 
HIV-1 gag 
polyprotein 
 
 
 
HIV Rev 
 
 
 
HIV RT 
 
 
 
 
HIV RT (RNase H) 
HSV-1 US11 
 
HutP 
IHF (E. coli) 
Ku 
 
L22 (ribosomal) 
 
LXR (rat) 
 
MetJ 
 
MMLV RT  
 
RNA 
 
DNA 
DNA 
 
RNA 
 
RNA 
 
RNA 
 
RNA 
DNA 
RNA 
RNA 
 
 
RNA 
 
 
 
 
RNA 
 
 
 
RNA 
DNA 
 
 
 
DNA 
RNA 
 
RNA 
ds-DNA 
RNA 
 
RNA 
 
DNA 
 
ds-DNA 
RNA 
RNA 
 
filtration (12) + 
EMSA(8) 
EMSA(8) 
surface plasma 
resonance (10)  
affinity chroma-
tography (20) 
affinity chroma-
tography (10) 
immuno-
precipitation (3) 
filtration (18) 
from [311] 
filtration (9-11) 
affinity chroma-
tography (8-10) 
filtration (17) 
filtration (8, 10) 
 
 
 
 
filtration (4) 
filtration (6) 
affinity chroma-
tography (10) 
filtration (9) 
filtration (15) 
capillary 
electrophoresis 
(4) 
filtration (8) 
affinity magnetic 
beads (12) 
filtration (7) 
EMSA (4) 
Filtration + 
EMSA (7) 
affinity chroma-
tography (9) 
affinity chroma-
tography (8) 
EMSA (11,12) 
No available 
filtration (17) 
 
1.9-24 nM [305] 
 
5 µM [306] 
1.3-24 nM [307] 
 
N.D.   [308] 
 
N.D. [309] 
 
N.D. [312] 
 
10-800 nM [313] 
9-160 nM [314] 
0.12 nM [315] 
0.49-2.4 nM [316] 
 
2 nM [317] 
1-50 nM 
(nucleocapsid 
proten); 
3-12nM (matrix 
protein) [318] 
     ?? [319] 
1 nM [320] 
19-36 nM [321] 
 
5 nM [322] 
1-11 nM [323] 
0.1-0.5 nM [119] 
 
 
30 nM [311] 
70-220 nM [324] 
 
57-168 nM [325] 
0.8-97 nM [326] 
0.3-4.5 nM [327] 
 
N.D. [328] 
 
1.1-24 pM [329] 
 
~ 2 nM [330] 
0.2-0.4 nM [331] 
7-23 nM [296] 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Y8D [337] 
1NBK [338] 
 
 
 
 
 
 
 
 
1ULL [339] 
 
484D [340] 
 
1HVU [341] * 
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Table 2.  Aptamer selected in vitro (continued) 
targets types Separation 
methods (rounds) 
Kds PDB IDs 
(3D-structures) 
nucleolin (RBD12) 
(hamster) 
NFATc 
 
NFκB (p502) 
            
           (p652) 
rho (E. coli) 
Rex  
RF-1 (E. coli) 
 
 
RNase H1 
RNAP (E. coli) 
 
RNAP II (yeast) 
S1 protein (E. coli) 
Sel B (E. coli) 
T4 DNA polymerase 
Taq DNA 
polymerase 
TBP (yeast) 
 
 
TCF-1 
 
 
 
TF IIIA (xenopus 
laevis) 
Tra2 (drosophila) 
tRNAIle synthetase 
(E. coli)  
tRNAGln synthetase 
(E. coli)  
TTF1 
 
Tth DNA 
polymerase 
 
 
U1A 
 
 
Wilms tumor 
suppressor (WT1) 
RNA 
 
RNA 
 
RNA 
 
 
RNA 
RNA  
RNA 
 
 
DNA 
DNA 
 
RNA 
RNA 
RNA 
RNA 
DNA 
 
RNA 
 
 
RNA 
 
 
 
RNA 
 
RNA 
DNA 
 
tRNA variants 
 
DNA 
 
DNA 
 
 
 
RNA 
 
 
RNA 
 
magnetic bead  
 
pulldown (9) 
affinity 
precipitation (10) 
filtration (14) 
filtration (12) 
filtration (8) 
filtration (8) 
affinity chroma-
tography + 
filtration (11) 
filtration (9) 
affinity chroma-
tography (11) 
filtration (15) 
filtration (13) 
filtration (4) 
filtration (4) 
filtration (12) 
 
filtration+SPR+ 
EMSA (12) 
filtration (7) 
GST-pull down 
(13) 
affinity chroma-
tography (13) 
EMSA (4) 
 
filtration (10) 
affinity chroma-
tography (7) 
filtration (7) 
 
affinity magnetic 
beads (15) 
filtration (12) 
heterodivalent 
aptamer from 
[346] 
immuno-
precipitation (3) 
filtration (18) 
filtration (10) + 
EMSA(1) 
5-200 nM [332] 
 
30 nM [333] 
 
1.34 nM [334] 
 
11-150 nM [335] 
0.1-10 nM [336] 
25-30 nM [8] 
30 nM [347] 
 
 
10-80 nM [348] 
0.1-6 nM [349] 
 
20 nM [350] 
4 nM [351] 
30 nM [352] 
5-30 nM [91] 
0.04-9 nM [346] 
 
3-10 nM [353] 
 
2 nM [354] 
0.1-0.5 µM [355] 
 
0.1 µM [356]  
 
0.66-11.6 nM [357] 
 
1 µM [358] 
1.5 µM [359] 
 
0.13 nM [360] 
 
3.3-67 nM [361] 
 
0.01-0.3 nM [346] 
2 nM [362] 
 
 
~ 1nM -0.1 µM 
[363] 
4.5-69 nM [130] 
0.7 µM [364,365] 
1IE2 [342] 
 
 
 
1OOA [343] * 
2JWV [344] 
 
 
1EXY [345] 
 
 
 
 
 
 
2B63 [366] * 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1EXD [360] 
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Table 2.  Aptamer selected in vitro (continued) 
targets types Separation methods 
(rounds) 
Kds PDB IDs 
(3D-structures) 
Prion 
rPrPC (hamster) 
            
          (human) 
 
PrPSC fibril (hamster) 
 
Toxins 
abrin toxin 
 
cholera whole toxin 
 
pepocin 
ricin toxin 
 
 
 
 
SEB 
 
 
 
 
Other proteins 
alfalfa mosaic virus 
coat protein 
bacteriophage MS2 
and Qβ coat protein 
 
 
bacteriophage PP7 
coat protein 
bacteriaphage R17 
coat protein 
β-catenin 
CED-9 (C. elegans) 
 
complement C5  
 
cytochrome C and 
hemin 
cytohesin 1 (sec 7 
domain) 
gp120 (HIV-1) 
 
 
RNA 
 
DNA 
 
2’-F-Py-RNA 
 
 
DNA 
 
DNA 
 
RNA 
RNA 
DNA 
 
 
 
DNA 
 
L-DNA 
 
 
 
RNA 
 
RNA 
 
 
 
RNA 
 
RNA 
 
RNA 
RNA 
 
2’-F-Py-2’-
OCH3-Pu-RNA 
DNA 
 
RNA 
 
2’-F-Py-RNA 
 
 
affinity chroma-
tography (11) 
affinity chroma-
tography (6) 
centrifugation (7) 
 
 
affinity chroma-
tography (8) 
affinity magnetic 
beads (5) 
filtration (8) 
filtration (9) 
affinity chroma-
tography (9) 
capillary 
electrophoresis (4) 
affinity magnetic 
beads (5) 
affinity chroma-
tography (12) 
 
 
filtration (6) 
filtration (7) 
filtration (12) 
 
 
 
filtration (4,12) 
 
filtration (11) 
 
GST pull down (8) 
filtration (6) + 
EMSA(3) 
filtration (12, +8) 
 
affinity chroma-
tography (6) 
affinity chroma-
tography (6) 
surface plasma 
resonance (5) 
 
 
N.D.[367] 
 
>10 nM [368] 
 
26.9 nM [369] 
 
 
28-130 nM [370] 
 
N.D. [371] 
 
20-30 nM [372] 
7.3 nM [373] 
0.1-0.5 µM [374]  
 
0.06-0.2 µM 
[374] 
N.D. [371] 
 
0.42 µM [375] 
 
 
 
0.3- >6 µM [376] 
0.2-0.5 µM [377] 
N.D. [378] 
 
 
 
0.7-25 nM [379] 
 
5 nM [380] 
 
5 nM [381] 
4, 16 nM [7] 
 
2-5 nM [382] 
 
0.3-5 µM [87] 
 
5 nM [383] 
 
5-20 nM [388-
390] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1XOK [384] * 
 
1U1Y [385] * 
6MSF [386] * 
5MSF, 7MSF 
[387] * 
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Table 2.  Aptamer selected in vitro (continued) 
targets types Separation methods 
(rounds) 
Kds PDB IDs 
(3D-structures) 
hemagglutinin A 
 
 
 
hemagglutinin B 
HSF (yeast) 
 
MCP-1 (mouse) 
 
streptavidin 
 
 
 
 
 
 
Tax 
Wheat germ 
agglutinin 
 
Nucleic acids 
5S RNA (E. coli) 
 
16S RNA A site 
 
ds-DNA (16bp) 
 
ds-DNA (22bp) 
 
hairpin (DNA, 
RNA) 
HCV IRES domain 
II 
HCV IRES domain 
IIa 
 
HCV IRES domain 
IIId 
HCV IRES domain 
IV 
 
HCV SL1 (RNA 
hairpin) 
RNA 
 
DNA 
 
RNA 
RNA 
 
2’-F-Py-RNA 
 
2’-F-Py-RNA 
 
RNA 
 
 
DNA 
 
RNA 
2’-F-Py-RNA 
 
 
 
RNA 
 
RNA 
 
RNA 
 
RNA 
 
2’-OCH3-Py-
RNA 
RNA 
 
RNA 
 
 
RNA 
 
RNA 
 
 
RNA 
 
surface plasma 
resonance (5) 
Ni-NTA resin 
affinity capture (3) 
filtration (9) 
filtration + EMSA 
(14) 
affinity magnetic 
beads (6) 
affinity magnetic 
beads (9) 
affinity chroma-
tography (6) + 
EMSA (3) 
affinity magnetic 
beads (13) 
filtration (6) 
affinity chroma-
tography (??) 
 
 
affinity chroma-
tography (12) 
affinity chroma-
tography (15) 
affinity chroma-
tography (5) 
affinity chroma-
tography (16, 26) 
SacI digestion, no 
separation (4) 
affinity magnetic 
beads (4) 
streptavidin 
magnetic bead 
capture (6) 
affinity magnetic 
beads (4) 
streptavidin 
magnetic bead 
capture (10) 
streptavidin 
magnetic bead 
capture (8) 
0.1 nM [391] 
 
N.D. [392] 
 
45 nM [393] 
20-80 nM [394] 
 
0.18-0.37 nM 
[395] 
7 nM [396] 
 
70-200 nM [397] 
 
 
57-85 nM [398] 
 
70 nM [399] 
1-20 nM [400] 
 
 
 
3 µM [401] 
 
1.24-2.9 µM 
[402]  
N.D. [403] 
 
0.18-63 µM [404] 
 
N.D. [405,406] 
 
28nM -33 µM 
[407] 
35 nM [408] 
 
 
4.4-130 nM [409] 
 
70 nM, 1 µM 
[410]  
 
20 nM [410] 
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Table 2.  Aptamer selected in vitro (continued) 
targets types Separation 
methods (rounds) 
Kds PD B IDs 
(3D-structures) 
HIV DIS (RNA hairpin) 
 
 
HIV TAR RNA element 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tRNAPhe (yeast) 
 
tyrS box antiterminator 
(B. subtilis) 
 
 
Complex targets 
RNAP, gag polyprotein, 
nACHR on membrane 
and U251 glioblastoma 
cells expressing 
tenascin-C as shown in 
Protein section  
 
tartrate : synthetic 
receptor complex 
anthrax spores 
differentiated PC12 cells 
PC12 MEN2A and 
MEN2B cells expressing 
RET 
human influenza A 
virus/Panama/2007/1999 
(H3N2) (HA) 
Jurkat T cell leukemia 
 
RNA 
 
 
DNA 
 
 
 
 
 
 
 
 
RNA 
 
 
 
 
 
 
RNA 
 
tRNA 
 
 
 
 
 
 
 
 
 
 
 
RNA 
 
DNA 
DNA 
2’F-Py-RNA 
 
 
RNA 
 
 
2’F-Py-RNA 
 
EMSA(5-7) 
 
 
streptavidin 
magnetic bead 
capture (15) 
?? 
streptavidin 
magnetic bead 
capture (9,15) 
affinity magnetic 
beads (9) 
streptavidin 
magnetic bead 
capture (9)+ 
EMSA (1) 
streptavidin 
magnetic bead 
capture (8,9) 
affinity chroma-
tography (10) 
streptavidin 
magnetic bead 
capture (7) 
 
 
 
 
 
 
 
 
 
affinity chroma-
tography (13) 
centrifuge (4) 
centrifuge (6) 
centrifuge (15) 
 
 
filtration (8) + 
microtiter plate 
(2) 
centrifugation 
(16) 
 
1.3-6.8 nM [411] 
 
 
20-120 nM [412] 
 
 
50 nM [413] 
0.3-1 µM, 20 nM 
[414] 
 
30-500 nM [414] 
 
30 nM [415] 
 
 
 
30-800 nM [414] 
 
 
20 nM [416] 
 
0.3, 7 µM [417] 
 
 
 
 
 
 
 
 
 
 
 
0.21 mM [418] 
 
<10 spores [419] 
N.D. [420] 
30-70 nM [421] 
 
 
0.188 nM [422] 
 
 
N.D. [423] 
 
2B8R, 2B8S 
[424] *  
1BAU [425] 
 
 
 
 
 
 
 
 
 
2OOM, 2PN9 
[426] 
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Table 2.  Aptamer selected in vitro (continued) 
targets types Separation 
methods 
(rounds) 
Kds PD B IDs 
(3D-structures) 
Leukemia cells 
CCRF-CEM 
M. tuberculosis 
 
Prohead (DNA-
gp3) 
 
Qβ replicase 
 
Ramos cells 
(IGHM) 
Rouse sarcoma 
virus 
Red blood cell 
ghost (human 
CD71) 
30S ribsome ± S1 
ScVL-1 virus 
Trypanosome 
cruzi 
   cell surface 
receptor 
   flagellar pocket 
protein 
  VSG protein 
 
 
 
YPEN-1 cells (rat 
pigpen) 
DNA 
 
DNA 
 
RNA 
 
 
RNA 
 
DNA 
 
(2’F-Py)-RNA 
 
DNA 
 
 
RNA 
RNA 
 
 
2’F-Py-RNA 
 
RNA 
 
2’F-Py-RNA 
 
 
 
DNA 
 
centrifugation 
(16) 
centrifugation 
(10) 
sucrose gradient 
centrifugation 
(7) 
filtration (12)  
filtration (13)  
centrifugation 
(20) 
filtration (12)  
 
filtration (25) 
 
 
filtration (11-13) 
EMSA (8) 
 
 
centrifugation 
(8) 
centrifugation 
(12) 
VSG filtration + 
live parasite 
centrifugation 
(9) 
centrifugation 
(8) 
 
0.8-227 nM 
[427] 
0.4, 5.3 µM 
[428]  
N.D. [429] 
 
 
1 nM [430] 
10 nM [430] 
0.76-207 nM 
[431,432] 
<< 0.1 µM [433] 
 
1 nM [434] 
 
 
4-7 nM [351] 
0.2-3 nM [435] 
 
 
40-400 nM 
[436] 
60 nM [437] 
 
0.16-2 nM [438] 
 
 
 
N.D. [439] 
 
 
 
 
PDB ID: protein data bank identity.  If a PDB ID is followed by a *, it is a crystal structure. 
Otherwise the PDB ID is a solution structure determined by nuclear magnetic resonance. 
Matrix for affinity chromatography: agrose or sepharose unless indicated. 
Matrix for filtration: nitrocellulose membrane 
AChR: human acetylcholine receptor,  AMV: avian myeloblastosis virus  
APC: human activated protein C, ARM: arginine-rich motif, bFGF: basic fibroblast growth factor,     
α-CGRP:  rat neuropeptide calcitonin gene-related peptide, DIS: dimerization initiation site, 
eIF: eukaryotic initiation factors, EMSA: electrophoretic mobility shift assay             
FMN:  flavin mononucleotide,    FAD: flavin adenine dinucleotide 
FIV: feline immunodeficiency virus,  GnRH: Gonadotropin-releasing hormone 
HCV:  hepatitis C virus,  HGF: hepatocyte growth factor, HIV:huamn immunodeficiency virus 
hNE: Human neutrophil elastase,  hnps-PLA2: human nonpancreatic secretory phospholipase A2 
HSF: heat shock factor,  HSV-1: Herpes simplex virus-1 
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hTSH: human thyroid stimulating hormone    
HutP: histidine utilizing protein,   IGHM: Immunoglobin Heavy mu chain 
IRES: internal ribosome entry site,  IHF: integration host factor,   Ig: immunoglobulin         
KGF: keratinocyte growth factor,   KMP-11: Kinetoplastid membrane protein-11    
LXR: Liver X receptors,   MCP-1: Monocyte chemoattractant protein-1 
MMLV: moloney murine leukemia virus,      mAb: monoclonal antibody                       
 nAChR: nicotinic acetylcholine receptor,  NAD: niacinamide adenine dinucleotide 
NFATc: nuclear factor of activated T cells, NGF: nerve growth factor                        
NMM: N-mehtylmesoporphyrin IX,    NMN: niacinamide mononucleotide        
N/OFQ: Neuropeptide nociceptin/orphanin FQ      
PDGF: platelet-derived growth factor,    PSMA: prostate-specific membrane antigen     
PTPase: Protein tyrosine phosphatase,   RANK: receptor activator of NF-Kb,      
RdRp: RNA-depedent RNA polymerase,   RET: receptor tyrosine kinase,    
RF-1: release factor 1, RNAP: RNA polymerase,   RT: reverse transcriptase                 
SAM: S-adenosyl methionine    SAH: S-adenosyl homocysteine     
ScV: Saccharomyces cerevisiae double-stranded RNA virus, SEB: staphylococcal enterotoxin B   
sLex: sialyl Lewis X,   SPR: surface plasma resonance 
TBP: TATA-binding protein,  TF: transcription factor     
THM: 5-N-(6-aminohexyl)carbamoylmethy-2’-deoxyuridine, TTF1: thyroid transcription factor 1       
ValP: valyl phosphonate moiety, VEGF: vascular endothelial growth factor 
VSG: variant surface glycoprotein  
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Table 3.  Allosteric aptamers 
 
effector allosteric module allosteric effect reference 
hemin cytc aptamer                           Kd decreased by 15x [87] 
tetramethylrosamine activation domain            activate transcription by 10x         [83] 
ATP, theophylline, or 
flavine 
mononucleotide   
malachite green aptamer       Kd decrease by 3-25x              [84] 
R06/DIS                            DIS/R06 aptamer               Kd decreased by 10x                 [81]                
hybridization oligo ATP aptamer                        activate ATP aptamer                 [88] 
hybridization oligo            binary malachite green 
aptamer                       
activate malachite green 
aptamer                                            
[85] 
hydridization oligo      binary Hoechst 7e 
aptamer    
activate Hoechst 7e aptamer         [86] 
glycine glycine riboswitch                         cooperativity [89] 
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Figure 1.   Modifications of nucleosides and phosphodiester backbone in aptamers 
R1= H, OH, F, OCH3 and NH2;   R2= hydrophobic, hydrophilic and charged groups 
R3= O, S;    R4= O, S 
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Figure 2. SELEX pool, primer and procedure 
The SELEX pool contains a random region (30-60 nt long) flanked by two fixed regions. The fixed 
regions were used for PCR amplification with primer 1 and 2. A T7 promoter is required for in vitro 
transcription for RNA-SELEX but not for DNA-SELEX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N(30-60) ss-DNA 
random pool 
T7 
promoter 
Primer 1 
Primer 2 
A 
RT-PCR 
ss-DNA random pool (1012-1015) 
Klenow extension/ 
PCR 
ds-DNA 
ss-DNA/RNA 
strand separation/ 
in vitro transcription 
incubation 
target ss-DNA/RNA 
        + 
      target 
Free 
ss-DNA/RNA 
target-binders 
separation 
 cloning, sequencing & 
 characterization after 
 2-26 rounds of selection 
B 
 50 
 
 
Figure 3.  The distribution of SELEX rounds needed to obtain an aptamer summarized from Table 2 
(total 312 SELEX experiments) 
The average round number for a SELEX is 10 and the mode is 12. 
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ABSTRACT
Living organisms have evolved protection mechanisms against many reactive small molecules 
that are undesirable and even lethal.  These mechanisms range from catalytic inactivation to ejection 
through membrane efflux pumps.  We have examined another means of controlling the reactivity of 
small molecules, which is steric protection by a nucleic acid aptamer.  We used the malachite green 
aptamer (MGA) as a model system and have shown that the MGA can control the rate of bleaching of 
its target molecule, malachite green (MG).  Bleaching occurs by a pH-dependent second order 
reaction in which an OH- attacks the central (C1) carbon of MG to form a carbinol base.  While 
bound to the MGA, MG bleaching is prevented.  The MGA effect is reversed by an antisense 
oligonucleotide complementary to the MGA binding pocket.  Computational cavity analysis of the 
NMR structure of the MGA-MG complex predicted that the OH- is sterically excluded from the C1 of 
MG in the complex. These predictions were confirmed experimentally using variants of the MGA 
with changes in the MG binding pocket. This work shows that a nucleic acid aptamer can utilize 
steric hindrance to control access to specific chemical groups on small molecules. This finding has 
potential for in vivo applications such as in controlling metabolic reactions and protein modifications 
by small reactants. 
INTRODUCTION 
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Aptamers are short single-stranded nucleic acids that can bind to their targets with high 
specificity and high affinity and can be selected in vitro to recognize a large range of types and sizes 
of molecular targets (1).  The related ribozymes have the additional ability to perform chemical 
catalysis.  However, the distinction between aptamers and ribozyme is blurred when it comes to 
catalysis.  Although aptamers are selected for their binding abilities, some perform catalytic functions.  
Several catalytic aptamers have been isolated by selecting for their ability to bind a stable transition 
state analog.  One example is an RNA aptamer that promotes isomerization of its target molecule, a 
bridged biphenyl, with a Kcat/Km of 8.7 x 10-4 M-1S-1 (2).  DNA and RNA aptamers selected against 
N-methylmesoporphyrin (NMMP), a stable transition state analog of porphyrin metalation, can insert 
Cu(II) into mesoporphyrin IX with Kcat/Km’s of 0.13 M-1S-1 and 2100 M-1S-1 respectively (3,4).  The 
DNA aptamer selected for NMMP also binds hemin and the hemin-DNA aptamer complex has 
peroxidase activity with Kcat/Km of 278 M-1S-1 (5).   
Even when not selected against a transition state analog, the structures of some aptamer targets 
can be distorted when bound by the aptamer, which may lower the energy barrier to chemical 
conversion.   For example, a DNA aptamer selected to bind sulforhodamine B catalyzes the oxidation 
of dihydrotetramethylrosamine to tetramethylrosamine, albeit at a very slow rate (6).  Another 
example is the malachite green aptamer (MGA), which enhances the rate of hydrolysis of a malachite 
green acetate ester by 1000-fold (7). 
The MGA binds its target, malachite green (MG), with a reasonably high affinity (KD ~1 µM) and 
concurrently distorts the MG structure to flatten it.  Binding by the MGA results in a large increase in 
fluorescence emission by MG (8).   
The central carbon of MG is susceptible to attack by a base such as OH-, which results in the 
formation of a colorless form (MG-OH).  We show here that, whereas MG readily reacts with OH- in 
solution the presence of stoichiometric proportions of the MGA inhibits the formation of MG-OH.  
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Inhibition of this reaction by the MGA requires structural integrity of the MG-binding pocket of the 
MGA because inhibition is reversed by an oligonucleotide complementary to the binding pocket.   
Computational analysis of the NMR structure of the MGA-MG complex showed no possible 
route for an OH- of a minimum possible size to reach the reactive central carbon of MG.  The 
computational analysis was confirmed by mutational analysis of the MGA and structural probing of 
the MGA variants.   
These studies show that an aptamer can fold to fit around its target so perfectly that even a small 
molecule the size of a hydroxyl group cannot penetrate the complex.  This observation suggests that 
nucleic acids could play a role in vivo to protect sensitive metabolites or proteins from modification 
by small reactive molecules. 
EXPERIMENTAL PROCEDURES 
Chemicals and Oligonucleotides- Malachite green oxalate (MG) was purchased from Sigma.  MG 
carbinol base (MG-OH) was prepared as follows: A 90 ml solution of 17 mg/ml MG in 0.5 M HEPES, 
pH 7.4 was left at 23 ºC for 24 h.  The precipitated product was centrifuged at 1500 g for 10 min. The 
pellet was collected then dried at 74 ºC for 6 h. All pH’s reported here were measured at room 
temperature (~23 ºC) 
Oligonucleotides were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA) or by 
the DNA Synthesis and Sequencing Facility at Iowa State University as listed here.  MGA (9): 
GGAUCCCGACUGGCGAGAGCCAGGUAACGAAUGGAUCC,  MGA (U25C): GGAUCCCGA-
CUGGCGAGAGCCAGGCAACGAAUGGAUCC,  MGA(A31C): GGAUCCCGACUGGCGAGA-
GCCAGGUAACGACUGGAUCC,  MGA(G8C, G24C, G29C): GGAUCCCCACUGGCGAGAGC-
CAGCUAACCAAUGGAUCC, 1AS: GATCCATTCGTTACCTGGC and Shuffled AS: TCTCTAG-
AGTCTCTGCACG.   
                                                 
1
 AS: antisense oligonucleotide targets the region of MGA from G19 to C37 
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In addition to chemical synthesis, in vitro transcription by T7 RNA polymerase was also used to 
generate a  100 nt random RNA whose sequence was GGGAGACAAGAAUAAACGCUCAA(N53)-
UUCGACAGGAGGCUCACAACAGGC 
Mass Spectrometry- Electrospray ionization of 1 mM MG in ddH2O was performed with a Finnigan 
TSQ700 triple quadrupole mass spectrometer (Finnigan MAT, San Jose, CA) fitted with a Finnigan 
ESI interface.  The sample was introduced into the electrospray interface through an untreated fused-
silica capillary with a 50 µm i.d. and 190 µm o.d.  A mixture of 75 :g/ml horse skeletal muscle 
myoglobin and 12 :g/ml Met-Arg-Phe-Ala (MRFA) tetrapeptide in a 50:50 methanol:water solution 
was used for tuning and routine calibration of the instrument.  The tuning mixture in a polypropylene 
vial was infused into the mass spectrometer at a rate of 3 :l/min on a Harvard Apparatus (model 22, 
South Natick, MA) syringe pump.   
Electron impact ionization of MG-OH was performed on a TSQ700 triple quadrupole mass 
spectrometer (Finnigan MAT, San Jose, CA) fitted with a Finnigan EI/CI ion source. The sample was 
introduced into the mass spectrometer using the solids probe, which was heated gradually from 100 to 
400 degrees.  The instrument was used as a single quadrupole and scanned from 35 to 650 Daltons. 
NMR Spectrometry- Solid state 13C-NMR spectra of MG and MG-OH were recorded at room 
temperature at 150 MHz by a Bruker AV-600 with CPTOSS as the pulse program. 
1H-NMR spectra were acquired of samples with 50 µM MGA ± 100 µM MG; 50 µM 
MGA(A31C) ± 100 µM MG;  50 µM MGA(U25C) ± 200 µM MG; 50 µM MGA(G8C-G24C-G29C) 
± 500 µM MG and 100 µM MG in 10 mM KH2PO4, 5 mM MgCl2, 10 mM KCl, pH 5.8, 5% D2O / 
95% H2O.  Spectra were collected using a Bruker Avance 700 spectrometers equipped with a 5 mm 
HCN-Z gradient cryoprobe.  All 1D 1H-NMR spectra were acquired using a WATERGATE pulse 
sequence with water flipback (Bruker sequence p3919fpgp) to minimize solvent saturation transfer.  
Spectra were averages of 512 transients.  Spectral width was 18182 Hz (25 ppm).     
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Affinities of MGA Variants for MG- The binding of the MGA variants to MG causes the λmax of MG 
absorption to shift from 618 nm to between 629-632 nm depending on the variant (9). The binding 
also enhances MG fluorescence (8).  Based on these properties, the affinities of the MGA variants 
were determined by UV-Visible spectroscopy either using a Biowave S2100 Diode Array Spectro-
photometer (WPA) or a ND-1000 Spectrophotometer (NanoDrop) or by a fluorescence spectrophoto-
meter (Cary Eclipse, Variant, Palo Alto, CA).  The E coli tRNA (Roche, Indianapolis, IN) and AS 
were used as controls for the effects of RNAs that interact with MG nonspecifically.  
The UV-visible spectra were obtained of duplicated samples of MG and each MGA and its 
variants with at least 6 different concentrations of each MGA and its variants.  The concentrations of 
the MGA and variants were adjusted to ensure saturation of MG in each case.  The λmax for each scan 
was recorded and plotted against the concentration of the appropriate MGA variant or control RNAs, 
AS or tRNA.  The plots were fitted to λ= λ0 +∆λ[M]/(KD+[M]) using a nonlinear regression function 
in the Costat program (CoHort Software, CA), where λ is the maximal absorption wavelength of MG 
in the presence of different concentrations of the MGA variant, AS or tRNA, λ0 is the maximal 
absorption wavelength of free MG, ∆λ is the difference of maximal absorption wavelengths between 
free MG and MG saturated with each alternate RNA, KD is the dissociation constant and [M] is the 
concentration of the RNA.  
To obtain KDs of the MGA and its variants, and MG, the fluorescence emission spectra for MG 
were determined in 100 mM Tris, 100 mM KCl, 5 mM MgCl2, pH 9.0 and in the presence of each of 
11 different concentrations of the MGA variants. The samples were excited at 630 nm and the 
emission spectra were recorded from 640-700 nm with 650 nm as the maximal excitation wavelength.  
The data were fit to F650/Fmax=[M]/(KD+[M]) using the Costat program (CoHort Software, CA) where 
F650 is the fluorescence intensity at 650 nm of samples, Fmax is the F650 when MG is completely 
saturated, [M] is the concentrations of the MGA variants and KD is the dissociation constant for MG 
and the MGA variants. 
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Kinetics of MG-OH formation- The UV-visible spectra of MG with or without each MGA variant, AS 
or shuffled AS were determined by using either a Biowave S2100 Diode Array Spectrophotometer 
(WPA) or a ND-1000 Spectrophotometer (NanoDrop).  Three independent experiments were done of 
each of the described conditions.  The rates of production of MG-OH were monitored for up to 46 h 
by recording A(λmax).  The λmax ranged from 618 nm to 632 nm depending on the concentration and 
the MGA variants.   Then A(λmax) was plotted against time and fitted by a nonlinear regression 
function in Costat to the equation, A=A0/(1+ktC0), in which A0 is the A(λmax) at t=0, A is the A(λmax) 
at each time point, k is the reaction rate, t is the time, and C0 is the initial concentration of MG.  The 
half life of MG-OH formation was calculated as t1/2= 1/kC0. 
Cavity Analysis of Free MG and the MG-MGA Complex- Analysis of the NMR structure of the MGA 
(1q8n.pdb) by LSQMAN (10) indicates that the central chain is E and the average RMSD between 
chains = 0.709 Å (using  C4*  P  C1*  C2*  C3*  O2*  O3*  O4* atoms to align chains).  Chain N has 
the highest deviation from chain E with the RMSD between chains = 0.870 Å, thus both chains E and 
N were analyzed for cavities.  Because no important difference was found between these two chains, 
only the results for chain E are reported.  Cavity analysis of the MGA binding pockets and free MG 
were performed using SURFNET (11).  A radius of 1.32 Å was chosen as the smallest possible radius 
for a hydroxide ion (12) while the maximum radius was set to 3 Å.  The figure was created with 
SPDBV (13) and POV-Ray (Persistence of Vision Raytracer Pty. Ltd.). 
Structure probing of the MGA variants- RNase I footprinting was used to study the structural 
alterations of the binding pocket of the MGA due to mutations (A31C; U25C and G8C-G24C- G29C).  
RNase I can cleave RNA in single-stranded but not in double-stranded regions. The MGA variants, 
including MGA, MGA(A31C), MGA(U25C) and MGA(G8C-G24C-G29C), were first labeled with γ-
32P-ATP (MP Biomedicals, Solon, OH) by T4 polynucleotide kinase (Promega, Madison, WI) at their 
5’-ends.  Twenty µl labeling reaction mixtures containing 5 µM RNA, 1.5 µCi/µl  γ-32P-ATP, 1 U/µl 
T4 polynucleotide kinase, 70 mM Tris-HCl (pH 7.6), 10 mM MgCl2 and 5 mM DTT were incubated 
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for 1.5 h at 37ºC.  The labeled MGA variants were purified by electrophoresis through 10% 
polyacrylamide gels in the presence of 7 M urea, then incubated with RNase I in the presence or 
absence of MG to probe the RNA structure.  Reaction mixtures of 10 µl containing 0.125 µM 
32P-labeled RNA, 0.5 x 10-4 U/µl RNase I, 100 mM KCl, 5 mM MgCl2, 10 mM HEPES, pH 7.4, were 
incubated at 23ºC for 10 min in the absence or presence of MG.  Partial alkaline hydrolysis of the 
labeled RNAs was done in 50 µM Na2CO3, pH 9.0 at 95ºC for 5 min.  RNase T1 digestion of the 
labeled RNAs was carried out in 10 µl reaction containing 0.5-1 U/ µl RNase T1, 5 M urea, 350 mM 
sodium citrate, 0.7 mM EDTA, pH 5.0, at 50ºC for 4 min.  The RNA hydrolysis and cleavage 
reactions were stopped by bringing the reaction mixtures to 47.5% formamide, 0.05% bromophenol 
blue, and 0.05% xylene cyanol FF.  The samples were resolved by electrophoresis through 10% 
polyacrylamide gels in the presence of 7 M urea.  The radioactivity was recorded from the dried gels 
using a phosphor screen and imaged with a Typhoon 8600 Variable Model Imager (GE Healthcare). 
RESULTS 
Conversion of MG to MG-OH.  MG loses color by a mechanism that is pH-dependent and follows 
second order kinetics (Fig. 1).  The chemical form of the decolorized MG was characterized by mass 
spectrometry and NMR spectroscopy.  The mass spectrum of MG had an expected peak at 329 m/z 
and the MG-OH spectrum contained an additional 346 m/z peak as  expected of hydroxylated MG 
(Fig 2A).  In the NMR spectra of  MG and MG-OH, the C1 peak was shifted from the 175.91 ppm in 
MG to 82.59 ppm in MG-OH.  The C11 of MG at 165.115 ppm was shifted to 149.08 ppm in MG-
OH and the double peaks of N(CH3)2 and +N(CH3)2 (40.91 ppm and 39.95 ppm) in MG became a 
single peak of N(CH3)2 (40.39 ppm) in MG-OH (Fig 2B).  These results are consistent with the 
conclusion that MG-OH is hydroxylated at C1 and that the decolorized MG is in the form of a 
carbinol base (Fig 2C).   
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The Malachite Green Aptamer Binding Pocket Protects MG from Conversion to MG-OH.  With 
the route of OH- attack on MG being limited by the equatorial phenyl rings, anion attack can only 
proceed by polar routes (Fig. 4A). Because the MG binding pocket is formed by bases that lie above 
and below MG, it seemed possible that the MGA might further protect MG from conversion to MG-
OH by sterically hindering the entrance of OH- by the polar routes.  We tested this hypothesis by 
incubating MG with various concentrations of the MGA and found that the MGA inhibited MG-OH 
formation with a dependence on MGA concentration (Fig. 3A, B).  At 6 :M MGA, a concentration 
that is about 6 times the KD for the MGA-MG interaction, the rate of MG conversion was almost zero.  
By contrast, 10 :M 100 nt random RNA had no effect on the rate of MG to MG-OH conversion (Fig. 
3 A, B).   
If the MGA protects the MG in its binding pocket from hydroxyl attack by steric hindrance, then 
a distortion of the binding pocket should result in loss of its effect on MG bleaching.  This result was 
observed in experiments in which the reaction mixture included an oligonucleotide (AS) with a 
sequence complementary to bases 19 to 37 in the MGA sequence, which constitute one half of the 
MG-binding pocket.  Addition of AS (but not its shuffled sequence version) to a mixture of MGA and 
MG reversed the protection by MGA of MG bleaching with ~30% reversal at 2AS/MGA and almost 
complete reversal at 10AS/MGA. ( Fig. 3 C,D).  
Cavity Analysis of the MGA-MG Complex Shows No Gap for OH- Entry.  Our results suggested 
that the ability of the MGA to inhibit hydroxylation of MG is due to the configuration of the MG-
MGA complex that sterically hinders the OH- access to the C1 of the MG located in the binding 
pocket.  Due to the very small size of OH-, this condition requires a very snug fit of MG in the 
binding pocket of the MGA.  Cavity analysis was used to test the hypothesis.  Whereas the C1 of free 
MG is accessible from the poles (Fig. 4B,C), cavity analysis of MG sitting in the MGA binding 
pocket showed that MG was protected from polar attack by G8-C28 and C7-G29-G24-A31, which 
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does not allow a gap of the minimum size of an OH- group to reach C1 from the solvent surface of the 
MGA (Fig. 4D).  
Mutations in the MGA Binding Pocket Compromise the Ability of the MGA to Protect MG 
Conversion To MG-OH.  To test the hypothesis that steric hindrance in the MGA binding pocket 
prevents hydroxyl attack, variants of the MGA with mutations around the binding pocket were made 
including MGA(A31C), MGA(U25C) and MGA(G8C-G24C-G29C) based on cavity analysis and 
their locations in the binding pockets. 
Based on the measured KD value of each MGA variant (Table I), a concentration of each MGA 
variant equivalent to 10-15 times of its KD was chosen at which MG would be saturated by the RNA.  
Under these conditions the rate of MG bleaching was negligible in the presence of the MGA, 
intermediate for the MGA(A31C) and MGA(U25C) and large for the MGA(G8C-G24C-G29C) and 
tRNA (Fig. 5, Table I).  
Structural Probing Shows Structurally Altered MG Binding Pockets in the MGA Variants. To 
determine whether there is structural change in the binding pocket of the MGA variants, RNase I 
footprinting was performed of the MGA variants in the presence of various concentrations of MG. 
The data showed that MG binding to the MGA protected the binding pocket and destabilized the 
tetraloop (Fig. 6A).  The MGA(A31C showed a similar cleavage pattern to the MGA except there 
was increased cleavage if U32 and C31 (Fig. 6B). In the MGA(U25C), exactly the same cleavage 
pattern was observed as for the MGA (Fig. 6C).  By contrast, all regions of the MGA(G8C-G24C- 
G29C) were protected by MG except for C29 (Fig. 6D). 
1H-NMR spectra showed proper folding of the MGA variants and binding of MG.  To determine 
whether the MGA variants still folded properly and bound MG, 1H-NMR spectra were acquired for 
the MGA variants in the presence and absence of MG.  The spectrum of MG alone was also acquired 
as a control, which showed sharp peaks in 6.8-6.9, 7.25-7.35, 7.45-7.50 and 7.60-7.65 ppm regions 
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(Fig. 7).  These peaks were similarly broadened in the presence of the MGA and all MGA variants, 
indicating a similar binding mode of MG to the MGA variants as for MGA. 
The number of peaks from the MGA variants in the 10-15 ppm region, which reference the base-
pairings in the MGA structure, was 9-10 for all MGA variants in the absence of MG.  In the presence 
of MG, there were 13-14 peaks for MGA, MGA(A31C) and MGA(U25C) and 7 for MGA(G8C-
G24C-G29C).  These results are consistent with the conclusion that the MGA variants, fold properly 
into a structure similar to MGA and that can bind to MG.  
In the presence of MG the spectra of the MGA and MGA variants differed, especially in the 
region of 6.5 – 9.0 ppm region where the proton exchange rates are not affected by pH, salt and other 
buffer conditions. We interpret these results to show that MGA and its variants fold into similar but 
nonidentical structures that can all bind MG.   
DISCUSSION  
MG is held tightly in a pocket of the MGA that is created by a bulge between two short stems 
resulting in a structurally modified MG (14).  Our results show that this interaction is so snug that it 
prevents access of a molecule as small as a hydroxyl ion to the central carbon of MG. 
We characterized the conversion of MG to MG-OH by UV-Visible spectrophotometry, mass 
spectrometry and NMR spectrometry.  The results of these studies suggest that the most likely form 
of MG-OH contains a carbinol group at position C1.  MG bleaching is also pH-dependent and second 
order.  Thus, it appears that the C1 of MG is attacked by an OH- to form MG-OH.  This reaction 
product was also predicted in a study of MG bleaching in alkaline solution (15).    
The MGA inhibited MG hydroxylation in a concentration-dependent manner with a stoichiometry 
that suggested steric hindrance rather than a catalytic mechanism.  The specificity of the effect of the 
MGA on MG was demonstrated by the observation that high concentrations of a random RNA had no 
effect on MG hydroxylation (Fig. 3A,B).  The ability of an oligonucleotide (AS), complementary to 
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the binding pocket of the MGA, to reverse the effect of the MGA on MG bleaching (Fig 3C,D) 
showed that the MGA must bind MG to prevent hydroxylation.  Similar reversibility has been shown 
in other systems in which the activities of aptamers are regulated (16,17). 
Several mechanisms were considered for how the MGA could protect MG from OH- attack.  First, 
the MGA could alter the charge on C1 to make it less susceptible to OH- attack.  The MGA has been 
shown to change the charge distribution across MG, but physical chemical calculations showed that 
C1 is more positively charged in the MG-MGA complex compared to in solution (14).   A more 
positively charged MG would be more susceptible to OH- attack rather than less as we have observed.  
By this analysis, we excluded charge distribution as the mechanism by which the MGA prevents MG 
hydroxylation.   
To test the hypothesis, that the MGA might protect MG from hydroxylation by steric hindrance. 
we first carried out a computational structural analysis of the MG-MGA complex (18) and free MG.  
The results of these studies showed that the rings A, B and C of MG could protect MG from OH- 
attack from the sides but allowed OH- attack from the poles at the top and bottom.  Cavity analysis of 
the MG-MGA complex showed that the MGA binding pocket further protected MG from OH- attack 
from the poles.  Thus, it appeared that the mechanism by which the MGA protects MG from 
hydroxylation was by steric hindrance (Fig. 4). 
To confirm the prediction made by cavity analysis, we tested the effects of several MGA variants 
on MG hydroxylation. Mutations in the MGA binding pocket were chosen that might alter the pocket 
sufficiently to allow OH- access to C1 of MG.  The A31C mutation changes part of the base 
quadruple (C7-G29-G24-A31) that sits above MG and the U25C mutation changes the U-turn 
connecting the top and bottom portions of the binding pocket.  The G8C-G24C-G29C mutation 
changes the G8-C28 and C7-G29 base pairs between which MG intercalates and was expected to 
completely alter the binding pocket in the region where MG intercalates between the G8-C28 and C7-
G29 base pairs.   
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One-dimensional NMR spectra of these RNAs and the footprinting results suggested that the 
pockets remained intact albeit alterations in structure. The 1H-NMR spectra of the MGA and all its 
variants were consistent with their proper folding.  In the absence of MG these RNAs showed 9-10 
peaks in the 10-15 ppm region, which corresponds to ≥ 9-10 base pairings in the MGA variants.  This 
is consistent with the reported secondary structure of the MGA (18).  On binding MG, the number of 
peaks in the 10-15 ppm region of the 1H-NMR spectra increased to 13-14 in the MGA, MGA(A31C) 
and MGA(U25C) and remained at 7 in the MGA(G8C-G24C-G29C). These results are consistent 
with the RNase I footprinting results and lead to the interpretation that the MG-binding pocket is 
formed in the MGA, MGA(A31C), MGA(U25C) but not  in the MGA(G8C-G24C-G29C) that binds 
only  nonspecifically.   
Structural changes in the binding pockets of the MGA variants are indicated by the  following 
evidence: 1) enhanced RNase I cleavage of U32 and C31 in the MGA(A31C), 2) changed λmax of 
the MG interaction with the MGA(U25C), 3) significantly altered RNase I footprint of the 
MGA(G8C-G24C-G29C) compared with the MGA.   
The KDs of the MGA variants for MG differed widely with the MGA(G8C-G24C-G29C) 
showing a significant loss of affinity for MG.  Intermediate changes in the KDs were observed for the 
A31C and U25C variants. Although A31 makes no direct contact with MG, the A31C mutation 
changed part of the base quadruple (C7-G29-G24-A31) that sits above MG in the MGA binding 
pocket.  The U25C mutation changed the U-turn that connects the top and bottom parts of the binding 
pocket.  These changes were not evident from the NMR structure. 
With MG saturated by the concentration of each RNA at 10-15 times its KD, the MGA(A31C), 
MGA(U25C) and MGA(G8C-G24C-G29C) protected MG from hydroxylation in decreasing order of 
effectiveness with the effect of the MGA(G8C-G24C-G29C) being the same as a nonspecific binder 
(tRNA).   
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In conclusion, in this model system, we have shown that, when sequestered in the binding pocket 
of its cognate aptamer, MG can be protected from attack by a molecule as small as 1.32-3 angstroms.  
The use of steric hindrance to control protein function by aptamers has been reported for enzyme 
exosites (19-22), substrate binding sites (17,23-32), catalytic sites (33-35), and cellular localization 
sites (36).  However, this is the first report to our knowledge of an aptamer targeted to a small 
molecule that can protect it from reacting with an even smaller hydroxyl group.  This capability of an 
aptamer to wrap so snugly around its target as to prevent access of even small ions might find 
application in protecting small molecules from reactive species.  The additional ability to regulate the 
aptamer structure with an oligonucleotide that is complementary to the aptamer binding pocket 
provides a means of rapidly releasing the sequestered small molecule.  Aptamers can also function 
inside living cells.  Thus, this novel finding has potential applications for regulating molecular 
reactivity of small molecules both in vitro and in vivo. 
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FIGURE LEGENDS 
Fig. 1 The pH dependence of MG bleaching.  A time course of MG bleaching was determined at each 
of a range of pHs using the buffers 16.7 mM acetate, pH 5.0; 100 mM KCl, 5 mM MgCl2, 10 mM 
HEPES, pH 7.2; 9.8 mM Tris, pH 9.0; 0.1 mM NaOH, pH 10; 1 mM NaOH, pH 11 or 10 mM NaOH, 
pH 12.  From these time courses the rate constant of reaction (k) and the half-lives (t1/2) were 
determined and plotted against pH. k, ());  t1/2, ().  The insert shows a time course for the MG 
bleaching that can be fit to a curve for a second order reaction.  This experiment was repeated three 
times for each pH. 
Fig 2. The chemistry of MG bleaching.   (A, left) The mass spectrum by ESI of MG (molecular mass 
of 329 Da). (A, right) The mass spectrum of MG-OH by EI (molecular mass 346 Da). (B) The NMR 
spectra of MG (top) and MG-OH (bottom). (C) MG bleaching is proposed to proceed by an  OH- 
attack on the C1 of MG, forming the carbinol base.  
Fig. 3.  The malachite green aptamer protects MG from bleaching.  A,B: The kinetics of MG 
bleaching. 2 µM MG was incubated in 10 mM HEPES, 100 mM KCl, 5 mM MgCl2, pH 7.2-7.4 in the 
absence (L) or presence of (◊) 10 µM 100nt random RNA or in the presence of various concentrations 
of the MGA: 0.5 µM (●), 1 µM (x), 2 µM (t), 4 µM (+), 6  µM (○) MGA.  C,D: The kinetics of MG 
bleaching in the presence of the MGA and varying concentrations of AS.  2 µM MG was incubated 
for 2 min alone (◊) or with 10µM MGA (∆) in 10 mM HEPES, 100 mM KCl, 5 mM MgCl2, pH 7.2-
7.4. To this mixture was then added 500 µM shuffled AS (t) or AS at concentrations of 20 µM (●) or 
100 µM (○) AS. A, C: The changes in MG color were tracked as a function of time.  B,D:  The 
constants k and t1/2 were determined from the plots in A and C.  The figure shows the results of one of 
three independent experiments with consistent results. 
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Fig. 4.  Cavity analysis by Surfnet of MG alone and in the MGA binding pocket.  A) MG (magenta) is 
flanked in the binding pocket of MGA (1q8n.pdb) by C7, G24, G29, and A31 (orange) on one side 
and G8 and C28 (yellow) on the other.  Stem I (red), the base triples (green), Stem II (blue), and the 
Tetraloop (purple) are also shown.  B) MG contains three aromatic rings around the central carbon 
(green).  Hydroxide molecules can attack from above or below the plane, but C) the rings block 
approach within the plane of the ring.  D) Stereoview of the MG binding pocket of MGA, colored as 
above, with cyan mesh indicating the area accessible to an hydroxide of minimum radius.  The space 
above and below the plane of MG is blocked by the bases of the binding pocket and is therefore not 
accessible, as indicated by the lack of mesh.  The foreground of the image has been slabbed away to 
assist in viewing the interior of the binding pocket. 
Fig. 5.  Mutations around the MGA binding pocket compromise its ability to protect MG.  MG 
bleaching at the presence of the MGA variants at concentrations equivalent to 10-15 times KD was 
measured by spectrophotometry.  The concentrations of interacting components were:  : 3 or 30 µM 
MG;  : 30 µM MG, 3 mM tRNA; ■: 3 µM MG, 10 µM MGA; ○: 3 µM MG, 20-30 µM 
MGA(A31C); ◊: 30 µM MG, 140-200 µM MGA(U25C); ∆: 30 µM MG, 3 mM MGA(G8C, G24C, 
G29C). The figure shows the results, for the MGA and each MGA variant, of one of two to four 
independent experiments were performed that all gave consistent results.    
Fig. 6.  Footprinting analysis of the binding pockets of the MGA variants.  A. RNase I footprinting of 
the MGA with and without increasing MG concentrations (0.05 to 4 µM).  B. RNase I footprinting of 
the MGA(A31C) with and without 20 µM MG which was equivalent to 10 times KD.  C. RNase I 
footprinting of the MGA(U25C) with and without 140 µM MG which was equivalent to 10 times KD.  
D. RNase I footprinting of the MGA(G8C-G24C-G29C) with and without 3 mM MG that was 
equivalent to 10 times KD.  Each experiment was repeated as least twice.  
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Fig. 7. 1H-NMR spectra showed proper folding of the MGA variants which could bind MG.  The 1H-
NMR spectra includes two regions: 11-15 ppm (A) and 6.5-9.0 ppm.  The samples were 100 µM MG, 
50 µM MGA ± 100 µM MG, 50 µM MGA(U25C) ± 200 µM MG, 50 µM MGA(A31C) ± 100 µM 
MG, and 50 µM MGA(G8C-G24C-G29C) ± 500 µM MG. 
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TABLES 
 
Table I.  Affinities and λmax of the interaction of MG with the MGA and its variants.  
 
RNA MG Kd (µM) λmax 
(nm) 
t1/2 of MG 
bleaching 
MGA  
MGA(A31C)  
MGA(U25C)  
MGA(G8C-G24C-G29C)  
AS  
tRNA  
-  
(0.1-15 :M) 
(0.1-15 :M) 
(1-400 :M) 
(0.025-1.7 mM) 
(0.025-1.2 mM) 
(0.020-3 mM) 
 
0.2 :M 
0.2 :M 
0.4, 2 :M  
20 :M 
20 :M 
20 :M 
2, 20 :M 
1.03 ± 0.53 
1.93 ± 0.97 
13.8 ± 3.40 
274 ± 65 
172 ± 13 
210 ± 41 
632 
632 
629 
629 
629 
629 
618 
802  ± 611  h 
21.8 ± 16.2 h 
20.9 ± 11.5 h 
4.76 ± 2.78 h 
not determined 
7.38 ± 0.04 h 
0.70 ± 0.07 h 
 
The MGA and its variants, tRNA and AS were tested for their abilities to bind MG.  The KD’s were 
determined using the concentrations of MG and RNAs shown in the table.   The incubations were 
performed in 100 mM Tris, 100 mM KCl, 5 mM MgCl2, pH 9.0.  Each titration included at least 6 
different concentrations of the RNA.  The t1/2 of MG bleaching was measured in the presence of 
concentrations equivalent to 10-15xKD of the MGA variants or tRNA.  The data for t1/2 are the 
averages of three independent experiments shown with the standard deviation of the average. 
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ABSTRACT 
Experimental structural analysis by molecular biophysical methods provides atom-level 
resolution that is the basis for understanding molecular function.  However, due to limitations in the 
experimental technology, the dynamics must often be inferred from static structures.  Computational 
methods have been developed to fill this void, but have often not been rigorously tested against the 
experimental data.  Here we explore the interaction between the malachite green aptamer (MGA) and 
its target molecule, malachite green (MG) by using molecular dynamics (MD) simulation with 
experimental confirmation.  MD simulation predicted that the MG binding pocket of the MGA is 
largely pre-organized and that binding of MG involves reorganization of the pocket and a 
simultaneous twisting of the MGA terminal stem around the pocket.  These predictions were 
confirmed by analysis of the MGA-MG interaction by RNase I footprinting, melting profiles, 1D 
NMR, isothermal titration calorimetry, and stopped-flow kinetics. Thus, by using molecular dynamics 
modeling to extend the structural information derived by NMR and crystallography we were able to 
predict an experimentally verifiable dynamic model of the unoccupied MGA that has not yet been 
obtained by biophysical analysis.  The strategy used here may serve as a general approach to obtain a 
realistic simulation of the 3D-structure of an unoccupied aptamer starting with the experimentally 
determined structure of the aptamer-target complex, which then allows dynamical studies of the 
interaction of aptamer and its target.   
Keywords: thermodynamics, kinetics, molecular dynamics simulation, malachite green, 
aptamer 
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INTRODUCTION 
X-ray crystallography and NMR are powerful tools for establishing molecular structure with 
atomic resolution.  However, there are many instances in which the use of these technologies is not 
possible due to the limitations of the methods or lack of adequate samples.  Although these methods, 
particularly NMR, can provide information about molecular dynamics, this information cannot 
always be obtained under physiological conditions or under the same conditions as the protein or 
nucleic acid is studied for its function in vitro.  Computational simulations are commonly used to 
provide further insight to molecular structure and function when the current limitations of biophysical 
applications are reached.  However, few simulations are rigorously tested experimentally and thus the 
value of this approach is still uncertain. 
Aptamers are single stranded nucleic acids that bind to their targets with high specificities 
and affinities (KDs in the pM to µM range) that approach those of antibodies.  Although there are a 
few tertiary structures of unoccupied aptamers (thrombin aptamer 1, nucleolin aptamer 2 and NFκB 
aptamer 3), more than 40 tertiary structures of aptamer-target complexes have been solved by X-ray 
crystallography or by NMR 4; 5 and have been deposited in a protein data bank {www.pdb.org) 6.  
These 3D structures provide static views of the physical interactions between aptamers and their 
targets but only NMR reveals information about the dynamics of the aptamer-target interaction. 
However, good NMR data cannot always be obtained under conditions equivalent to those in vivo or 
as the molecules are studied in vitro.  Knowledge of the dynamics of aptamer structures are important 
because it provides opportunities to develop regulated aptamers that can be used for many useful 
sensor applications.   
Various experimental approaches have been used to study aptamer dynamics, including 
single molecule force measurements 7; 8, fluorescence resonance energy transfer 9; 10, NMR 11; 12; 13; 14; 
15; 16
, stopped-flow kinetics 17; 18; 19, isothermal titration calorimetry (ITC) 17; 20 and chemical and 
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enzymatic structure probing 10; 21.  Aptamer-target interactions can involve multiple steps 7; 10; 15; 16; 17; 
18; 19
 and binding can be enthalpic 17; 20; 22or entropic 23. Aptamers differ greatly in their kinetic 
parameters with measured association rates varying between 103 to 109 M-1s-1, dissociation rates of 
10-6 to 102 s-1 or dissociation half lives of 10-3 s to 50 h reported for different aptamers, with the 
thrombin 24 and CD30 aptamers 25 being two extreme examples. According to dynamical and 
structural studies, three different models of aptamer-target interaction have been proposed: adaptive 
recognition (induced fit) 4, preformed (lock and key) 21, and a combination of the two 3; 10; 13; 14.    
Molecular dynamic (MD) simulations have been applied to understand the dynamics of aptamer-
target interactions for aptamers that recognize FMN 26; 27, theophylline 28; 29; 30, L-argininamide 22, 
paromomycin 31, thrombin 32, glutaminyl-tRNA synthetase 23 and the HIV transactivation response 
element 33.  These studies examined the entropic and enthalpic contributions to binding to develop 
structural models of aptamer-target interactions.  In these studies, the free energies of binding differed 
between the simulated and experimental structures by 7-16% while the root mean square deviations 
(RMSD) differed by 2-4 D.  The results of these studies suggest that MD simulation could be an 
effective means of predicting the dynamic nature of   aptamer-target interactions based on initial 
biophysical data. 
To examine the ability of MD simulations to predict the dynamical aspects of aptamer-target 
interactions that are not available from biophysical analysis, we chose to study the malachite green 
aptamer (MGA), which is a 38 nt RNA aptamer consisting of stem I (residues 1-6, 33-38), a binding 
pocket (residues 7-11 and 22-32), stem II (residues 12-14, 19-21) and a tetraloop (residues 15-18) 
(Figs. 1,8) 34; 35.  We show here that MD simulation of the MGA in the presence and absence of its 
malachite green (MG) target predicted a dynamical structure of the unoccupied MG that has not been 
solved experimentally.  The simulated structure was shown to be consistent with biochemical probing 
of the MGA and the MGA-MG complex.  The results of molecular simulations combined with 
experimental approaches that included thermodynamic, kinetic and structural probing suggest a two-
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step kinetic model for the interaction of the MGA with MG.  Our studies demonstrate the application 
of MD simulations to extending the results of biophysical measurements to understand the 
mechanism and dynamics of molecular interactions. 
RESULTS 
MD simulation of MGA with and without bound MG 
Both NMR and crystal structures have been solved for the MGA in complex with MG or 
TMR 34; 35.  However, no structure has been solved for the unoccupied MGA, leaving an important 
gap in our knowledge of the structure of this aptamer that limits our understanding of the molecular 
event involved in the process of aptamer-target interactions.  To address this problem, we used MD 
simulation to predict the structure of the unoccupied aptamer.  Model 1 of the 25 MGA-MG NMR 
structures (PDB ID: 1Q8N) was used as the input.  
To simulate the unoccupied MGA, the coordinates of the MGA-MG complex were used with 
the MG removed. The MGA and MGA-MG complex were both solvated with water and Mg2+ and 
simulated over 7.7 and 7.0 ns respectively.  The simulations reached equilibrium after 0.5 ns as 
judged by constant temperature and no more increase in RMSD compared with the starting structure.  
The molecular coordinates were then allowed to evolve over 7.2 and 6.5 ns respectively.  The two 
equilibrated structures were compared in four structural regions: 1) stem I (residues 1-6, 33-38), 2) 
binding pocket (residues 7-11, 22-32), 3) stem II (residues 12-14, 19-21) and 4) the tetraloop 
(residues 15-18) (Fig. 1).   
The simulations predicted that stem I of both the MGA and MGA-MG structures are unstable 
with dynamic formation and disruption of H-bonds over the simulation period.  MG binding 
stabilized the A3-U36 base pairing while it destabilized the G2-C37 (data not shown) and U4-A35 
base pairing (Fig. 1 (a)).  MG binding also switched the C6-G33 base-pairing from strong H-bonding 
(N4-H-O6, N3-H-N1 and O2-H-N1) to weaker H-bonding (O2-H-N1) (data not shown).  These large 
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fluctuations in stem structure were not evident in the NMR pdb dataset.  By contrast with stem I, the 
simulated H-bond structure and stability of stem II was similar to that observed by NMR and was not 
predicted to be altered by formation of the MGA-MG complex (data not shown).  Alignment of the 
average simulated structure of MGA-MG complex and the average simulated structure of MGA 
showed that stem I of the MGA-MG was predicted to be altered relative to its position in the MGA 
(Fig. 1 (a)). 
In the MGA binding pocket MG is stacked between two sets of hydrogen-bonded bases, a 
base quadruple C7-G29-G24-A31 on top and a G8-C28 base-pair underneath.  In the simulated 
unoccupied MGA, the base quadruple was absent. In its place was observed a base triple (G24-G29-
A31) with dynamic G24-G29 base pairing and no H-bonding between C7 and G29.  Thus, the MD 
simulation predicts that formation of the base quadruple accompanies the binding of MG.  By contrast 
the G8-C28 base-pair that forms the lower stacking platform for MG was predicted to be present in 
the unoccupied MGA and this base-pairing was stabilized in the MG-MGA structure.  Two other base 
triples C10-G23-A27 and U11-A22-A26 that are also present in the binding pocket are predicted to 
preexist in MGA and neither are predicted to be altered upon MG binding.  The C10-G23-A27 base 
triple was simulated as very stable while the U11-A22-A26 base triple was very dynamic (data not 
shown).   
Base–stacking of the tetraloop was monitored in the simulation by the distance between the 
C5 atom of residue A16 and the C4 atom of residue G17.  The simulation showed dynamic stacking 
and unstacking between A16 and G17 in the tetraloop that was destabilized in the MGA-MG complex.  
The relative position and orientation of tetraloop also changed between the average simulated 
structures of MGA and the MGA-MG structure (Fig. 1(b)). 
In addition to the simulation of MGA and MGA-MG solvated with Mg2+, MGA-MG solvated 
with K+ was also carried out.  After 0.5 ns simulation, the system reached equilibrium and then the 
coordinate was allowed to evolve for another 2.5 ns.  Consistent with the simulation result of MGA-
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MG solvated with Mg2+, the simulation of MGA-MG solvated with K+ also showed dynamic open-
close stem I, a binding pocket consisting of dynamic base quadruple (G24-C7-G29-A31), a stable 
base-pair (G8-C28), two dynamic base triples (C10-G23-A27 and U11-A22-A26), a stable stem II 
and a dynamic tetraloop.   The simulation of MGA-MG solvated with Mg2+ and K+ also showed 
structure difference as shown by the RMSD (2.302 Å for the whole molecule and 1.889 Å for the MG 
binding pocket of MGA) (Table 3).  The main simulated structure difference between MGA-MG 
solvated Mg2+ and K+ existed in stem I and binding pocket.  There were dynamic formation and 
disruption of H-bonds in G2-C37 and U4-A35 at the presence of Mg2+ but in C5-G34 and C6-G33 at 
the presence of K+.  In addition, H-bond formed in A3-U36 at the presence of Mg2+ but didn’t exist at 
the presence of K+.  In the base quadruple of the MG binding pocket of MGA-MG complex, H-bonds 
formation was between C7-G29, G29-G24 and G29-A31 at the presence of Mg2+ but was between 
C7-G29, C7-G24 and G29-A31 at the presence of K+ (data not shown).  To sum, the simulation of 
MGA-MG at the presence of Mg2+ and K+ gave consistent overall structure with some difference in 
stem I and binding pocket. 
Thus, the simulation predicted that stem I of the MGA-MG complex is more unstable than 
observed by NMR, that the binding pocket of the unoccupied MGA is partially formed and that the 
stem I and tetraloop structure is altered on MG binding. 
RNase I footprinting confirms predicted MGA structures 
RNase I footprinting of MGA in the presence and absence of MG was performed to test the 
predictions of the MD simulations.   RNase I cleaves any residues in single-stranded regions but not 
double stranded regions of RNA.  The results showed strong cleavage of C7, G24 and U25 and weak 
or negligible cleavage of other residues in the MGA binding pocket of the unoccupied MGA.  The 
aptamer was protected against cleavage by RNase I in these regions upon binding MG (Fig. 2).  These 
results are consistent with the predicted preorganized binding pocket and induced fit mechanism of 
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MG binding.  MG binding to MGA also resulted in decreased cleavage by RNase I of stem I and 
slightly increased cleavage of the tetraloop. These results are consistent with the predicted global 
conformational change of MGA upon MG binding.  Thus, the RNase footprinting results appeared 
more consistent with the simulated structure than the NMR-derived structure of the MGA-MG 
complex.   
1H-NMR spectra show buffer effects on the MGA structure  
The NMR-derived structure and the RNase I structural probing of the MG-MGA complex 
were performed in buffers that differed in pH and concentrations of MgCl2 and KCl.  To determine if 
the MGA structure is sensitive to these differences, we examined the effects of these buffer 
conditions on the MGA conformation in the presence and absence of MG using 1H-NMR 
spectroscopy (Fig. 3).  The spectra showed that under all conditions the number of peaks in the 10-15 
ppm region, from the imino NH(H1,3) resonance (N-H...N) that are involved in base-pairing, 
increased in the presence of MG.   Also, under all conditions when MGA was present a broadening 
effect was observed on the MG peaks in the range 6.8-7.6 ppm that includes resonance of amino NH2 
and CH (H2,6,8) on the benzyl rings.  These results demonstrate that MG was bound by MGA under 
all conditions tested.  However, the spectral differences for MGA and the MGA-MG complex showed 
that pH, MgCl2 and KCl concentrations all affect the structures of the MGA and the MGA-MG 
complex.  Thus, the difference between the NMR-derived structure and the RNase I-probed structure 
could be due to the differences in the buffers used for these analyses.   
Melting profiles (Tm) are consistent with simulation predictions 
To further examine the possibility that the discrepancy between the NMR-derived data and 
results from the RNase I footprinting assays might be due to differences in buffer conditions, we 
examined the melting profiles of MGA with and without MG in different buffer conditions and 
determined the Tm values (Table 1, Fig 4).  Depending on the pH and salt constituents, the Tm value 
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of the MGA-MG complex was 6-14°C higher than that of unoccupied MGA, indicating 
reorganization to a more stable structure as a result of MG binding.  Changing the pH from 5.8 to 7.2 
and changing the concentration of KCl from 10 mM to 100 mM decreased the Tm of MGA with and 
without MG by ~7°C and ~3°C respectively while 5 mM MgCl2 increased the Tm value of the MGA-
MG complex by 3°C.  These data suggest that the buffer pH and salt constituents alter the structure of 
the MGA and MGA-MG complex, which may explain why the RNase footprinting results are 
inconsistent with the NMR-derived structure.   
The melting profiles of MGA-MG complex in buffer N (NMR conditions) and buffer F 
(footprinting conditions) differed dramatically with the latter showing two transitions.  The first 
transition is consistent with an increase in base-pairing with increased temperature in the 40ºC range, 
while the second transition is consistent with melting of the molecular structure.  The lower 
temperature transition may reflect more flexibility in the molecule at higher temperatures allowing the 
bases in a strained stem I to more readily base pair.  These results are consistent with the predictions 
of the MD simulations. 
Footprinting of tandemly-linked MGAs confirms the MD-predicted twisting 
A prediction of the MD simulation is that MG binding by MGA is accompanied by formation 
of the C7-G29-G24-A31 base quadruple (Fig. 1) and switching of the C6-G33 base pair from three H-
bonds (N4-H-O6, N3-H-N1 and O2-H-N1) to one H-bond (O2-H-N1) (data not shown).  Alignment 
of the average simulated structure of the equilibrated MGA and MGA-MG either on the whole MGA 
or just in the region containing the binding pocket showed that the predicted MGA-MG and MGA 
structures deviated in the stem I and tetraloop regions (Fig. 1(b)).  Thus, the simulation predicted that, 
with MG binding, the MGA twists along the vertical axis of the binding pocket and stem II resulting 
in a global conformational change of MGA in the regions of stem I and the tetraloop.   
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To test the predicted twisting of MGA on MG binding, we prepared an RNA molecule 
(4MGA) consisting of 4 tandemly linked MGAs with a shorter linker of 7 bases (UAAAAAC) 
between each MGA unit.  If the prediction is correct, the twisting force generated by the MGA-MG 
interaction should change the structure of the linkers making them more or less available to RNase I 
digestion.  RNase I footprinting of 4MGA showed that, as for MGA, the binding pocket of each 
MGA unit was protected from RNase I cleavage upon MG binding.  The data also showed that, as 
predicted from the MD simulation, increasing the MG concentration resulted in increasing cleavage 
of the linker regions (Fig. 5).  This result is consistent with the twisting motion predicted by the 
simulation to occur in the MGA upon MG binding.   
Thermodynamic parameters are consistent with a structural rearrangement of the MGA upon 
MG binding 
  Isothermal titration calorimetry was used to determine the thermodynamic parameters of the 
MG-MGA interaction (Fig. 6, Table 2).  Although decolorization of MG (due to hydroxylation of the 
C1 carbon) occurred slowly during the titration in buffer at pH 7.0, no significant heat release was 
attributable to decolorization. This was demonstrated by a blank titration under the same experimental 
condition (data not shown).  The calculated KD for the MGA-MG interaction was 0.33 ± 0.09 µM and 
was similar to that measured by RNase I probing (0.26 – 1.86 µM), stopped-flow kinetics (0.20 µM) 
and fluorescence spectrophotometry (0.6 µM, data not shown).  The ITC analysis showed that the 
MGA-MG interaction had a favorable enthalpy (∆H= -24.7 ± 0.97 kcal/mol) and unfavorable entropy 
(∆S=-53.2 ± 2.6 kcal/mol/deg), which is consistent with a possible structural rearrangement during 
MG binding.  TMR differed from MG by an additional oxygen bridging two benzyl rings, which 
makes TMR flatter than MG.  TMR bind to MGA with even higher affinity (KD=95 nM).  Unlike MG, 
TMR is stable under the buffer condition.  The thermodynamics of MGA-TMR interaction (∆H= -
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15.3 ± 0.60 kcal/mol, ∆S=-19.1 ± 2.5 kcal/mol/deg) (Table 2) also indicated a structural 
rearrangement during MGA-target interaction. 
Kinetic parameters are consistent with structural rearrangements during MG binding 
Stopped-flow kinetics was used to measure the association rate (kon) and dissociation rate (koff) 
of the MG-MGA interaction (Fig. 7).  From these studies we determined kon as 2.32 ± 0.76 x 10-6 M-
1s-1, koff as 0.39 ± 0.13 s-1 and KD as 0.2 ± 0.02 µM. The measured kon of the MGA-MG interaction is 
~ 1000 fold slower than the diffusion limit (~109 M-1s-1).  This time delay in MG binding is consistent 
with the predicted structural rearrangement of MGA during formation of the MG-MGA complex. 
DISCUSSION 
Predictions of the MD simulation compared with experimental data 
Previous MD simulations of aptamers have resulted in simulations that differed by 2-4 D 
(RMSD) from the experimental structures 22; 23; 26; 27; 28; 29; 30; 31; 32; 33.  Our simulated average structure 
of the MGA-MG complex differed from the average NMR structure with an RMSD of 3.463 D for 
the whole complex and an RMSD 2.604 D for the binding pocket only.  Even the two experimental 
determined 3D structures of MGA-MG 34 and MGA-TMR 35 complex differed by an RMSD of 4.070 
D for the whole molecules and an RMSD of 2.698 D for the binding pocket (Table 3).  The likely 
reasons for the differences for these experimentally-determined structures are different pH and salt 
conditions in each determination and that TMR differs from MG by an additional oxygen atom 
bridging two benzyl rings to make TMR a flatter molecule than MG.  
There are some discrepancies among the structures determined by MD simulation, RNase I 
footprinting, NMR spectrometry and crystallography. These discrepancies were in the stem I and in 
the binding pocket.  The simulation showed a dynamic open-close stem and this mobility was verified 
by RNase I probing.  However, this dynamic feature of stem I was not observed in the 3D NMR 
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structure MGA-MG and the crystal structure of MGA-TMR complex. The binding pocket of MGA-
MG complex had ~2.7 Å difference in RMSD between the MD simulation and the NMR-determined 
structure (Table 3).  The base-pairing in the binding pocket of the MGA differed between the 
experimental and simulated structures with the experimental determination showing only U11-A22 
base pairing 34 whereas the simulated structures predicted base-pairing of G8-C28, C7-G29-A31, 
C10-G23-A27, U11-A22-A26.  The 1H-NMR and temperature stability studies reported here show 
that the MGA-MGA structure is sensitive to pH and the salt concentration and composition of the 
buffer solution.  The buffer conditions differed among the MD simulation (pH 7.0, 150 mM Mg2+ or 
300 mM KCl), RNase I footprinting (pH 7.2-7.4, 100 mM KCl, 5 mM MgCl2), NMR (pH 5.8, 10 mM 
KCl) and crystallography (pH 4.5, 23 mM KCl, 40 mM SrCl2, 6.7 mM MgCl2).  These results suggest 
that the discrepancies of stem I structure obtained by the different methods could be due to 
differences in the conditions of measurements.  
There is only a U11-A22 base pair in the binding pocket of unoccupied MGA in the buffer 
condition for 3D- structure determination by NMR 34 but the MD simulation showed base triples of 
C10-G23-A27, U11-A22-A26, G24-G29-A31 and base pair of G8-C28 in unoccupied MGA.  
Evidence of this pre-organization of the binding pocket in unoccupied MGA was found by RNase I 
footprinting.  In the MGA-MG complex, the binding pocket was maintained through the simulation 
with some changes and a broader dynamic range compared to what was found by 3D-NMR. For 
example, in MD simulation the G24 was much more dynamic in the C7-G29-G24-A31 base 
quadruple (data not shown) compared to that in the 3D NMR structure.  
Overall, we found that the MD simulation is more consistent with the RNase I footprinting 
results than the NMR and crystal structures.  The most likely reason for these differences may be the 
buffer conditions used, and particularly the pH.  Both the MD simulation and the footprinting analysis 
were done at neutral pH whereas the NMR and crystal structures were performed with the aptamer-
target complex at pH 5.8 and 4.5.   In addition, Mg2+ and K+ also play roles. 
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The MD simulation also gave new insight into the dynamics of the MG-MGA interaction.  
For example, the global conformational change of the MGA upon MG binding due to the twisting of 
the MGA along the binding pocket and stem II was not readily evident from RNase I footprinting of 
MGA and the 3D-structure of MGA-MG and MGA-TMR determined by NMR and crystallography.  
Similar phenomena of global structure change due to twisting of an aptamer on target binding has 
also been reported in NFκB-aptamer interaction 3.  An advantage of MD simulation is that it is able to 
generate simulated 3D structures of molecules such as the MGA that are very mobile.   Whereas, for 
experimental applications such as NMR or crystallography it is necessary to identify buffer conditions 
that stabilize a more narrow range of molecular structures and thus limit molecular motion in order to 
obtain interpretable data. 
A model for the mechanism by which MGA binds MG 
Three models of aptamer-target interactions have been proposed, including adaptive 
recognition (induced fit) 4, preorganized structure (lock and key) 21 and the combination of 
preorganization-induced fit 3; 10; 13; 14.  According to these models, two kinetics pathways are possible 
for aptamer-target interactions. The pathway for a “lock and key” mechanism is a single step reaction 
with the target fitting precisely into the preorganized pocket.  For the induced fit mechanism, there is 
an intermediate complex of the aptamer and target molecule in which the binding pocket is not 
organized for target binding.  After the two molecules interact in this intermediate form the aptamer 
reorganizes to create a suitable high affinity binding pocket. 
The thermodynamic and kinetic constants for the MGA-MG interaction suggest a structural 
rearrangement during the MGA-MG interaction.  The ITC analysis showed that the MGA-MG 
interaction had a favorable enthalpy and unfavorable entropy. From this it could be proposed that MG 
binding to the MGA involves a structural rearrangement for which the entropy penalty is 
compensated for by a favorable enthalpy.  This proposal is consistent with our footprinting data of 
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MGA and the MGA-MG complex.   An induced-fit mechanism was also proposed on the basis of the 
observed increased base-pairing in the binding pocket of MGA on MG binding 34. However, neither 
footprinting nor NMR data can rule out the lock and key model.  
Short RNAs can be very dynamic and heterogeneous in conformation and this feature can 
sometimes be observed after they are resolved by polyacrylamide gel electrophoresis (PAGE) in the 
absence of denaturants.    MGA showed one major band and two minor bands when resolved through 
a 10% polyacrylamide gel thus suggesting some heterogeneity in structure (data not shown).  
Therefore, it is possible that a minor population (e.g. ~1%) of the MGA exists in a form that has a 
completely preformed pocket and that cannot be detected by NMR or footprinting. Thus, a structural 
rearrangement in the MGA could involve equilibration amongst unoccupied MGA structures or a 
structural rearrangement in the MGA-MG complex after its initial formation.  H-bond analysis of the 
simulated MGA structures showed no preexisting C7-G29 base pairing in the MGA.  Thus, the 
simulation predicts that the rearrangement occurs post MG binding.   
A proposed kinetic pathway for formation of the MG-MGA complex, shown in figure 8, 
invokes a mixed pre-organized and induced-fit model for the MG binding pocket.  In the model, the 
MG interacts with a partially organized binding pocket on the MGA and induces the formation of the 
mature binding pocket by expelling the C7 sitting in the pocket.   The binding pocket then reorganizes 
around the MG which becomes stacked between the G8-C28 base pair and the newly formed base 
quadruple of C7-G29-G24-A31.  The process of optimizing the MG position in the reorganized 
binding pocket results in twisting of the MGA along its binding pocket and stem II to form the 
equilibrium MGA-MG complex.  
The value of MD simulation for modeling unavailable empty aptamer structures 
Due to the dynamic nature of short nucleic acids, the 3D-structures of aptamers are difficult 
to obtain experimentally either by NMR or crystallography.  Although more than 40 experimentally 
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determined 3D-structures of aptamer-target complexes are available, only a few 3D-structures of 
unoccupied aptamers have been reported to our knowledge.  In this study, we developed a simulated 
3D-structure of unoccupied MGA for which experimental 3D-structure is not available.  The modeled 
structure was consistent with interpretations of experiment data from RNase I structure probing, 
melting profiles, thermodynamic and kinetic measurements.  The strategy used here may be generally 
useful for understanding the 3D-structures of unoccupied aptamers and for studying the dynamics of 
aptamer-target interactions. 
MATERIALS AND METHODS 
Materials 
The following describes the sources of reagents used in these studies:  SalI and XbaI (New 
England Biolab), T4 polynucleotide kinase, RNase I and calf intestine alkaline phosphatase (Promega, 
Madison, WI), RNase T1 and AmpliScribeTM T7-FlashTM transcription kit (Epicentre, Madison, WI), 
Taq DNA polymerase (GenScript, Piscataway, NJ), dNTP and NTP (Fermentas, Glen Burnie, MD), 
γ-
32P-ATP (MP Biomedicals, Irvine, CA), MG and tetramethylrosamine (TMR) (Sigma, St. Loius, 
MO), SYBR Green I (Invitrogen, Carlsband, CA) and other chemicals (Fisher, Suwanee, GA).  
The following oligonucleotides were chemically synthesized with standard desalting by either DNA 
Synthesis and Sequencing Facility (Iowa State University) or Integrated DNA Technology (Coralville, 
IA): MGA (38 nt RNA): 5’-ggaucccgacuggcgagagccagguaacgaauggaucc-3’; oligo 1: 5’-aaaaacgga-
tcccgactggcgagagccaggtaacgaatggatcct-3’; oligo 2: 5’-tttttaggatccattcgttacctggctctcgccagtcgggatccg-
3’; oligo 3:  5’-tcgacggatcccgactggcgagagccaggtaacgaatggatcct-3’; oligo 4: 5’-ctagaggatccatt
cgttacctggctctcgccagtcgggatcgc-3’; primer 1: 5’-gtccgctctagaggatccattcg-3’; primer 2: 5’-
taatacgactcactatagggagcagcacgtcgacggatcccgac--3’ 
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Molecular dynamics simulations 
MD simulation of the MGA- MG complex and the unoccupied MGA were carried out with 
NAMD2.6, which was developed by the Theoretical and Computational Biophysics Group in the 
Beckman Institute for Advanced Science and Technology at the University of Illinois at Urbana-
Champaign (http://www.ks.uiuc.edu/Research/namd/) 36.  The setup for simulation and analysis of the 
simulation results was done with VMD1.8.6 (http://www.ks.uiuc.edu/Research/vmd/) 37.  The 
CHARMM topology file (top_all27_prot_na.rtf) and the parameter file (par_all27_prot_na.prm) 38 
were modified to include MG for setting up and running the simulation.  For MG, the topology and 
parameter files were generated manually according to previously reported quantum-chemical 
calculations 39. 
The procedure is described briefly as follows.  The MGA-MG complex (PDB ID: 1Q8N, 
model 1) 34and the MGA was derived from the MGA-MG complex by manually deleting MG were 
solvated in a water box (75 D x 53 D x 49 D) containing 9246 TIP3 H2O.  Ions (38 K+ or 19 Mg2+ for 
MGA and 38 K+, 1 Cl- or 19 Mg2+, 1 Cl- for MGA-MG) were randomly added into the solvated 
system using the autoionization plugin in VMD.  The solvated and ionized systems were then run on 
NAMD with CHARMM.  For the simulation parameters, the electrostatic and van der Waals 
interaction distance cutoff was set to 12 D.  The full-system periodic electrostatics was calculated 
with a particle mesh Ewald summation of ~ 1  D grid space.  The timestep was set to 2 fs.  After 100-
2000 steps of minimization, the unconstrained simulation was run under a periodic boundary 
condition at a constant temperature (298K) and pressure (1.01325 bar) for 3 ns for MGA-MG 
solvated with K+ , 7 ns for MGA-MG solvated with Mg2+ and 7.7 ns for MGA solvated with Mg2+. 
Plasmid construction and in vitro transcription 
To generate the RNA molecule, 4MGA, that contains four tandem units of MGA, the plasmid, 
p4MG, was constructed by inserting four co-annealed oligonucleotides, oligo 1-4, into the plasmid 
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ptz’U6 cut with SalI and XbaI.  When co-annealed, these four oligonucleotides encoded an RNA with 
four tandem MGA each separated by a 7 nt linker.  The obtained plasmid containing the 4MGA 
sequence inserted downstream from a T7 polymerase promoter was called p4MG. 
To obtain the RNA, the 4MGA DNA in the p4MG plasmid was amplified by polymerase 
chain reaction (PCR).  In the PCR reaction mix was 4 ng/µl p4MG, 0.5 µM primer 1, 0.5 µM primer 2, 
200 µM dNTPs, 0.025 U/µl Taq DNA polymerase, 1.5 mM MgCl2, 50 mM KCl, 10 mM Tris (pH 9.0) 
and 0.1% Triton X-100 in 500 ul reaction. The reaction was amplified at 94oC, 3 min;  20 cycles of 
94oC 30 sec, 68oC 30 sec, 72oC 1 min; 72oC, 7 min.  The 4MGA-DNA was then used for in vitro 
transcription by T7 RNA polymerase to generate 4MGA RNA.  The 4MGA RNA was 202 nt long 
with sequence of 5'-gggagcagcacgucgacggaucccgacuggcgagagccagguaacgaauggauccuaaaaacggauc-
ccgacuggcgagagccagguaacgaauggauccuaaaaacggaucccgacuggcgagagccagguaacgaatggauccuaaaaacgg-
aucccgacuggcgagagccaggtaacgaauggauccucuagagcggac -3'.   
RNase I footprinting 
Structural changes upon MG binding to MGA and 4MGA were studied by RNase I 
footprinting.  To label the 4MGA RNA, it was first dephosphorylated.  A 50 µl reaction mixture 
containing 20 µM 4MGA, 0.2 U/µl calf intestine alkaline phosphatase, 50 mM Tris pH 9.3, 1 mM 
MgCl2, 0.1 mM ZnCl2, 1 mM spermidine was incubated at 37oC for 30 min.  Chemically synthesized 
MGA had no 5’ phosphate.  MGA and 4MGA were radiolabeled by 5' end labeling, which was 
carried out in 20 ul reaction mixtures of 7 µM MGA or 4MGA, 1 U/µl T4 polynucleotide kinase, 2 
µCi/µl γ-32P-ATP, 70 mM Tris, pH 7.6, 10 mM MgCl2 and 5 mM DTT at 37oC for 1.5h.  Following 
5’ end-labeling, RNase I footprinting was carried out.  In the titration footprinting, 30-100 nM 
32P-MGA or 32P-4MGA in 100 mM KCl, 5 mM MgCl2, 10mM HEPES, pH 7.2, 25 oC were treated 
with 10-4 U/µl and 5x10-4 U/µl RNase I respectively in the presence of a range of malachite green 
concentrations (0.1 to 4 µM) each in 10 :l reaction mixtures.  For the controls, partial alkaline 
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hydrolysis of the labeled RNAs was done in 50 µM Na2CO3, pH 9.0 at 95 oC for 2 to 5 min.  RNase 
T1 digestion of the labeled RNAs was carried out in 10 µl solution containing 0.5-1 U/µl RNase T1, 5 
M urea, 350 mM sodium citrate, 0.7 mM EDTA, pH 5.0, at 50oC for 4 min.  The RNA 
hydrolysis/cleavage reactions were stopped by bringing the reaction mixtures to 47.5% formamide, 
0.05% bromophenol blue, and 0.05% xylene cyanol FF.  The samples were analyzed by 7M urea 8-
12% polyacrylamide gels.  The gels were dried and the radioactivity was recorded using a phosphor 
screen that was imaged with a Typhoon 8600 Variable Model Imager (GE Healthcare, Piscataway, 
NJ).   The image data were quantified by ImageQuant (GE Healthcare) and fit to equation Y= 
a*[M]/(KD+[M])+b by nonlinear regression with Costat (Cohort, CA).  In the equation, Y presented 
the normalized cleavage against that in the absence of MG.  [M] was MG concentration. KD was 
dissociation constant of MG-MGA interaction. The a and b were constants.  The lanes of partial 
alkaline hydrolysis and RNase T1 digestion were used for identification of cleavage bands. 
1H-NMR spectrometry  
To test for effects of buffer conditions (pH and salts) on the structures of MGA and the 
MGA-MG complex, one-dimensional NMR spectra of MGA-(MG) were recorded at 25 °C for 50 µM 
MGA ± 100 µM MG in 5% D2O and 95% H2O including 10 mM KCl, 10mM KH2PO4, pH 5.8; 10 
mM KCl, 10mM KH2PO4, pH 7.2; 10 mM KCl, 10mM KH2PO4, 5 mM MgCl2, pH 5.8; 100 mM KCl, 
10mM KH2PO4, pH 5.8.  Spectra were collected using a Bruker Avance 700 spectrometer equipped 
with a 5 mm HCN-Z gradient cryoprobe.  All 1D 1H-NMR spectra were acquired using a 
WATERGATE pulse sequence with water flipback (Bruker sequence p3919fpgp) to minimize solvent 
saturation transfer.  Spectra were averages of 512 transients. Spectral width was 18182 Hz (25 ppm).  
Melting profiles 
  The melting profiles of the MGA with and without MG were determined under different 
buffer conditions using a MiniOpticon real-time PCR system (BIO-RAD, Hercules, CA) in the 
  
118 
temperature range of 30 – 90oC with a 0.5oC increase per step.  The samples contained 2 µM MGA 
and 0.7x SYBR Green I with or without 20 µM MG, in solutions containing 10 mM KCl, 10 mM 
KH2PO4, pH 5.8; 10 mM KCl, 10 mM KH2PO4, pH 7.2; 10 mM KCl, 10 mM KH2PO4, 5 mM MgCl2, 
pH 5.8; 100 mM KCl, 10 mM KH2PO4, pH 5.8 or 100 mM KCl, 10 mM HEPES, 5 mM MgCl2, pH 
7.2.  The measure of base stacking was the fluorescence of SYBR Green due to its being stacked 
between bases. 
Isothermal titration calorimetry (ITC) 
The thermodynamics of the MG-MGA interaction was determined by ITC with VP-ITC 
(MicroCal, Northampton, MA).  For ITC, 300 µl of 75 µM MG or TMR in 100 mM KCl, 5 mM 
MgCl2, 10 mM HEPES, pH 7.0 or 250 µM MG in H2O were in the syringe and titrated into 1.428 ml 
of 10 µM MGA in same buffer in sample cell at 25oC.  The titrations of 75 µM MG or TMR, or 250 
µM MG into same buffer served as the blank.  A total of 30 injections were performed with an initial 
1 µl injection followed by 10 µl injections and separated by a 60 sec initial delay.  Each 10 ul 
injection was of 20 sec duration and 300 sec spacing.  Other parameter settings included a 2 sec filter 
period, 15 µcal/sec reference power, 310 rpm stir speed, high feedback model, fast equilibrium & 
auto ITC equilibration.  The ITC raw data were analyzed using Origin7.0 software provided by 
MicroCal Inc. with the “one set of sites” fitting model.   
Stopped- flow kinetics 
The MGA-MG interaction was studied by stopped-flow kinetics using a MOS-250 
spectrometer linked to a stopped-flow SFM-400 apparatus by a MPS-60 microprocessor unit (Bio-
Logic, Claix, France).  The MGA-MG interaction was monitored by quantifying the shift in maximal 
absorption of MG from 618 nm to 630nm 40.  For kon measurements, MGA was mixed with MG in 
100 mM KCl, 5 mM MgCl2, 10 mM HEPES, pH 7.2 at 25oC with final concentrations of MGA as 20, 
25, 30, 35 or 40 µM and MG as 2 µM.  The binding was monitored by the change in the absorbance at 
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613 nm (A613) over the period from 20 to 120 msec after mixing.  For koff experiments, a mixture of 
MGA and MG was mixed at t=0 with TMR to a final concentration of 2 µM MG, 3 µM MGA, 50µM 
TMR.  The MGA has a much higher affinity for TMR than for MG (40-90 nM vs. 0.2-0.8 µM).  
Therefore, TMR in excess was used to prevent the reassociation of MGA and MG. The dissociation 
of MG from MGA was tracked by the change of absorbance at 632 nm (A632) in the periods of 20 
msec to 20 sec, which is not affected by TMR absorbance (λmax=551 nm for TMR and 567 nm for 
TMR-MGA). The kinetic data were fit with an exponential function using Pro5.03 software to obtain 
koff and kobs.  kon is the slope of the linear curve kobs = kon *[MGA] + c where [MGA] is the 
concentrations of MGA and c is a constant. 
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FIGURE LEGENDS 
Figure 1.  Dynamics of the MGA-MG interaction predicted by MD simulation.   
The distances between two atoms were calculated from the MD simulation as a function of simulated 
time. (a) H-bond (stem I and binding pocket) and base-stacking (tetraloop) distances.  The atom pairs 
are stated at the top of each graph and the graphs are organized in the figure by location in the MGA 
structure.  Distances are shown for these pairs in MGA (blue) and MGA-MG complex (red). (b) The 
alignment of the MGA (transparent) and the MGA-MG complex (opaque) along the stem II and 
binding pocket with the binding pocket silver, stem II blue, stem I green, tetraloop pink and MG 
(magenta). 
Figure 2.   The structural change of the MGA upon MG binding determined by RNase I 
footprinting.   
RNase I footprinting is of the MGA in the presence and absence of 0.1 to 4 µM MG shows changes in 
accessibility of RNase I to phosphodiester bonds in the binding pocket [X:A22-U32; ○:C7-U11] , 
stem I (□) and tetraloop (∆).  Four experiments were performed with two independently synthesized 
MGAs.  A representative gel is shown in (a) and the quantitation of the four experiments as average is 
shown in (b). Y represents the cleavage by RNase I normalized against that at 0 µM MG.   
Figure 3.   1H-NMR spectra of the MGA, MGA-MG complex and MG under different buffer 
conditions.  
Buffer compositions were based on the buffer N used for NMR analysis and all contained 10 mM 
KH2PO4 with the variable constituents outlined in the table 
Figure 4.  The melting profiles of the MGA and the MG-MGA complex in different buffers.   
MGA was incubated in the presence or absence of MG in buffer N (10 mM KCl, 10 mM KH2PO4, 
pH 5.8) that was used for the NMR structure determination or buffer F (100 mM KCl, 10 mM HEPES, 
5 mM MgCl2, pH 7.2) that was used here for footprinting.  A melting profile was performed using 
SYBR green I to report the extent of base pairing as a function of temperature. In the figure, N and F 
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in the parenthesis following MGA or MGA-MG shows the buffer. The averages of four independent 
experiments with four repeats in each independent experiment are presented.  Note that, unlike A260 
which increases with melting due to the loss of the hyperchromatic effect of base stacking, the 
fluorescence of SYBR green decreases with melting due to the loss of base pairs between which it can 
stack. 
Figure 5.   Twisting of the MGA is suggested by the RNase I footprinting of tandemly linked 
MGAs.   
RNase I footprinting of 4MGA in the presence and absence of 0.1 to 20 µM MG was performed five 
times with two independently synthesized preparations of 4MGA.  A representative gel is shown. 
Figure 6.  Thermodynamics of the MGA-MG interaction.   
The thermodynamic parameters for the MGA and MG interaction in a buffer containing 10 mM 
HEPES, 100 mM KCl, 5 mM MgCl2, pH 7.0 were obtained by ITC.  Top panel:  The raw ITC data 
with the blank subtracted showing the heat released rate with time.  Bottom panel: The integrated data 
from the top panel showing the normalized heat release plotted against the molar ratio of MG/MGA.  
Presented are the results of one of the three independent titrations. 
Figure 7. The kinetics of the MG-MGA interaction.   
The on and off rates of MGA-MG binding were determined by stopped-flow analysis as described in 
Methods with 2 µM MG and varying concentrations of MGA (20, 25, 30, 35 and 40 µM) for 
determining kon and 2 µM MG, 3 µM MGA and 50 µM TMR for the koff determination. Left panel: 
The data used to derive kon. right panel: the data used to derive koff . Two independent experiments 
were performed to determine both  kon and koff with the results of at least three time courses 
averaged for each individual curve. 
Figure 8. The model for the mechanism of MG-MGA recognition.   
The MGA and MGA*-MG structures are the averaged simulated 3D-structure at equilibrium. The 
MGA-MG intermediate is a hypothesized intermediate state that might occur during the transition 
  
126 
from MGA to MGA*-MG. In this model MG first enters the partially preorganized binding space in 
MGA to form a MGA-MG intermediate. Then MG expels C7 from the preorganized binding space of 
MGA to induce the formation of the base quadruple (C7-G29-G24-A31), optimizing the binding 
pocket for MG occupation and simultaneously twisting  the MGA along the binding pocket and stem 
II to form the final MGA*-MG.  The individual structures were prepared with VMD1.8.6.  The top 
part of the figure showed the whole molecule and the bottom part showed the base-quadruple (C7-
G29-G24-A31) and the base pair (G8-C28) between which MG binds. The MGA consists of stem I 
(green, transparent), binding pocket (opaque), stem II (blue, transparent) and tetraloop (pink, 
transparent).  In the MGA binding pocket, C7 is colored blue, G24, G29 and A31 are yellow, and G8 
and C28 are cyan all of which presented as Licorice form. The rest of the residues were presented as 
newribbon format with A9, U25, A30 and U32 colored as silver, base triple of C10-G23-A27 as 
orange and base triple of U11-A22-A26 as magenta2.  MG is presented as licorice format and colored 
with magenta. 
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TABLES 
Table 1. The Tm values of MGA and MGA-MG in various buffers 
 
MGA  MGA-MG 
buffers 
Tm (oC) t-test between 
B-F and N 
 Tm (oC) t-test between 
B-F and N 
Low temperature 
Transition (oC) 
N 53.2 ± 2.4   65.0 ± 1.5   
B 46.7 ± 0.8 P = 2.6 x 10-7  57.6 ± 4.9 P = 4.9 x 10-7  
C 54.1 ± 2.0 P = 0.22  68.0 ± 0.6 P = 2.3 x 10-5  
D 51.1 ± 2.9 P = 0.04  60.6 ± 1.0 P = 1.7 x 10-7  
F 49.6 ± 2.0 P = 8.1 x 10-6   65.9 ± 1.8 P = 0.04 41.1 ± 1.9 
 
Transition temperatures were determined for the MGA in the presence and absence of MG under the 
following buffer conditions: N) 10 mM KCl, 10 mM KH2PO4, pH 5.8, B) 10 mM KCl, 10 mM 
KH2PO4, pH 7.2, C) 10 mM KCl, 10 mM KH2PO4, 5 mM MgCl2, pH 5.8, D) 100 mM KCl, 10 mM 
KH2PO4, pH 5.8 and F) 100 mM KCl, 10 mM HEPES, 5 mM MgCl2, pH 7.2.  Shown for the derived 
Tm and low temperature transition are the average temperatures ± the standard deviation.  Four 
independent experiments were performed under these conditions to obtain the results shown. 
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Table 2. Thermodynamics of MGA-MG/TMR interaction determined by ITC 
 N KD 
(µM) 
∆H 
(kcal/mol) 
∆S 
(cal/mol/deg) 
∆G 
(kcal/mol) 
R2 
MGA-MG 0.65 ± 0.04 0.33 ± 0.09  -24.7 ± 0.97 -53.2 ± 2.6 -8.88 ± 0.23 0.995 
MGA-MG * 1.64 ± 0.05 2.14  -20.19 ± 0.86 -41.8 -7.73 0.990 
MGA-TMR 1.10 ± 0.02 0.095 ± 0.005  -15.3 ± 0.60 -19.1 ± 2.5 -8.95 ± 0.13 0.995 
 
Thermodynamic constants of MGA-target interaction were determined in buffer (100 mM KCl, 5 mM 
MgCl2, 10 mM HEPES, pH 7.0) or in H2O (*).  Each column in the table shows N: number of 
binding site, KD: dissociation constant, H: enthalpy, S: entropy, G: free energy and R2: onesite model 
fitness 
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Table 3.  Comparing the MD simulations with the NMR and crystal structures 
  
NMR 
MGA-MG-
Mg2+ 
MGA-MG-
K+ 
MGA-
Mg2+ 
MGA-TMR 
(crystal) 
NMR   2.745 2.604 2.524 2.698 
MGA-MG-Mg2+ 3.780   1.889 1.902 2.869 
MGA-MG-K+ 3.463 2.302   2.113 2.543 
MGA-Mg2+ 4.404 2.098 3.407   2.903 
MGA-TMR (crystal) 4.070 3.876 3.805 4.546   
 
The averaged NMR-derived MGA-MG structures, MGA-TMR crystal structure and averaged 
simulation structures were compared for identity with the RMSD being an indicator of the fit.  A 
larger RMSD indicates a bigger difference between two structures.  The RMSD values above the 
shaded areas are from comparisons of the binding pocket structure of the MGA alone and RMSD 
values below the shaded areas are from comparisons of the whole MGA structure.  All atoms except 
the hydrogens were compared.  
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CHAPTER 5. GENERAL CONCLUSIONS 
CONTROLLING CHEMICAL REACTIVITY WITH APTAMERS 
A novel concept has been developed to control chemical reactivity by an aptamer-antisense 
oligonucleotide (AS) pair.  The basic idea is to sequester a reactant inside the binding pocket of an 
aptamer that binds the reactant specifically and avidly.  The sequestrated reactant is then unavailable 
to other reactants and the chemical reaction is thus inhibited.  The sequestration of a reactant by an 
aptamer can be reversed by an AS against the aptamer.  Through the aptamer-AS pair, a chemical 
reaction can be controlled in a reversible way.  This concept has great potential in controlling 
metabolic reactions in vivo.  For aptamers to sequester metabolites in vivo, they should have high 
affinity and specificity to compete with the enzymes for binding.  We have demonstrated the 
feasibility of this concept using the MGA to control MG bleaching in vitro.  This represents a first 
step to toward intervening in metabolism in vivo using the concept of the aptamer–AS pair.  Future 
effort should be made to move this concept to work in vivo.  Current methodologies, including gene 
knock-down, antisense oligonucleotide (AS)  technology, small interfering RNA (siRNA), chemical 
inhibitors among others, mainly aim at controlling the activity or expression level of enzymes that 
catalyze metabolism by targeting genes or mRNA or protein of the enzymes.  Aptamers are unique in 
their ability to target at the metabolite level.  This ability gives our approach unique advantages in 
situations that a metabolic step is catalyzed by multiple enzymes or a single enzyme with gene 
redundancy. In this latter situation, knocking down a single gene or inhibiting a single enzyme will 
not inhibit the metabolic step.  By targeting at the metabolite level, we can directly shut down a 
reaction reversibly with our aptamer-AS approach.   
In addition, to control metabolism, aptamers could sequester endogenously toxic and reactive 
small molecules from damage to organisms.  For example, an elevated level of methylglyoxal has 
been linked to neuronal and other diseases [1].  Developing aptamers against these small 
endogenously toxic compounds could be used for therapy. 
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In conclusion, a novel concept has been developed to control chemical reactivity by aptamer-
AS pair, which has great potential in controlling metabolism and small toxic compounds among other 
applications. 
DYNAMICS OF AN APTAMER-TARGET INTERACTION REVEALED BY MD 
SIMULATION WITH EXPERIMENTAL VALIDATION 
MD simulation has been used to study the dynamics of nucleic acids in general and aptamer-
target interactions in particular.  The proper use of MD simulation yields results in good agreement 
with experimental data.  The gap that we wanted to fill was to establish if MD simulation could 
extend structural and dynamical information beyond the limitations of current experimental 
techniques.  Using the MGA-MG interaction as an example, we were able to discover the twisting 
force due to MG binding and used MD simulation to establish a model of the MG-MGA interaction 
as the combination of pre-organization and induced fit.  The simulation results were validated by 
experimental studies.  Thus, we integrated the MD simulations, thermodynamic and kinetic results to 
propose a two-step mechanism for MG-MGA interaction.  Most importantly, we provided a simulated 
3D-structure of unoccupied MGA with experimental validation.  To my knowledge, the experimental 
3D-structure of MGA has not been reported.  In sum, we show that MD simulation can complement 
experimental approaches and can be used to dissect the mechanism of the MGA-MG interaction and 
provide a simulated 3D-structure of unoccupied MGA.  With so many experimental structures of 
aptamer-target complex available, MD simulation could be used to explore the dynamics of many 
aptamer-target interactions.  The dynamics of ions and water molecules in aptamer-target interaction 
are also not easily studied by experimental approaches.  MD simulation could provide a unique tool to 
decipher the role of ions and water and provide the basis of developing hypotheses for experimental 
validation [2]. 
Although we see MD simulation as a powerful tool to study aptamer-target interactions, we 
need to be cautious regarding its limitations.  The standard force fields (CHARMM and AMBER) 
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may not describe the behavior of divalent ions accurately and the simulation environment may not 
represent the real experimental conditions.  Currently, typical MD simulations are run at ~ 10 ns scale 
and many biological events happen at the ~µs and ~ms scale and therefore can not be revealed by MD 
simulations.  To conclude, MD simulations, when performed in combination with experimental 
approaches, can be a powerful tool to study the dynamics of aptamer-target interactions that are not 
evident from the static 3D-structures.  This approach can also provide new insights into the dynamics 
that is beyond the limitations of the conditions used for high-resolution data collection in NMR and 
crystallography.. 
PERSPECTIVE 
Aptamer development has gone through 18 years.  These studies have shown their application 
in medicine with the first aptamer drug, Macugen, approved by Food and Drug Administration at the 
end of 2004.  Macugen is a pegylated VEGF aptamer that is used to treat age-related macular 
degeneration.  SomaLogic and Archemix are two companies that own the proprietary rights to 
develop aptamers for diagnosis and therapy.  In addition to their potential applications in medicine, 
aptamers also serve as good tools to study biological systems.  Currently, aptamer selection is still 
done manually and it is time consuming.  Although automation of selection has been attempted, no 
commercial instrument is available now.  To meet the high demand of aptamers that recognize 
various targets, high throughput and highly efficient selection technology needs to be developed.   
One unique feature of aptamers is their ability to distinguish the difference of even a single 
chemical group.  Chemical modifications including acetylation, methylation, phosphorylation, 
ubiquitination, SUMOylation, ADP ribosylation, deimination and proline isomerization occur in 
proteins and some modifications also occur in nucleic acids. These modifications act as epigenetic 
codes and play an important role in biological systems.   I see aptamer development to decipher the 
epigenetic code as an exciting field. 
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In addition to aptamers selected in vitro, aptamers also exist in nature.  Dr. Larry Gold first 
proposed nucleic acid-protein and nucleic acid-metabolite linkage maps in 1997.  He also proposed a 
Genomic SELEX approach to study natural aptamers [3].  The hypothesis was confirmed by the 
discovery of riboswitches by Dr. Ronald Breaker’s lab.  Riboswtiches are RNA elements in the 
untranslated regions of mRNA that can specifically bind to metabolites and regulate transcription as 
well as translation.  Riboswitches may be just the tip of the iceberg of natural aptamers.  It has been 
proposed that genomes are filled with aptamers [4].  Appropriate approaches to select for these 
aptamers are in need of development. Discovering natural aptamers will be an exciting field in the 
near future.   
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APPENDIX. SELECTING APTAMERS AGAINST MOUSE LCN2 
PROTEIN 
 
ABSTRACT 
To develop aptamers as a tool to study mouse lipocalin 2 (Lcn2) function, Sequential 
Evolution of Ligands by Exponent enrichment (SELEX) was carried out.  After 10 rounds of 
selection, 21 aptamer candidates were identified with 2 sequences constituting 50% of the 
candidate population. Secondary structure predictions showed that those candidates either adopt 
three way junction or multiple stem-loop structure. Further characterization of the aptamer is 
ongoing.  
INTRODUCTION 
Mature mouse Lcn2 consists of 180 amino acids, not including the 20 amino acids of the 
signal peptide.  Mouse Lcn2 was first discovered to be a growth factor induced and 
superinducible protein [1].  It has also been shown to be an acute phase protein [2].  Although 
many different functions have been proposed for mouse Lcn2, they are controversial and the in 
vivo role of this protein is unclear [3, 4].  Development of tools to study mouse Lcn2 will help to 
elucidate its function. 
An aptamer is a ss-DNA or RNA that can bind to its target with high specificity and high 
affinity.  Aptamers are selected in vitro by a procedure called SELEX [5, 6].  Compared with 
antibodies, aptamers are smaller in size.  They can also be fine-tunable in vitro.  Aptamers 
selected in vitro have already been shown to function in vivo to knockdown protein functions [7-
13].  Here we proposed to select aptamers against mouse Lcn2 as a tool to study mouse Lcn2 
function.  
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METHODS 
Materials 
T7 RNA polymerase (recombinant protein prepared by Meiguan Yan), Inorganic 
pyrophosphatase (New England BioLabs, Boston, MA), NTPs and dNTPs (Fermentas, Glen 
Burnie, MD), and Taq DNA polymerase (GenScript, Piscataway, NJ), thermoscript reverse 
transcriptase (Invitrogen, Carlsbad, CA), DNase I (Epientre, Madison, WI), TOPO XL PCR 
cloning kit (Invitrogen, Carlsbad, CA ), Talon metal affinity resin (Clonetech, Mountain View, 
CA), α-32P-ATP (MP Biomedicals, Solon, OH), other chemicals (Fisher, Pittsburgh, PA).  His-
mouse Lcn2 (recombinant protein prepared by Dr. Pierre Palo).  Oligonucleotides 484, 485 and 
487 were synthesized by Integrated DNA Technology (Coraville, IA) with standard desalting. 
Their sequences are:  
Oligo 484: TAATACGACTCACTATAGGGAGACAAGAATAAACGCTCAA 
Oligo 485: GCCTGTTGTGAGCCTCCTGTCGAA 
Oligo 487: GCCTGTTGTGAGCCTCCTGTCGAA(N53)TTGAGCGTTTATTCTTGTCTCCC 
SELEX procedure 
Selection of aptamers against mouse Lcn2 was carried out using affinity chromatography 
as the separation methods [14]. First, ds-DNA were generated by Taq DNA polymerase extension 
with 600 µl mixtures containing 1.67 µM oligo 487, 3.33 µM oligo 484, 0.5 mM each dNTPs, 50 
mM KCl, 10 mM Tris HCl (pH 9.0 at 25°C), 1.5 mM MgCl2, and 0.1% Triton X-100, 0.05 U/µl 
Taq DNA polymerase. The reaction was carried out at 95oC for 3 min then 65oC for 5 min then 
72oC for 40 min. The extension products were gel purified and 0.357 nmol of ds-DNA was used 
for in vitro transcription to generate the starting RNA pool for SELEX.  For in vitro transcription, 
the reaction was done at 42oC for 1h, containing  5 mM of each NTPs, 30 mM Tris, 10 mM DTT, 
2 mM spermidine, 20 mM TritonX-100, 20 mM MgCl2, pH 8.5, 0.7 µM T7 RNA polymerase, 0.2 
U/ml inorganic pyrophosphatase and various amounts of DNAs (375 pmol DNA from the initial 
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pool).  The RNA was digested with DNase I and gel-purified.  The purified RNA pool was 
incubated with his-mouse Lcn2 coupled to Talon Metal affinity resin in 50 mM KH2PO4, 
150 mM NaCl, 5mM MgCl2, pH 7.4 at 23oC for 0.5-1h.  The unbound RNA was then washed 
away with binding buffer and the bound RNA was eluted with 150 mM imidazole, pH 7.2.  The 
eluted RNA was then subjected to reverse transcription (RT)-PCR.  In RT, 20 µl reaction was 
carried out at 65oC for 1h containing 1 mM each dNTPs, 1.25 -2.5 µM oligo 485, 0.75 U/µl 
thermoscript reverse transcriptase, 50mM Tris acetate (pH 8.4 @ 25 oC), 75 mM potassium 
acetate, 8mM magnesium acetate and various amounts of the captured RNA. One third of the RT 
product was subjected to PCR in 500 µl reactions containing 1mM each dNTPs, 2 µM oligo 484, 
2 µM oligo 485, 0.0125 U/µl Taq DNA polymerase,  50 mM KCl, 10 mM Tris HCl (pH 9.0 at 
25°C), 1.5 mM MgCl2, and 0.1% Triton X-100. The PCR was carried out with 1 cycle of 93 oC, 
3min; 6-12 cycles of 93 oC, 30 s; 65 oC, 1 min; 72 oC, 1 min and 1 cycle of 72 oC, 5 min. The 
PCR product was then purified by phenol/chloroform extraction and ethanol precipitation.  If 
necessary, 10 µCi α-32P-ATP was added to the in vitro transcription reaction mixture to label the 
RNA. The radioactivity of the 32P-RNA bound to resin and that washed away was measured by 
liquid scintillation counter to monitor binding enrichment.  The selection-amplification cycles 
were then repeated as specified in Table 1. In addition to the positive selection described above, 
negative selections were also carried out every 3 rounds using resin only incubated with RNA.  
Dilution of the mixture of RNA and mouse Lcn2 resin was used to increase selection stringency 
from round 3 to round 10.  At round 10, the RT-PCR products of the RNA binders were cloned 
using TOPO XL PCR cloning kit.  A total of 72 clones were picked up for high throughput 
plasmid preparation and sequencing at Iowa state University DNA facility. The sequencing 
results were then analyzed with Vector NTI 10. 
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RESULTS 
SELEX progress 
As shown in table 1, the total RNA binding to mouse Lcn2 increased from 0.4% at round 
1 to 17.9% at round 10 while RNA binding to resin was ~ 0.8%. This indicated that the RNA pool 
had been enriched for mouse Lcn2 binders. 
Aptamers identified from SELEX 
A total of 72 clones from round 10 were subjected to sequencing, among which 56 
meaningful sequences were obtained.  Among the 56 sequences, there were 21 different 
molecules (figure 1). They were clustered into different families with A1 and A4 constituting 
greater than 50% of the population (figure 2). Secondary structure analysis by s-fold 
(http://sfold.wadsworth.org) [15, 16] showed that these aptamer candidates adopted either three-
way junction or multiple stem-loop structure (figure 3).  
FUTURE WORK 
Further characterization of the aptamer candidates is under way. This includes 
determination of the Kd of the aptamers, minimization of the aptamers and studies of their effects 
on mouse Lcn2 function. 
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TABLES AND FIGURES 
 
Table 1. Summary of SELEX conditions for selecting mouse Lcn2  aptamers 
incubation round 
Lcn2 
(µM) 
RNA 
(µM) 
Volume 
(µl) 
Diluted 
to (µl) 
Wash 
(ml) 
Elute 
(ml) 
PCR 
cycles 
B% 
1 
2 
3 (-) 
3(+) 
4 
5 
6(-) 
6(+) 
7 
8 
9(-) 
9(+) 
10 
7.75 
7.75 
- 
50 
50 
43 
- 
19 
38.75 
38.75 
- 
38.75 
46.5 
16 
8.35 
148 
148 
74.7 
31 
47 
21 
50 
50 
40 
40 
63.5 
200 
200 
30 
30 
30 
30 
30 
65 
20 
20 
50 
10 
10 
 
 
 
400 
200 
400 
 
200 
200 
200 
 
200 
500 
5 
5 
0.2 
5 
5 
5 
0.05 
5 
5 
5 
0.25 
5 
10 
0.4 
0.4 
 
0.4 
0.4 
0.4 
 
0.4 
0.4 
0.4 
 
0.4 
0.4 
10 
10 
 
10 
8 
9 
 
7 
8 
6 
 
11 
10 
0.4% 
 
 
 
 
 
 
1.8% 
 
 
0.8% 
9.8% 
17.9% 
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Figure 1.  21 different species obtained from 56 clones of utc-SELEX   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 10710 20 30 40 50 60 70 80 90(1)
GGGAGACAAGAAUAAACGCUCAAC--CUCCACAGGCACGCUUUGUUGACCUCCGGCUCAUACCUUUUCGAAGACAA-GCUUCGACAGGAGGCUCACAA----CAGGCA1 (1)
GGGAGACAAGAAUAAACGCUCAAU--CUCCACCGGCACGCUUUGUUGACCUCCGGCUCAUACCUUUUCGAAGACAA-GCUUCGACAGGAGGCUCACAA----CAGGCE3 (1)
GGGAGACAAGAAUAAACGCUCAAGA-CUCCGGAAGUGC-CUGUGUCGGUCUUACGUUCCU-CUUUUUCCAUGUUUGCGCUUCGACAGGAGGCUCACAA----CAGGCC5 (1)
GGGAGACAAGAAUAAACGCUCAACC-CUGAGGC-UCUGCUGUGC-UCAUGCCACUCUCCCUUCCUUUCGUCUAGUGCCGUUCGACAGGAGGCUCACAA----CAGGCA3 (1)
GGGAGACAAGAAUAAACGCUCAAGCUCUGGUGCCUGUGCUUCGCGUUAUUUCCCUCUCGCUU--UUUGGGGU-GUUCCUUUCGACAGGAGGCUCACAA----CAGGCH1 (1)
GGGAGACAAGAAUAAACGCUCAACU--UGUGCCUGCUGAUCGGUCUGUUUUCUUUCUGCCGCUUUUGCGCCU-GUUCUCUUCGACAGGAGGCUCACAA----CAGGCC1 (1)
GGGAGACAAGAAUAAACGCUCAAGUGAUGUGCCUGCGCUUGAUCCUUCUUUACC-CGUCCUGCUGCCUGUUU--CGUUCUUCGACAGGAGGCUCACAA----CAGGCC2 (1)
GGGAGACAAGAAUAAACGCUCAACUGUGCCUGUUCGGGGUUAUUCUUGUUUAGC-CUCACUUGUGUGGGACU--CUAUGUUCGACAGGAGGCUCACAA----CAGGCC9 (1)
GGGAGACAAGAAUAAACGCUCAA-GUCCCAUUGUCGUCCUCUUCACUGUUGCGGCCUCGGGGACUGUUCACUC-UGUUUU-CGACAGGAGGCUCACAA----CAGGCA4 (1)
GGGAGACAAGAAUAAACGCUCAA-GUCCCAUUGUCGUCCUCUUCACUGUUGCGGCCUCGGGGACUGUUCACUC-UGUUUUUCGACAGGAGGCUCACAA----CAGGCH9 (1)
GGGAGACAAGAAUAAACGCUCAAGGGCCCUAUGUUGUGGGUUGGAUUUAGUAUCGAUGGC----CAUUCACUUCUGGAGUUCGACAGGAGGCUCACAA----CAGGCA6 (1)
GGGAGACAAGAAUAAACGCUCAA-GUGCCUGUGCUUUUGCCUUUCUCCCUUUCUCUUGGCUGGUUCCUGCUCC--CCGGUUCGACAGGAGGCUCACAA----CAGGCA9 (1)
GGGAGACAAGAAUAAACGCUCAA-GUGCCUGUAGUGCAUCUGCUCCUUCCUGCAUGUGGCU--UUCCUGCCCUUUCUUUUUCGACAGGAGGCUCACAA----CAGGCB3 (1)
GGGAGACAAGAAUAAACGCUCAAUGUGCCCGUUGCUGCCUGUCUCUGCCUCUUUCGUG-CUCGUUACU-UGUGCCUGGUUUCGACAGGAGGCUCACAA----CAGGCB9 (1)
GGGAGACAAGAAUAAACGCUCAACGUGCCUGUGGC--UCUUUCUACGCCCCGC-CUUG-CUUUGUUCUGUUCCUCGGGUUUCGACAGGAGGCUCACAA----CAGGCG1 (1)
GGGAGACAAGAAUAAACGCUCAACGUGCCUGUAUCG-UCUUGCCCUGUCGCCC-CCUG-UAGUUUGCUCUUUGUCUGUCUUCGACAGGAGGCUCACAA----CAGGCD7 (1)
GGGAGACAAGAAUAAACGCUCAACGUCCGUUUACUCGACCCUCUGUGAUGAGCC-CUCUCUCGUUGUUGUGC---CUGGUUCGACAGGAGGCUCACAA----CAGGCB7 (1)
GGGAGACAAGAAUAAACGCUCAA-GUCUGUUGAUGCUGCUGCCACUGAAUACUUGGCACC--GUGCCUAUGCCAUCGAAUUCGACAGGAGGCUCACAA----CAGGCC3 (1)
GGGCGA----AUUGGGCCCUCUA----GAUGCAUGCUCGAGCGGCCGCCAGUGUGAUGGAUAUCUGCUGUUU----GCCUUCGACAGGAGGCUCACAA----CAGGCB1 (1)
GGGCGA-AUUCUGCAGAUAUCCAUCACACUGGCGGCCGCUCGAGCAUGCAUCUAGAGGGCCCAAUUCGCCCU------AU-AGUGAGUCGUAUUACAAUUCACUGGCB2 (1)
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Figure 2. Phylogenetic tree of Lcn2-SELEX according to alignment in Vector NTI 
A1 (0.0085)
E3 (0.0115)
C5 (0.1146)
A3 (0.0825)
H1 (0.0824)
C1 (0.1222)
C2 (0.1423)
C9 (0.1477)
A4 (0.0017)
H9 (-0.0017)
A6 (0.1403)
A9 (0.1096)
B3 (0.1148)
B9 (0.1049)
G1 (0.0992)
D7 (0.1051)
B7 (0.1331)
C3 (0.1482)
B1 (0.1941)
B2 (0.3513)
Frequency
14/56
2/56
2/56
2/56
1/56
2/56
1/56
2/56
12/56
2/56
3/56
2/56
1/56
1/56
2/56
2/56
1/56
1/56
2/56
1/56
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Figure 3. Representative secondary structures of mouse Lcn2 aptamer candidates 
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